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Resistance to anthelmintics is increasingly becoming a problem for the agricultural industry. Emodepside is a 
novel anthelmintic that is effective against a variety of parasitic nematodes in which resistance to other 
anthelmintics has developed (Harder and Samson-Himmelstjerna, 2002). This suggests that emodepside has a 
novel mode of action. The aim of this study was to further investigate the mechanism of action of emodepside 
using the model organism Caenorhabditis elegans.
The latrophilin receptors have previously been implicated in the mechanism of action of emodepside. The 
natural compound from which emodepside is derived (PF1022A) has been shown to bind the Haemonchus 
contortus receptor latrophilin receptor HC110R (Saeger et al 2001). Caenorhabditis elegans have latrophilin 
homologues, lat-1 and lat-2. Targeting of lat-1 by RNA interference reduces the sensitivity of the C. elegans 
pharynx to emodepside (Willson et al 2004). Targeting of either lat-1 or lat-2 by RNA interference reduced the 
sensitivity of C. elegans to emodepside’s effects on locomotion. Simultaneous targeting of lat-1 and lat-2 by 
RNA interference reduced the sensitivity of C. elegans to emodepside’s effects on locomotion to a similar extent 
(Amliwala 2005). RNA interference of latrophilin receptors does not abolish emodepside’s effect, indicating 
either an incomplete knock down by RNA interference or the presence of an additional mechanism of action. To 
further investigate role of the latrophilin receptors, the sensitivity of C. elegans mutants carrying deletions in lat-
1(ok1465) and lat-2(tm463) were tested. Neither of these putative null mutants displayed any difference in 
sensitivity to emodepside’s effects on locomotion compared with the N2 wild type strain. In order to investigate 
the possibility of a redundancy between lat-1 and lat-2 a lat-2(tm463) lat-1(ok1465) double mutant was 
constructed. The lat-2(tm463) lat-1(ok1465) double mutant did not display any difference in sensitivity to 
emodepside’s effects on locomotion compared to N2. However, both lat-1(ok1465) and lat-2(tm463) lat-
1(ok1465) have reduced sensitivity to emodepside’s effects on the pharynx (Bull 2007). This suggests that lat-1
has a role in mediating emodepside’s effects in the pharynx but not in the motor nervous system. Therefore, an 
alternative mechanism by which emodepside acts in the motor nervous system must exist.
The voltage gated calcium sensitive potassium channel slo-1 was previously identified through a mutagenesis 
screen as a mediator of emodepside’s effect in C. elegans (Amliwala 2005). In this study, further emodepside 
resistant mutants were isolated. Through the use of genetic complementation tests it was demonstrated that all 
emodepside resistant mutants are alleles of slo-1. The slo-1(js379) loss of function mutants is highly resistant 
(insensitive to 10 μM emodepside) to the effects of emodepside, suggesting emodepside activates SLO-1. 
Sequencing of slo-1 in mutants isolated for the mutagenesis screens revealed the presence of mutations in 
regions of SLO-1 involved in the regulation of potassium conductance, supporting the idea that emodepside 
affects SLO-1 channel activity. slo-1 loss of function mutants are reported to have an increased reversal 
frequency and an increased sensitivity to the acetylcholine esterase inhibitor aldicarb (Wang et al 2001). Using 
these phenotypes as a read out of SLO-1 function, the relationship between emodepside sensitivity and SLO-1 
function was characterised.
In order to confirm a role for slo-1 in the action of emodepside, slo-1(+) was expressed in a slo-1(js379) mutant 
background. This resulted in restoration of emodepside sensitivity, confirming that SLO-1 mediates 
emodepside’s effects on locomotion. Expression in either body wall muscle or neurons restored emodepside 
sensitivity. The effect of emodepside on the rate of aldicarb induced paralysis was investigated. In general, 
aldicarb hypersensitive worms have increased ACh release and aldicarb resistant worms have reduced ACh 
release (Mahoney et al 2006). Emodepside reduced the sensitivity of N2 worms to aldicarb, indicating that it 
causes a reduction in ACh release. These results indicate that emodepside acts on SLO-1 in both muscle and 
neurons to inhibit locomotion. A direct activation of SLO-1 by emodepside was hypothesised. This was pursued 
using HEK293 exogenous expression system and patch clamp analysis. The identification of SLO-1 as a target 
for emodepside provides potential for the development of further anthelmintics as well as the possibility of 
identifying novel applications for emodepside.
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1Chapter 1 
Introduction
21.01 Nematodes
Nematodes may be defined as “Of or belonging to the large phylum Nematoda (or Nemata), 
comprising worms with slender, tapering, unsegmented bodies that are round in cross-section, 
which may be free-living or parasites of animals or plants” (Oxford English Dictionary). The 
nematode phylum may be categorised into five clades based on small subunit ribosomal 
sequence (Blaxter et al 1998). Each of these five clades contain both free living and parasitic 
nematodes, suggesting independent emergence of parasitism within clades. Table 1.01 shows 
the nematode phylogeny (Blaxter et al 1998).
V Strongylida ●
Rhabditida (including C. elegans) ●●●
Diplogasterida ●●
IV Rhabditida ●
Rhabditida ●
Rhabditida ●
Rhabditida ●
Aphelenchida ●●●
Tylenchida ●●●
III Oxyurida ●
Spirurida ●
Rhigonematida ●
Ascaridida ●
Plectidae ●
Chromadorida ●●
Monhysterida ●
II Enoplida ●●
Triplonchida ●
I Trichocephalida ●
Dorylaimida ●●
Mermithida ●
Mononchida ●●
Table 1.01 Nematode phylogeny. Nematode phylogeny as defined by small subunit 
ribosome sequence (Adapted from Blaxter et al 1998). 
Bacteriovore ●
algivore-omnivore-predator ●
fungivore ●
plant parasite ●
entomopathogen ●
invertebrate parasite ●
vertebrate parasitic ●
3Research of nematodes and the treatment of nematode infections is important. They have a 
high financial cost on agriculture as well as a high human cost in the developing world. The 
free living nematodes Caenorhabditis elegans (C. elegans) is widely used as a model system 
for research in a variety areas of biological science and is particularly useful as it is 
genetically tractable (Brenner 1974). 
1.02 C. elegans
C. elegans is a small free living soil nematode. There are two sexes, a hermaphrodite and a 
male, each about 1 mm long when adult. The life cycle takes about 3 days and the life span is 
about 17 days (Figure 1.01). The hermaphrodite produces both sperm and oocytes and can 
therefore either self-fertilize or be fertilized by a male. A self-fertilized hermaphrodite can lay 
approximately 300 eggs over the course of 3 days, and then live for a further 10 to 15 days.
Figure 1.01. Life cycle of C. elegans showing the different stages of growth, L1, L2, L3, 
L4 and adult. At L4 stage the forming vulva is visible. If worms are deprived of food in 
larval stages they will enter a growth stage known as dauer, in which development is arrested. 
When food becomes available development will continue. (After Wood et al 1980).
C. elegans 
life cycle
4If food is limited at an early stage of development (L2), the worm may form dauers. In this 
state the worm does not feed and will not desiccate. It can remain in this phase for 3 months 
or more, until food becomes available and normal development can resume. The 
hermaphrodite and male worms consist of 959 and 1031 somatic cells respectively. The 
haploid genome size is 9.7 x 107 base pairs, and contains about 20,000 genes. The genome 
consists of five pairs of autosomal chromosomes and a pair of sex chromosomes: XX in the 
hermaphrodite and XO in the male (Wood 1988). Males arise infrequently in C. elegans
populations, about 0.1%. This can be increased through heat shock of L4 hermaphrodites. 
Once males have been obtained, a population containing up to 50% males can be maintained 
through mating. C. elegans can be easily maintained in the laboratory on agar plates. It is also 
very amenable to genetic manipulation, through mutagenesis, transgene expression and RNA 
interference.
1.03 C. elegans as a parasite model
C. elegans provides a useful model for the investigation of the mode of action of 
anthelmintics. The usefulness of this model is dependent on the similarity between C. elegans
and the parasite for which the anthelmintic is intended. C. elegans belongs to clade V group 
of nematodes. Clade V also includes the ruminant parasitic nematodes, the strongylida 
(including H. contortus). Ascaridia, another important group of nematodes, are in clade III. It 
would be expected that the value of C. elegans as a model will reduce as the phylogenetic 
distance between the species to be compared increases. C. elegans have many similarities 
with regard to anatomy, neurobiology and genetics when compared with nematodes across the 
clades. 
51.04 C. elegans physiology
C. elegans are cylindrical in shape. They essentially consist of an inner and outer tube 
separated by the pseudocoelomic space. The inner tube contains the gonad, pharynx and 
intestine and the outer tube contains neurons, muscle, excretory system, hypodermis and 
cuticle. Figure 1.02 shows a photograph and diagram of a gravid adult C. elegans with the 
pharynx, nerve ring (brain), intestine and the reproductive system highlighted.
Figure 1.02. Anatomical features of an adult C. elegans. Key features of C. elegans 
anatomy are highlighted. The pharynx (pale blue), intestine (green), gonad (yellow), vulva 
(pink) and nerve ring (red). (After White 1988) (Photograph courtesy of Neil Hopper).
Pharynx: The C. elegans pharynx is required for the ingestion and mechanical digestion of 
food. The pharynx consists of 34 muscle cells, 9 marginal cells, 9 epithelial cells, 5 gland 
cells and 20 neurons (Albertson and Thomson, 1976). There is a basement membrane 
isolating the pharynx from the rest of the animal, making it an almost completely self 
contained system. The structure of the pharynx consists of four regions, the procorpus, 
metacorpus, isthmus and terminal bulb (Figure 1.03 A). The procorpus and metacorpus acts as 
a sieve, trapping food whilst allowing fluid to be regurgitated. The terminal bulb acts to grind 
up the food before it is passed into the intestine through the pharyngeal-intestinal valve. The 
pharyngeal nervous system coordinates the pharyngeal muscle cells allowing food to be 
sucked in, broken down and passed into the intestine. This process is referred to as pharyngeal 
pumping. The pharyngeal pumping of C. elegans can either be counted manually or electro-
physiologically. The method of recording pumping electro-physiologically is referred to as 
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6the electro-pharyngeogram or EPG (Raizen and Avery 1994, Cook et al 2006). This is an 
extra-cellular recording that can be performed on intact worms or on isolated pharynxes. As 
well as producing a read-out of pump rate, this technique can also be used to provide 
information on neuronal activity of the pharynx. The EPG trace has excitatory and inhibitory 
components that can be attributed to the function of specific pharyngeal neurons (Figure 1.03 
B).
A) B)
Figure 1.03. C. elegans pharynx and EPG. A) The pharynx consists of the procorpus, 
metacorpus, isthmus and terminal bulb. B) The EPG consists of initial excitatory spikes, 
followed by a series of small inhibitory spikes that are attributed to glutamate release from the 
M3 neuron. This is followed by relaxation of the corpus and terminal bulb. (From Cook et al
2006)
Reproductive system: The reproductive system of the hermaphrodite C. elegans consists of 
the gonadal sheath, the spermatheca, the spermatheca-uterine valve, the uterus and the vulva. 
Distal gonadal sheath cells form a covering for the germ line component of each gonad arm, 
and are important for the promotion of germ line proliferation. Proximal gonad sheath cells 
are required for oocytes maturation and have contractile properties and are required for 
transfer of oocytes into the spermatheca. The spermatheca contains sperm and is the site of 
oocytes fertilisation. Once fertilised, the newly formed embryo passes through the 
spermatheca-uterine valve into the uterus. The uterine and vulval muscles are then used to 
force the eggs out through the vulva (Kimble and Hirsh 1979). The stage of gonad 
development can be used to determine the larval stage of a worm. For example, when the 
gonad development is at the four cell stage the worm is at L1. At later developmental stages, 
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7the appearance of the vulva can be used to determine the larval stage of a worm (Hirsh et al
1976).
Nervous system and motor control: The nervous system consists of 302 neurons. The 
majority of neurons are located in the head and make up the nerve ring. It also contains a 
variety of sensory neurons. The nerve ring is a region of high neuronal density that encircles 
the pharynx. C. elegans has two nerve cords, dorsal and ventral, that project from the nerve 
ring and run the length of its body. Neurons and muscles are either electrically coupled, via 
gap junctions, or chemically coupled. Chemical synapses occur en passant in C. elegans.
C. elegans moves in a sinusoidal pattern on solid media. The pattern of movement is achieved 
through the alternate contraction of dorsal and ventral sets of muscles. It is able to move in 
this way due to the organisation of its nervous system and musculature. An adult worm has 95 
body muscle cells. These are arranged in quadrants running the length of the body. The left 
ventral quadrant contains 23 muscle cells and the other three quadrants contain 24 muscle 
cells each (Sulston & Horvitz 1977). Figure 1.04, which is taken from White et al (1986), 
shows a cross section of a worm with the muscle and nerve cords marked. The body muscle 
cells can be divided into three groups on the basis of synaptic input. Those that receive motor 
input from the nerve ring (the anterior four muscles in each quadrant), those that receive 
motor input from the nerve ring and ventral cord (the next four muscles in each quadrant) and 
those that receive input from the ventral cord alone (the remainder of the cells). The muscle 
cells in each row are coupled by gap junctions. Motor neuron cell bodies are situated in the 
ventral cord. These motor neurons either innervate ventral or dorsal muscle cells. Motor 
neurons that innervate dorsal muscle cells pass processes from the ventral cord and must then 
pass over to the dorsal cord. These processes are known as commissures. Muscle cells and 
motor neurons synapse along the ventral and dorsal nerve cords. The muscle cells of 
nematodes are unusual in that they have processes that extend from the main body of the 
muscle cells to the nerve cord. These processes are known as muscle arms. Muscle arms have 
multiple digits that synapse with the dorsal and ventral nerve cords (White et al 1986).
8Figure 1.04. Cross section of C. elegans body. The dorsal and ventral nerve cords are 
marked. Body wall muscle cells have extensions called extend muscle arms that synapse with 
excitatory and inhibitory motor neurons in the cords. (From White et al 1986).
1.05 Neuronal circuit for movement
There are four classes of motor neuron that innervate ventral muscles and four classes of 
motor neuron that innervate dorsal muscles, VAn, VBn, VDn, VCn and DAn, DBn, DDn, 
Asn, respectively. Each class of motor neuron consists of multiple members that are repeated 
along the length of the body.  VAn and DAn have anterior projecting axons and can be 
considered to be of the same class. VBn and DBn have posterior projecting axons and can be 
considered to be of the same class. These motor neurons receive input from interneurons. 
VDn and DDn receive synaptic input solely from motor neurons VAn, DAn, VBn and DBn. 
VCn and ASn are less prominent with regard to their innervation of body wall muscle (White 
et al 1986). VA, DA, VB and DA are excitatory and release ACh, causing muscle contraction 
9(Johnson and Stretton 1985). DV and DD are inhibitory and release GABA, causing muscle 
relaxation. The network shown in figure 1.05 shows how relaxation on dorsal and ventral 
muscles can be coordinated. Ventral excitatory motor neurons (VB and VA) synapse with 
dorsal inhibitory neurons (DD) (Stretton et al 1978, White et al 1986). Therefore, when the 
ventral muscle contracts, the dorsal muscle relaxes. This system of cross inhibition also 
applies for dorsal excitatory (DA and DB) and ventral inhibitory (VD) motor neurons. These 
properties of C. elegans motor neurons are inferred from studies on Ascaris lumbricoides
(Stretton et al 1978). The idea that this system is present in C. elegans is supported by genetic 
analysis and cell ablation studies. McIntire et al (1993) showed that laser ablation of DD and 
VD in live C. elegans prevented sinusoidal movement and resulted in the simultaneous 
contraction of dorsal and ventral muscles. In the unc-25 mutant, which is unable to synthesise 
GABA, simultaneous contraction of dorsal and ventral muscles was observed.
Figure 1.05. Neuronal network regulating body wall muscle. The ventral and dorsal 
muscle cells receive excitatory and inhibitory input from cholinergic motor neurons VB, DB, 
DA and VA (red) and GABAergic motor neurons DD and VD (black). Interneurons AVA, 
AVD, AVB and PVC (green) provide input to the motor neurons. (After White et al 1986).
In order for this circuit to produce rhythmic sinusoidal locomotion an oscillating pattern of 
neuronal activity is required. Cells that have oscillating patterns of activity are known as 
pattern generators. In Ascaris lumbricoides the inhibitory neurons, the equivalent of DD and 
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VD in C. elegans, are thought to generate this oscillating pattern (Angstadt and Stretton 
1989). Little is known regarding the origin of this oscillating pattern in C. elegans. 
Synaptic input to the motor neurons of the ventral cord is provided by the interneurons AVA, 
AVB, AVD, AVE and PVC. These are marked in figure 1.05. DB and VB receive input from 
PVC and AVB, which drive forward locomotion. DA and VA receive input from AVA and 
AVD, which drive backward locomotion (Chalfie et al 1985). Karbowski et al (2008) suggest 
that the pattern generator is located in the head in C. elegans. It is proposed that this signal is 
propagated downstream by interneurons and/or muscle cell coupling (via gap junctions). As 
well as requiring a pattern generator for movement, a mechanism for the propagation of the 
sinusoidal wave is required. The presence of body wall stretch receptors has been proposed. 
These would act to regulate adjacent motor neurons, thereby allowing propagation of the 
wave (White at al 1986).
1.06 Neurotransmitters
C. elegans have a variety of classical and non-classical neurotransmitters similar to those in 
mammalian brain. Similar mechanisms of metabolism and inactivation are also present (Isaac 
et al 1996). C. elegans neurotransmitters include 5-HT, dopamine, tyramine, octopamine, 
ACh, GABA and glutamate as well as a multitude of neuropeptides. 
ACh acts at the C.  elegans NMJ and is the most common excitatory neurotransmitter (Rand 
2007). Over a third of neurons in C. elegans are cholinergic. C. elegans have both nicotinic 
and muscarinic type ACh receptors. 27 different genes coding for nicotinic ACh receptor 
subunits have so far been identified. The nicotinic ACh receptors of the body wall muscle 
have been characterised through expression in Xenopus oocytes and electrophysiological 
recording. There are both levamisole sensitive and levamisole insensitive nicotinic ACh 
receptors expressed in the body wall muscle. The levamisole sensitive receptors consist of 
three different types of subunit, UNC-29, UNC-38 and UNC-63, which are thought to form a 
heteromeric receptor. Both UNC-38 and UNC-63 are ACh binding α subunits, UNC-29 is a 
non-α subunit. Loss-of-function mutations in these subunits results in resistance to 
levamisole. Loss-of-function mutations in nicotinic ACh receptor subunits lev-1 and lev-8
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results in mild resistance to levamisole (Culetto et al 2004, Richmond and Jorgensen 1999). A 
nicotinic receptor that is levamisole insensitive is also present in the body wall muscle. This is 
thought to be a homomeric receptor that is made up of ACR-16 α-subunits (Touroutine et al
2005). C. elegans have three genes that encode receptors with homology to muscarinic 
receptors, gar-1 gar-2 and gar-3. 
Many other genes involved in the regulation of cholinergic transmission have been identified. 
C. elegans have three genes coding for acetylcholine esterase, ace-1, ace-2 and ace-3. There 
is a level of redundancy between these genes, with individual mutants displaying mild 
phenotypes but a triple mutant of ace-1, ace-2 and ace-3 being lethal (Johnson et al 1988). 
unc-17, initially identified by Brenner et al (1974), codes for a vesicular acetylcholine 
transporter (Alfonso et al 1993). unc-17 loss-of-function mutations are lethal, suggesting that 
it is essential. Genes coding for choline acetyltransferase (cha-1) and choline transporters 
(cho-1) have also been identified (Rand 2007).
GABA acts on C. elegans body wall muscle where it causes relaxation and on the enteric 
muscles to cause contraction (Jorgensen 2005). 26 of the 302 neurons in C. elegans are 
GABAergic. These include the previously mentioned DD and VD body wall muscle motor 
neurons, RME head motor neurons, AVL and DVB enteric motor neurons and the interneuron 
RIS. GABA has inhibitory effects on the body wall muscle that are mediated by GABA-gated 
chloride channels. These GABAA receptors are encoded by the gene unc-49 in C. elegans. 
Three distinct GABAA receptor subunits are generated from this single gene and are thought 
to co-assemble to form a heteromultimeric GABA receptor (Bamber et al 1999). The 
excitatory effects of GABA on enteric muscles are mediated by a GABA-gated cation 
channel, exp-1. These receptors receive synaptic input from the AVL and DVB motor neurons 
(McIntire 1993). EXP-1 resembles UNC-49 except in the pore forming domain, which 
confers cation selectivity (Beg and Jorgensen 2003). Other GABA receptors have been 
identified through sequence homology. These include a G-protein coupled GABAB receptors 
(Jorgensen 2005).
The biogenic amines dopamine, octopamine, 5-HT and tyramine regulate a variety of 
behaviours in C. elegans, including locomotion, egg laying, defecation and foraging. These 
neurotransmitters act on both neurons and muscle to modulate these behaviours. Genes 
coding for seventeen putative biogenic amine receptors have been identified in C. elegans 
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(Chase and Koelle 2007). Genes coding for enzymes required for the synthesis of biogenic 
amines have also been identified. These include: tph-1 (tryptophan hydroxylase) which is 
required for the synthesis of 5-HT (Sze et al 2000), tbh-1 (tyramine β-hydroxylase) and tdc-
1(tyrosine decarboxylase) which are required for octopamine synthesis (Alkema et al 2005) 
and cat-2 (tyrosine hydroxylase) which is required for dopamine synthesis (Lints and 
Emmons 1999). The expression pattern of these genes has been used to identify which 
neurons release specific biogenic amine neurotransmitters. 
Glutamate mediates both excitatory and inhibitory synaptic signaling. In C. elegans, there are 
ionotropic and metabotropic glutamate receptors. The ionotropic glutamate receptors are 
heteromeric ligand-gated ion channels. They can be classified based on their pharmacological 
properties. There are those that bind N-methyl-D-aspartate (NMDA receptors) and those that 
do not (non-NMDA receptors). Non-NMDA receptors are further categorised into those that 
bind α-amino-3-hydroxy-5-methyl-4isoxazole propionic acid (AMPA receptors) and those 
that bind kainate (kainate receptors). There are thought to be ten ionotropic glutamate 
receptors in C. elegans, two NMDA receptors (nmr-1 and nmr-2) and eight non-NMDA 
receptors (glr-1 to glr-8), based on sequence homology with pharmacologically characterized 
mammalian receptors. Expression of these receptors is almost exclusively in interneurons and 
motor neurons (Brockie et al 2001). 
As well as cation selective ionotropic glutamate gated channels, there are chloride selective 
glutamate gated channels. A key role of these channels is the regulation of the timing of 
pharyngeal muscle relaxation. avr-15 codes for a glutamate-gated chloride channel that is 
expressed in extra-pharyngeal neurons and pharyngeal muscle cells PM4 and PM5. The 
glutamate-containing neuron M3 synapses onto PM4 and acts to regulate the timing of muscle 
relaxation during pumping (Avery 1993). Inhibitory post synaptic potentials (IPSPs) can be 
observed in the EPG trace during normal pharyngeal pumping and are not generated when M3 
is not functional. The pharynx of the avr-15 loss-of-function mutant ad1051 does not generate 
IPSPs, demonstrating that it is required for glutamate’s inhibitory action on the pharynx.
C. elegans also have metabotropic glutamate receptors. These are G-protein coupled 
receptors. Genes coding for three such receptors have been identified, mgl-1, mgl-2 and mgl-3 
(Dillon et al 2006). Little is known about the role that these receptors play in glutamatergic 
signaling in C. elegans.
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C. elegans has over a hundred genes coding for various types of neuropeptides. C. elegans 
neuropeptides include insulin-like peptides (ins genes), FMRFamide-related peptides (flp
genes) and non-insulin like / non-FMRFamide like peptides (nlp genes). Neuropeptides are 
derived from larger precursor molecules that are cleaved to produce active molecules. 
Neuropeptides are processed by two key enzymes. Protein convertase, which is required for 
the initial cleavage of the precursor peptide (Kass et al 2001), and carboxy-peptidase, which 
removes a flanking basic sequence from the peptides (Jacob and Kaplan 2003). FLP peptides 
have been shown to have a variety of physiological effects. Papaioannou et al (2005) 
demonstrated a role for the FLP peptides in the regulation of pharyngeal pumping. Liu et al 
(2007) showed that signaling mediated by the FLP peptides coded for by flp-8, flp-10, flp-12, 
and flp-20 are required for the sensory transduction involved in male turning behaviour. 
Peptides coded for by flp-1 have also been shown to regulate the egg laying interval 
(Waggoner et al 2000). The NLPs occur in the pharyngeal neurons (Li 2005) and excite 
pharyngeal muscle (Papaioannou et al 2008). NLPs have also been implicated in an innate 
immune response (Couillault et al 2004). The insulin-like peptides have been found to have a 
role in the life span of C. elegans (Gami and Wolkol 2006). However, these peptides are 
likely to be involved in many other processes that have yet to be identified.
1.07 Forward and reverse genetics
As well as being a good model for parasitic nematodes, C. elegans has the advantage of being 
amenable to genetic manipulation. Such manipulations include mutagenesis, RNA 
interference and trans-gene expression. When investigating molecular mechanisms in C. 
elegans either forward or reverse approaches can be taken. Reverse genetic techniques are 
hypothesis driven. Analysis of the phenotypes of mutants with specific mutations can be used 
to inform about the role of genes in a drug’s mode of action. Alternatively, RNA interference 
can be used to knock down the expression of specific genes. The drawback of the reverse 
genetic approach is that prior knowledge about the mechanism is required. In this respect, the 
forward genetic approach does not have this problem. No prior knowledge about the 
mechanism is required. Forward genetics also has been successfully used in determining drug
mode of action. This technique was pioneered in C. elegans by Sidney Brenner. This involves 
a random mutagenesis followed by screening for a specific phenotype. The mutation resulting 
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in the phenotype can then be mapped and the gene involved identified. Brenner (1974) 
generated mutants partially resistant to the effects of the anthelmintic levamisole and 
identified specific genes involved in these resistance mechanisms. The completion of 
sequencing of the C. elegans genome (The C. elegans sequencing consortium 1998) now 
makes the process of mapping and identification of genes involved much easier. These 
techniques are further discussed in the methods section.
1.08 Human parasitic nematodes and other zoonotic parasites
It is estimated that more than one third of the world’s population harbour parasitic worms, of 
which 300 million suffer permanent ill health as a result (World health report 2000). Parasitic 
worm infections primarily affect populations in developing countries. Parasitic worms can be 
divided into three categories: nematodes, cestodes and trematodes, the latter two being 
platyhelminths. Humans become infected by cestodes through ingestion of under-cooked or 
raw meat containing larvae or material contaminated by faeces. Nematodes, which include the 
common round worm (Ascaris lumbricoides) thread worm (Enterobius vermicularis), hook 
worm (Ancylostoma duodenal) and whip worm (Trichuris trichiura), are transmitted through 
the ingestion of eggs from contaminated soil or by penetration of the skin by larvae. These 
nematodes and cestodes reside in the gut of their host. Other nematodes reside in various 
tissues of their hosts, including the lymphatic system, subcutaneous tissue, eye and skeletal 
muscle. These nematodes include Wuchereria bancrofti and Onchocerca volvulus which 
cause the diseases elephantiasis and onchocerciasis (river blindness). Trematodes cause 
schistosomiasis, infecting humans through penetration of the skin. They reside in the veins of 
the gut or bladder, resulting in inflammation of these tissues as well as haematuria and loss of 
blood in the faeces.
The control of parasitic nematodes in humans presents a challenging problem in the 
developing world. The problem is one of access to treatment. In 2001 the Partners for 
Parasitic Control (PPC) was launched in order to urge countries with endemic nematode and 
schistosome infections to tackle the problem, as well as developing a global databank. The 
PPC is composed of agencies of the United Nations, WHO Members States, research 
institutes and NGOs. One key goal of the PPC is to provide preventative treatment to 75% of 
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school aged children at risk of morbidity by 2010. Table 1.02 shows the proportion of the 
school aged children at risk of morbidity from nematode and schistosome infections that have 
received treatment from 2003 to 2007. The proportion in 2007 was 5.6%.
School age children 2003 2004 2005 2006 2007
Total treated 25,844,440 40,734,389 62,169,783 76,751,236 49,173,431
Total at risk of morbidity 878,209,058 877,987,807 877,861,438 877,082,032 878,082,032
in all endemic countries
Percent coverage achieved 2.9% 4.6% 7.1% 8.7% 5.6%
No. of countries reported data 48 54 59 62 48
Table 1.02. Preventative treatment of school age children for nematode and schistosome 
infections in endemic countries. Total numbers and proportion of school aged children at 
risk who have been treated for nematode and schistosoma infections in 2003, 2004, 2005, 
2006 and 2007. Data compiled by the World Health Organisation.
1.09 Nematode infections in live stock
Parasitic nematode infections result in poor food quality, poor animal health and low 
profitability. Anthelmintics are widely used to treat infections in all areas of agriculture. A 
1997 survey conducted by the US department of agriculture revealed that 77% of US beef 
cattle farmers treat their herds with anthelmintics (Corwin 1997). Ruminants are affected by 
many different parasitic nematodes that can reside in the abomasum, small intestine, large 
intestine or lungs. Haemonchus contortus resides in the abomasum of sheep and goats and is 
considered to be one of the most pathogenic parasites. It is a blood sucking parasite that is 
found predominantly in tropical and sub-tropical climates but has been found in European 
countries as far north as Sweden (Waller and Chandrawathani 2005). Infection by H. 
contortus may be hyperacute, acute, or chronic. In the hyperacute disease, death may occur 
within one week of heavy infection without significant signs. The acute disease is 
characterised by anaemia and oedema (Zajac 2006). Cooperia oncophora resides in the small 
intestine of cattle. C. oncophora produces a relatively mild disease state but it can be 
responsible for weight loss and poor productivity. Dictyocaulus viviparous, commonly known 
as lung worm, affects cattle. It can result in obstruction of the airways and collapse of alveoli. 
With large numbers of larvae present, the animal may die with severe interstitial emphysema 
(Zajac 2006). These are just a few examples of the most economically relevant parasitic 
nematodes that affect the health and productivity of live stock.
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1.10 Plant parasitic nematodes
Plant parasitic nematodes are one of the greatest threats to crops across the world. The potato 
cyst nematodes Globodera rostochiensis and Globodera pallida are such examples. The UK 
potato industry employs more than 30,000 people and maintains the economic viability of 
500,000 hectares of farm land. G. rostochiensis and G. pallida live and feed on the root tips of 
potatoes and other plants. This results in damage to the roots and can result in up to an 80%
reduction in yield from the crop (Kerry et al 2002).
1.11 Parasitic nematode infections of companion animals
Companion animals such as cats and dogs are commonly infected with parasitic nematodes. 
Treatment of infected pets is especially important as there is the potential for infection of 
humans, who are often in close contact. Domestic cats are commonly infected by the parasitic 
nematodes Toxicara cati and Toxicara leonina. Dogs are commonly infected by T. leonina
and T. canis, which can be lethal in pups. The larvae of these nematodes can migrate to the 
tissues of many species, including humans. Although this is usually asymptomatic, fever, 
eosinophilia and hepatomegaly can result. This condition is known as viscera larval migrans. 
A condition known as ocular larva migrans can occur when larva settle in the eye, causing 
impairment of vision (Fisher 2003).
1.12 Treatment of parasitic nematode infections in livestock and 
domesticated animals
Parasitic nematode infections are treated using a group of compounds known as 
anthelmintics. There are an increasing number of different anthelmintics available that have a 
variety of mechanisms of action.
Nicotinic ACh receptor agonists: Levamisole and pyrantel are both examples of 
anthelmintics that are nicotinic ACh receptor agonists. These drugs act at the nematode 
neuromuscular junction. Through the use of tension and electrophysiological recordings from 
Ascaris muscle strips Acever et al (1970) demonstrated that levamisole causes a contraction. 
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This results in a spastic paralysis of the worms which are then passed out through the faeces. 
Genetic evidence for the activation of nicotinic ACh receptors comes from work done in C. 
elegans. Fleming et al (1997) demonstrated that loss of function of nicotinic ACh receptor 
subunits unc-29, unc-31 and lev-1 resulted in a high level of resistance to levamisole.
GABA agonists: Piperazine causes flaccid paralysis and paralysed worms are passed out 
through the faeces alive. Martin (1982) demonstrated that both GABA and piperazine caused 
in increase in input conductance in A. suum muscle. This increase was shown to be reduced 
when the preparation was bathed in a low chloride Ringer, indicating piperazine increases 
chloride conductance. Later, patch clamp experiments directly demonstrated that piperazine 
caused an opening of chloride channels (Martin et al 1985).
Avermectins: The avermectins include ivermectin, doramectin, moxidectin and abamectin 
(Martin et al 1997). Ivermectin is widely used in veterinary medicine and is used to treat 
onchocerciasis. Abamectin is used as a pesticide for crop protection. Avermectins have been 
shown to act as antagonists of the A. suum muscle GABA receptors (Holden-Dye and Walker 
1990). However, this action was only observed at concentrations that were not clinically 
relevant. Attention has more recently turned to the glutamate gated chloride channels. 
Evidence for their role has come from pharmacological studies in Xenopus oocytes into which 
C. elegans RNA was injected. It was shown that a chloride dependent inward current could be 
induced by both glutamate and ivermectin and it was proposed that these currents were 
mediated by the same channel (Arena et al 1992). Activation of chloride dependent inward 
currents by glutamate and ivermectin was observed in oocytes expressing two specific C. 
elegans glutamate gated chloride channel subunits, α and β (Cully et al 1994). These currents 
could be induced by ivermectin in Xenopus oocytes expressing the α-type subunit alone. 
Mutations in the glutamate gated chloride channel α subunits has been shown to confer 
resistance to ivermectin. A triple mutant of avr-14, avr-15 and glc-1 confers a 4000 fold 
increase in survival when exposed to ivermectin (Dent et al 2000). AVR-15 has been shown 
to mediate ivermectin’s response in the C. elegans pharynx (Dent et al 2000; Pemberton et al 
2001).
Praziquantel: Praziquantel has little effect against nematodes and is used primarily as a 
treatment for schistosomiasis. Praziquantel causes a slow depolarisation of the tegument that 
is associated with an influx of calcium ions. This results in paralysis and death of the parasite. 
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Proposed sites of action for praziquantel include: voltage-activated calcium channels, 
intracellular messenger activated calcium channels, extracellular receptor operated calcium 
channels, non-selective cation channels also allowing entry of calcium, sodium / calcium 
exchanger, calcium ATPase, intrategumental calcium buffers, IP3 releasable store from the 
sarcoplasmic reticulum, calcium-induced calcium release channels (CICR channel), calcium 
ATPase pump: sarcoplasmic endoplasmic reticulum calcium (SERCA), electrical junctions 
between muscle cell and tegument, electrical junctions between muscle cells (Redman et al
1996).
Benzimidazoles: Benzimidazoles include mebendazole, thiabenazole and albendazole. The 
mode of action of benzimidazoles involves their binding to β tublin. α and β tublin polymerise 
to form microtubule structures which are major components of eukaryotic cilia and flagella. 
Benzimidazoles inhibit the formation of microtubules, resulting in damage to intestinal cells 
and starvation of the nematode (Van Den Bossche and De Nollin 1973, Sangster et al 1985). 
The time-frame in which these drugs act is therefore longer than anthelmintics that disrupt 
neuromuscular transmission.
Novel treatments: Due to the emergence of resistance to many commonly used 
anthelmintics, novel ways of combating nematode infections need to be continuously 
developed. These can be traditional pharmacological therapies or an alternative approach can 
be taken. There is the potential to vaccinate against nematode infections. A variety of 
potential antigens have been described for use in vaccination (Knox and Smith 2001, Bakker 
2004). Novel classes of anthelmintics include amino-acetonitrile derivatives (AADs) and 
cyclo-octadepsipeptides. AADs target a specific nicotinic ACh receptor subunit ACR-23 (in 
C. elegans), causing hypercontraction resulting in a spastic paralysis (Kaminsky et al 2008). 
The cyclo-octadepsipeptides are the subject of this thesis and will be discussed in the 
following sections.
1.13 Anthelmintic resistance mechanisms
Resistance to anthelmintics arises through spontaneous mutations in proteins key to their 
mode of action. Resistance typically arises due to the over use of anthelmintics. Resistant 
populations can then become established due to selection whilst using a single anthelmintic in 
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the treatment of parasitic worm infections (Williams 1997). These mutations causing 
resistance may either affect the binding of an anthelmintic to a receptor or proteins involved 
in the modulation of this receptor. Alternatively, mutations in proteins unrelated to the
anthelmintic’s mode of action, such as those involved in drug metabolism, may lead to 
resistance. Various mechanisms of resistance exist for a number of anthelmintics. In the 
following section some of these mechanisms are discussed. The nematode C. elegans has 
proved useful in understanding resistance mechanisms.
Mutation in a variety of nicotinic ACh receptor subunits has been shown to confer resistance 
to levamisole in C. elegans. Fleming et al (1997) showed that mutations in the α-nACh 
receptor subunit unc-38 and the non-α-nACH subunits lev-1 and unc-29 conferred a high level 
of resistance to levamisole. Although the generation of resistant C. elegans is useful for mode 
of action studies, it is not necessarily that informative about resistance in parasitic nematodes. 
C. elegans carrying mutations that confer high levels of resistance often have severe 
locomotor and egg laying phenotypes that could not be sustained by parasitic nematodes. The 
mechanisms of levamisole resistance in parasitic worms are not well understood. Sangster et 
al (1998) demonstrated that levamisole has high and low affinity binding sites in H. contortus 
larval and parasitic stage homogenates. Resistant isolates of H. contortus had a lower binding 
affinity for the [3H]m-aminolevamisole, suggesting an alteration in the low affinity binding 
site. Robertson et al (1999) analysed levamisole sensitive single channel currents in 
Oesophagostomum dentatun muscle. Currents in both levamisole sensitive and resistant 
isolates were recorded. Different channel populations were identified in terms of conductance 
in the resistant and sensitive isolates. This was interpreted as a shift in the proportion of the 
heterogenous nACh receptor subtypes to receptors less sensitive to the drug. Attempts to 
identify specific mutations that confer resistance in parasitic nematodes have been made 
without success. Correlation between H. contortus nACh receptor subunit sequence HCA1, a 
homologue of C. elegans unc-38, and levamisole resistance could not be established
(Hoekstra et al 1997).
Resistance to benzimidazoles has been shown to be due to a reduced binding to β-tubulin 
(Kohler 2001, Lacey 1988). In H. contortus reduced binding has been shown to be due to a 
point mutation in β-tubulin. A correlation between resistant alleles and a phenylalanine to 
tyrosine amino acid substitution at position 200 in the β-tubulin was established (Kwa et al 
1994). It was confirmed that this mutation conferred resistance through the use of the model 
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organism C. elegans (Kwa et al 1995). H. contortus β-tubulin isotypes of tub-1 were 
expressed in C. elegans ben-1(u462), a β-tubulin mutant resistant to the effects of 
thiabendazole. Expression of the tub-1 isotype encoding phenylalanine at amino acid position 
200 conferred thiabendazsole sensitivity to the ben-1(u462) mutant. Expression of the tub-1
isotype encoding tyrosine at amino acid position 200 failed to confer thiabendazole 
sensitivity, strongly suggesting that this point mutation is responsible for the resistance 
observed in H. contortus.
Resistance to ivermectin has been widely reported in a variety of species. In C. elegans a high 
level of resistance can be achieved by simultaneous mutation of three α-type glutamate-gated 
chloride channels, avr-14, avr-15 and glc-1 (Dent et al 2000). Although the phenotypes of 
this triple mutant are relatively modest, they may be less sustainable in parasitic nematodes. It 
may be that the lower levels of resistance are more relevant to understanding resistance in 
parasitic nematodes. A variety of genes were found to have a modulatory role in ivermectin 
sensitivity in C. elegans. These include the gap junction subunits unc-7 and unc-9 and 
mutants that are thought to have reduced permeability to ivermectin (osm-1, osm-5, dyf-11
and che-3) (Dent et al 2000). Genetic analysis of H. contortus resistant to ivermectin suggests 
that a single gene controls the resistance mechanism (Jambre et al 2000). Resistance in a 
Trichostrongylus colubriformis isolate was found to be dependent on more than one gene. 
Multiple mechanisms of resistance are likely to exist in many parasitic nematode species.
Resistance to currently used anthelmintics is continually developing. New anthelmintics that 
are effective against resistant populations therefore need to be developed in order to maintain 
an effective arsenal for the treatment of parasitic nematode infections. 
1.14 Cyclo-octadepsipeptides
The cyclo-octadepsipeptides are a group of compounds that have anthelmintic activity. 
Emodepside is a derivative of the natural compound PF1022A. PF1022A is a fermentation 
product of the fungus Mycelia sterilia, and is found in the microflora on the leaves of 
Camellia japonica. Sasaki et al isolated it and determined its structure in 1992 (Sasaki et al, 
1992). It belongs to a class of N-methylated, 24-membered cyclo-octadepsipeptides. Figure 
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1.06 shows the structure of PF1022A and a semi synthetic derivative, emodepside (BAY44-
4400).
A) B)
Figure 1.06. Structure of A) PF1022A and B) emodepside (BAY44-4400). (Adapted from 
Harder & Samson-Himmelstjerna, 2002).
Both of these compounds were patented by the Fujisawa Pharmaceutical Co. in 1993. Both 
PF1022A and emodepside have been shown to have potent anthelmintic activity in a variety 
of species. Initial experiments were performed by Tagaki et al. in 1991 on Ascaridia galli in 
chickens. Emodepside has now been shown to have efficacy in a variety of nematodes in 
cattle, sheep, horses, cats, dogs, chickens and rodents (Harder & Samson-Himmelstjerna, 
2002). Emodepside has resistance breaking properties. This is of key importance as it permits 
emodepside to be used to treat parasitic worm infections where other treatments have failed. It 
also suggests that emodepside has a novel mode of action as resistance often develops to a 
class of compounds rather than to a single compound. Emodepside was found to be effective 
against H. contortus isolates with resistance to ivermectin and levamisole and against C. 
oncophora isolates with resistance to ivermectin. PF1022A was found to be effective against 
H. contortus isolates with resistance to the benzimidazole, febantel (Harder and Von Samson-
Himmelstjerna 2002).
Essential characteristics to the success of the cyclo-octadepsipeptides as marketable 
anthelmintics include selective toxicity for the parasite and minimal host side effects. Much 
testing of PF1022A has been carried out against a range of parasitic nematodes and in various 
hosts, alongside the documentation of any side effects observed. Various methods of 
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application of the PF1022A have also been tested. No side effects resulted from PF1022A 
being administered orally to rats (in doses up to 100 mg/kg body weight), dogs (in doses of 5 
mg/kg body weight) or cattle (in doses of 5 mg/kg body weight ; Samson-Himmelstjerna et al
2000). The intramuscular administration of PF1022A to dogs (in doses of 5 mg/kg body 
weight) and its intravenous administration to cattle (in doses of 1 mg/kg of body weight) did 
not result in side effects either (Samson-Himmelstjerna et al 2000). In fact, none of the modes 
of administration of PF1022A to either rats, dogs, sheep, horses or cattle resulted in any side 
effects (Samson-Himmelstjerna et al 2000). Mice were also found to tolerate PF1022A 
administered orally at concentrations as high as 2000 mg/kg of body weight (Sasaki et al 
1992). The concentrations used in these experiments were highly effective at clearing 
parasitic nematode infections in the host animals. The fact that no side effects were observed 
in the hosts with the oral applications shows that PF1022A has toxicity selective for the 
parasites. However, it is possible that this could be due to reasons of drug mobility. The fact 
that no side effects were observed following systemic application suggests that the nature of 
the selective toxicity is molecular. Emodepside is currently marketed under the trade name 
Profender, which is a mix of emodepside and praziquantel. It is administered by absorption 
through the skin, again demonstrating the selective nature of its toxicity.
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1.15 Emodepside’s effects on C. elegans
Emodepside’s action in C. elegans: Emodepside causes inhibition of locomotion, pharyngeal 
pumping, egg laying and also slows development (Willson et al 2004, Amliwala 2005, Bull et 
al 2007). The effects of emodepside on pharyngeal pump rate in C. elegans were measured
using the EPG technique. Basal pump rate was stimulated using 500 nM 5-HT. The IC50 for 
emodepside on 5-HT stimulated pump rate is 4.1 nM. Amliwala (2005) exposed C. elegans 
eggs to emodepside on agar plates. The effect of emodepside on the rate of locomotion of the 
adult worms was measured. The IC50 for emodepside’s effect on locomotion is 4.2 nM in this 
assay. Bull et al (2007) investigated the effect of emodepside on growth rate and egg laying. 
Growth rate was retarded by emodepside at concentrations of 10 nM or higher. Emodepside 
concentrations of 20 nM and above were shown to have inhibitory effects on egg laying rate. 
1.16 Cyclo-octadepsipeptide mode of action
Understanding the molecular mechanism of action of cyclo-octadepsipeptides is of great 
interest. Knowledge of the molecular target for cyclo-octadepsipeptides provides the 
opportunity to design compounds with increased effectiveness. Cyclo-octadepsipeptides 
potentially have a variety of medical, veterinary and agricultural applications. An 
understanding of their mechanism of action would allow these potential applications to be 
more easily identified. The following section reviews our current knowledge of the mode of 
action of cyclo-octadepsipeptides.
Ionophore characteristics: Cyclo-octadepsipeptides such as valinomycin, enniatin A and 
beauvericin have been shown to have ionophore characteristics in planar lipid bilayers. 
PF1022A might also exert its anthelmintic effect through an ion carrier mechanism. The 
effects of a number of depsipeptides were investigated using three different approaches 
(GeBner et al., 1996). 1) in vivo activity against a variety of parasitic nematodes, 2) in vitro
studies using Ascaris suum and 3) electrophysiological studies on planar bilayers. It was 
shown that a number of octa-depsipeptides, which do not have ionophore characteristics, have 
potent anthelmintic activity. On the other hand, some depsipeptides with ionophore activity 
did not show any anthelmintic effects. Most notably the PF1022A isomer, PF1022-001, was 
shown to have similar ionophore activity in planar lipid bilayers but virtually no anthelmintic 
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activity when tested in vivo. The compound SBJ1822 on the other hand shows no pore 
forming activity in planar lipid bilayers but has a strong anthelmintic activity. The effects of 
PF1022A, SJB1822 and PF1022-001 on the spike potentials of A. suum muscle cells were 
investigated. It was shown that characteristic irregular potential spikes occurring in these cells 
were suppressed by a five hour incubation with PF1022A and SJB1822. PF1022-001 on the 
other hand had no effect on spike activity. Based on these observations it appears that it is not 
a pore forming activity but a more specific action that is required for anthelmintic activity 
(GeBner et al., 1996). The following section discusses the effects that emodepside has on 
neuromuscular transmission.
GABA-ergic effects of Cyclo-octadepsipeptides: The mechanism of action of PF1022A has 
been examined neuropharmacologically using Angiostrongylus cantonesis, and a variety of 
pharmacological agents (Terada, 1992). Paralysis of A. cantonesis by PF1022A was shown to 
be partially reversed by the action of GABA-ergic antagonists such as bicuculline and 
picrotoxin. This indicated that PF1022A might cause paralysis through stimulation of GABA 
release and/or by enhancing post-synaptic GABA effects. The effect of N-methylcytisine, 
which causes ACh release, was to reverse PF1022A-induced paralysis when applied with 
GABA-ergic antagonists. Additionally, the spasmogenic effects of N-methylcytisine and 
eserine (an ACh esterase inhibitor) in the presence of GABA-ergic antagonists are inhibited 
by PF1022A. This suggests that PF1022A causes a decrease in ACh effects. Terada et al 
(1992) suggest that PF1022A produces an inhibition of the cholinergic system whilst 
synergistically stimulating the GABA-ergic mechanism. Alternatively, these results may be 
explained by a general inhibitory effect of PF1022A. A decrease in GABA-ergic activity and 
an increase in cholinergic activity would both counteract a general inhibitory effect of 
PF1022A on nematode muscle. 
Chen et al (1996) also suggested that GABA receptors in the muscle of A. suum play a role in 
the mechanism of action of PF1022A. In these experiments, membrane protein was prepared 
from the homogenate of somatic muscle cells. PF1022A was shown to displace [2,3-3H(N)]-
GABA and [methyl-3H] bicuculline (an antagonist of mammalian GABAA receptors) in a 
concentration-dependent way. However, these results may have been misinterpreted as 
bicuculline has been shown not to antagonize A. suum GABAA receptors (Walker et al 1992). 
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Willson et al (2003) investigated the effect of emodepside at the neuromuscular junction, in 
the parasitic nematode A. suum. In these experiments, tension measurements of the dorsal 
muscle strip (DMS) and sharp electrode recordings from individual muscle cells were 
performed. 10 μM emodepside was shown to cause a relaxation of basal tension of the DMS. 
When the DMS was pre-treated with 30 μM ACh, causing rapid contraction, emodepside (1-
10 μM) caused a time-dependent reduction in the amplitude of the contraction. To investigate 
the emodepside-induced relaxation, Willson et al. (2003) investigated the effects of the 
inhibitory neurotransmitters GABA and neuropeptide PF2. In contrast to the slow and partial 
relaxation caused by emodepside, GABA caused a rapid and complete relaxation (ie. basal 
level of tension). Neuropeptide PF2, on the other hand, caused slow and incomplete 
relaxation, similar to that of emodepside. 
To investigate if these effects of emodepside were through a direct action on the muscle or via 
neurotransmitter release, experiments were conducted using a denervated DMS. The response 
to ACh of a denervated DMS preparation was not significantly inhibited by 10 μM 
emodepside but neuropeptide PF2 continued to inhibit it, suggesting that emodepside’s mode 
of action involves neurotransmitter release. The sharp electrode recordings from the muscle 
cells showed that emodepside caused a slow and irreversible hyperpolarisation. This 
hyperpolarisation was reduced with the removal of calcium (Ca2+), and was not observed in 
the presence of 4-aminopyridine (4-AP) and tetraethylammonium (TEA), both potassium (K+) 
channel blockers. These results are consistent with a role for Ca2+-dependent neurotransmitter 
release in the mechanism of emodepside, or alternatively with the requirement for Ca2+ for the 
activation of a current on the muscle membrane e.g. a Ca2+-dependent voltage-activated K+
channel.
Latrophilin receptors: α-Latrotoxin (αLTX) is a component of the venom of Lactrodectus 
spiders, the most common of which is the black widow spider (Frontali et al 1976). It was 
observed that α-Latrotoxin depleted nerve terminal of vesicles at the frog neuromuscular 
junction (Frontali et al 1976).  The effect of this venom is to cause global neurotransmitter 
release. A component of the mechanism of action of αLTX is through the formation of pores 
in cell membranes (Lui and Misler 1998, Orlova et al 2000), through which cations flow, 
resulting in depolarisation and the release of synaptic vesicles. Part of αLTX’s effects are 
mediated by receptors. αLTX interacts with two distinct membrane proteins, neurexin and 
latrophilin. Neurexin is a neuron specific protein that binds αLTX only in the presence of 
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calcium. They are thought to function as cell adhesion molecules in the synaptic cleft. The 
Drosophila neurexin mutant has been shown to be defective in synapse formation (Zeng et al
2007). Neurexin has been shown to bind to another cell adhesion molecule known as 
neuroligin, bridging the synaptic cleft (Levinson and El-Husseini 2007). The role of neurexin 
with regard to αLTX is thought to be one of anchoring it in the cell membrane (Bittner 2000). 
Latrophilin receptors are G-protein-coupled receptors (GPCR) (Krasnopernov et al 1999). 
Binding of αLTX to latrophilin is thought to result in activation of the GPCR and a pathway 
resulting in neurotransmitter release, this process is calcium independent.
Volynski et al (2000) demonstrated a mechanism of αLTX-induced neurotransmitter release 
independent of its pore forming activity. They performed experiments in which a non pore 
forming mutant of αLTX, αLTXN4C, was used. It was demonstrated to be non pore forming 
through whole cell recordings in COS7 cells expressing exogenous latrophilin. αLTX caused 
large inward currents but no current was observed with αLTXN4C. Binding levels of αLTX 
and αLTXN4C cannot account for these differences as it was shown, through Western blotting, 
that binding levels are similar. It was also demonstrated that αLTXN4C was unable to form 
tetramers but αLTXWT was. Tetrameric αLTX is thought to have the ability to form pores in 
the membrane, whereas monomeric and lower oligomeric forms are not. Volynski et al (2000) 
showed that application of αLTXN4C to rat synaptosomes loaded with [14C]-glutamate induced 
transmitter release. To check this release was not due to the presence of a small number of 
pores formed by αLTXN4C, La2+, an effective blocker of αLTX pores was added. The amount 
of [C14]-glutamate release was not significantly different. The effect of La2+ on αLTXWT
treated synaptosomes was to reduce the level of [C14]-glutamate release to levels seen using 
αLTXN4C. This demonstrates that αLTX has the ability to induce neurotransmitter release 
through a mechanism other than through the formation of pores in the membrane.
Saeger et al (2001b) identified a H. contortus latrophilin receptor HC110-R as a target for 
emodepside. A cDNA expression library was constructed from H. contortus using λZAPII. 
Nitrocellulose filters were incubated with a PF1022A-keyhole limpet haemocyanin (KLH) 
conjugate prior to incubation with an anti PF1022A-KLH antibody. Finally, incubation with a 
secondary antibody was conducted for detection. Sequencing of cDNA resulted in the 
identification of a 3539 bp cDNA sequence encoding an orphan seven transmembrane 
receptor. This was termed HC110-R, the structure of which is shown in figure 1.07. The 
binding of emodepside was shown to occur particularly in the 54 kDa amino-terminal region 
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of HC110-R. This was demonstrated through expression of the 54 kDa amino-terminal region 
in E. coli followed by poly-acrylamide gel electrophoresis and Western blot analysis. 
Homologues of HC110-R were identified in C. elegans through database and phylogenetic 
analysis. There are two latrophilin-like receptors in C. elegans: lat-1 (B0457.1) and lat-2
(B0266.2). LAT-1 has 47% amino acid identity with HC110-R. LAT-2 has homology with 
HC110-R in the galactose binding lectin domain (22% identity), the hormone receptor domain 
(19% identity) and the G-protein-coupled receptor proteolytic site and seven transmembrane 
domains (39% identity). These regions are highlighted in figure 1.07. HC110-R has an overall 
identity of 20% with LAT-2. LAT-2 has homology with LAT-1 in the galactose binding lectin 
domain (22% identity), the hormone receptor domain (22% identity) and the G-protein-
coupled proteolytic site and seven transmembrane domains (38% identity). Overall, LAT-1 
has 20% identity with LAT-2. Although the identity between these G-protein-coupled
receptors is relatively low, the C. elegans latrophilin receptors, LAT-1 and LAT-2, belong to 
the same class and sub-class of G-protein coupled receptors. They belong to the class of G-
protein-coupled receptors known as the secretin family (family B), and to the sub-class known 
as the LNB-7TM (B2) (Foord et al 2002). The B2 sub-class differs from other G-protein-
coupled receptors in that they have a large amino terminal region that can be cleaved at the G-
protein-coupled receptor proteolytic site. Of the G-protein-coupled receptors in C. elegans,
only three fall into the B2 family. LAT-1 and LAT-2 are most closely related. The third, 
F15B9.7, is more distantly related (Harmar, 2001).
Figure 1.07. Model of HC110R in the plasma membrane. The proposed binding region for 
α-LTX and PF1022A are marked. The conserved galactose binding lectin domain, hormone 
receptor domain and G-protein proteolytic site domain are highlight. Emodepside binding 
occurs in the amino terminal region. (Created using NCBI conserved domain search tool / 
adapted from Saeger et al 2001).
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Using fluorescence imaging techniques, Saeger et al (2001) demonstrated that α-LTX was 
able to induce an influx of Ca2+ in HEK293 cells transformed with HC110-R. PF1022-001 
and emodepside did not cause an influx of Ca2+ but did antagonise the effect of LTX on Ca2+
influx.
A series of experiments employing gene knock down in components of a hypothesized vesicle 
release pathway in C. elegans indicate that emodepside causes release of neurotransmitters, 
resulting in paralysis (Willson et al 2004). Willson et al (2004) investigated the role of 
latrophilin receptors in emodepside’s mode of action using the EPG technique. To determine 
whether the latrophilin receptor was involved in the potent effect of emodepside on the C. 
elegans pharynx, RNA interference (RNAi) was used to knock down the lat-1 gene. The 
pharynxes of the lat-1 RNAi treated C. elegans were shown to be resistant to concentrations 
of up to 100 nM emodepside. RNAi of lat-1 also led to a reduction in sensitivity to 
emodepside on locomotion.  RNAi of lat-2 lead to a reduction in sensitivity to emodepside on 
locomotion and a slight reduction in sensitivity to its effects on pharyngeal pumping (Willson 
et al 2004, Amliwala 2005).
The expression pattern of lat-1 was also examined. This was done using a lat-1::DsRed2 
reporter construct. In larval stages, staining was most prominent in the muscle. In adult 
worms, expression was predominantly in the anterior neurons, both pharyngeal and extra-
pharyngeal. This suggests that the role that the LAT-1 receptor plays in emodepside’s mode 
of action is neuronal in adult worms (Willson et al., 2004b). Willson et al (2004) went on to 
screen several mutant strains for emodepside resistance in order to investigate the possibility 
of emodepside’s involvement in latrophilin mediated neurotransmitter release. 
LAT-1 is a G-protein coupled receptor. The G-protein subunit Gαq has been shown to have a 
role in the activation of pharyngeal pumping and locomotion in C. elegans (Brundage et al
1996). The C. elegans Gαq, egl-30, activates phospholipase C when expressed in COS-7 
cells. The C. elegans G-protein subunit Gαo, goa-1, appears to negatively regulate synaptic 
transmission. goa-1 loss of function mutants have hyperactive locomotion and egg laying. 
Genetic analysis showed that Gαo negatively regulates Gαq (Miller et al 1999). Figure 1.08 
shows a simplified diagram illustrating the role of the G-protein subunits Gαq and Gαo in 
neurotransmitter release. Activation of Gαq results in an increase in diacylglycerol (DAG). 
Gαq activates PLC-β which hydrolyses phosphatidylinositol-4,5-bisphosphate (PIP2) to 
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inositol-1,4,5-triphosphate (IP3) and DAG. DAG then binds to the UNC-13, part of the 
synaptic vesicle release machinery that is responsible for vesicle priming (Hurley et al 1997). 
Binding of DAG to UNC-13 is thought to facilitate neurotransmitter release in C. elegans 
(Lackner et al 1999). Activation of Gαo results in a decrease in DAG. Gαo activates DAG 
kinase, which converts DAG to phosphatidic acid. Reduced DAG binding to UNC-13 would 
be expected to reduce neurotransmitter release. The role of Gαq, Gαo, PLCβ and UNC-13 in 
emodepside’s mode of action were investigated (Willson et al 2004).
Figure 1.08. G-protein coupled receptor regulation of neurotransmitter release. (Adapted 
from Bastiani and Mendel 2006).
Reduction-of-function Gαq mutant egl-30(ad806) showed reduced sensitivity to emodepside 
and a gain-of-function mutant egl-30(tg26) showed increased sensitivity on both pharyngeal 
pumping and locomotion. Gαo reduction-of-function mutant goa-1(n1134) showed increased 
sensitivity to emodepside both in pharyngeal pumping and locomotion (Willson et al 2004). 
PLC-β reduction-of-function mutants egl-8(md1971) and egl-8(n488) were shown to be less 
sensitive to emodepside’s effects on pharyngeal pumping and on locomotion. Two unc-13 
reduction of function alleles, s69 and e1091, showed reduced sensitivity to emodepside. 
These results support the hypothesis that emodepside binds to latrophilin to activate Gαq. Gαq 
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activates PLC-β resulting in an increase in the production of DAG. Binding of DAG to UNC-
13 results in neurotransmitter release. It is proposed that this release of neurotransmitter 
results in the paralytic effects of emodepside (Willson et al., 2004a), (Amliwala K et al., 
2004). Figure 1.09 shows the proposed mechanism of action of emodepside.
A mechanism of emodepside-induced neurotransmitter release is supported by studies using 
the fluorescent endocytotic marker FM4-64 (Willson et al 2004). FM4-64 is amphiphilic and 
is believed to be unable  cross the cell membrane bilayer. It can become incorporated into 
cells during endocytosis. Dissected pharynxes were incubated with FM4-64. FM4-64 was 
found to localize in neuronal puncta, which is consistent with its presence in synaptic regions 
of the pharyngeal neurons. Vehicle control experiments showed stable fluorescence for up to 
30 minutes, whereas addition of 100 nM emodepside caused loss of fluorescence over a 10 
minute period. This loss of fluorescence is though to reflect emodepside-induced exocytosis 
(Willson et al 2004).
Figure 1.09. Proposed mechanism of action of emodepside. It has been proposed the 
emodepside binds to the C. elegans latrophilin receptor (LAT-1) causing activation of Gqα. 
Gqα activates PLCβ which converts PIP2 to IP3 and DAG. DAG binds to UNC-13 and causes 
neurotransmitter release. (after Willson et al 2004).
However, some unresolved issues remain with regard to this mechanism. Although 
emodepside has been shown to bind HC110R, it has not been shown to bind to either of the C. 
elegans latrophilin homologues. Also, the low level of resistance to emodepside observed 
emodepside
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with RNA interference of the latrophilin receptors suggests that there may be more to the 
mechanism of action of emodepside. It would be expected that knocking out the emodepside 
receptor would result in a high level of resistance. The lack of this high level resistance may 
be explained by incomplete knock down by the RNA interference or it may be due to a 
functional redundancy between lat-1 and lat-2.
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1.17 BK channels
Amliwala (2005) conducted a mutagenesis screen in C. elegans to look for high level 
emodepside resistant worms. Mapping and sequencing led to the identification of mutations in 
the slo-1 gene. SLO-1 is a large conductance (BK) voltage-sensitive calcium-gated potassium 
channel. 
BK channels (voltage sensitive calcium gated): These channels have a  variety of names, 
including Maxi K channels, BK channels, SLO channels (slowpoke) but will be referred to as 
BK channels. They consist of a tetramer of α subunits that create a selective pore in the 
membrane. The α subunits have domains involved in voltage and calcium gating of the 
channel. The first BK channel gene to be identified was the Drosophila melanogaster slo (or 
slowpoke). The D. melanogaster slo gene mutant was generated through random mutagenesis 
and selected from a screen for temperature sensitivity. Intracellular recording from the dorsal 
longitudinal flight muscles revealed lengthened action potentials and reduction in the initial 
outward current. This implicated the BK channel in early repolarisation of muscle action 
potentials (Elkins et al 1986). The D. melanogaster BK channel genomic DNA and cDNA 
sequence were isolated and sequenced by Atkinson et al (1991). Hydropathy analysis of the 
amino acid sequence revealed a seven transmembrane region at the N-terminal. Sequence 
comparison with voltage-gated potassium channels showed homology with the fourth (S4) 
transmembrane domain. This region is thought to act as a voltage sensor (Papazian et al 
1991). There is also strong homology with voltage gated potassium channels in the region 
between transmembrane domains S5 and S6. This forms the ion pore (MacKinnon and Yellen 
1990). The D. melanogaster BK channel sequence is distinct from other potassium channel 
sequences other than in these two regions.
BK channels have several key domains. These include, seven transmembrane domains (S0 to 
S6), the S4 voltage sensor, the pore domain (S5/S6 linker), regulators of potassium 
conductance domains (RCK1 and RCK2) and the calcium bowl. Figure 1.10 shows a single 
channel α subunit with these key regions highlighted. 
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Figure 1.10. BK channel α subunit. Key features of the α subunit are highlighted. The S4 
voltage sensor controls voltage gating. The RCK1, RCK2 and calcium bowl control calcium 
regulation. The P-loop forms the pore through which potassium ions pass when a tetramer of 
α subunits assembles. (After Salkoff et al 2006, Wang et al 2001).
Voltage sensor and pore domain: The seven transmembrane domain includes the voltage 
sensor and the pore domain. The major difference compared to voltage-gated potassium 
channels is the presence of an extra transmembrane domain, S0. The presence of the S0 
domain places the N-terminus outside the cell. Meera et al (1997) demonstrated that 
antibodies targeted against epitope tags introduced into the amino terminal of the human BK 
channel KCNMA1 were able to bind in non- permeablised cells, suggesting the N-terminus is 
extracellular. The S4 voltage sensor consists of a sequence repeat of one positively charged 
amino acid (arginine or lysine) followed by two hydrophobic amino acids. The idea that this 
region acts as a voltage sensor is supported by the fact that mutations within the S4 domain 
alter voltage sensitivity (Lichtinghagen et al 1990). Direct evidence for a role of this domain 
in voltage sensing came from experiments that employed fluorescent probes attached to 
different positions in S4 domain. Changes in the fluorescence of these probes correlated with 
channel gating, suggesting a change in confirmation (Larrson et al 1996). The pore domain is 
also encompassed in the seven transmembrane domain. This pore domain sits between 
transmembrane domains S5 and S6. This region is highly conserved across all families of 
potassium channels and is responsible for the channel’s ion selectivity. Crystallography has 
been used to determine the structure of this region in the Kcsa channel (a homologue of the 
eukaryotic voltage-gated potassium channel) from  Streptomyces lividans (Doyle et al 1998,
Zhou and MacKinnon 2003, Nishida et al 2007). In the tetramer of α subunits, four pore 
domains come together to form a selective filter through which potassium ions can pass. 
Potassium ions approach the selectivity filter in a hydrated state but pass through it un-
hydrated. The selectivity filter is lined with carbonyl oxygen atoms, the orientation of which 
mimic the hydration of potassium ions. This allows for potassium ions to selectively pass 
through the channel. The single channel conductance of BK channels (~250 pS) is much 
S0 S1 S2 S3 S5S4 S6
NH2
COOH
P loop
+
+
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greater than that of other potassium channels, yet they share the same selectivity filter. It is 
thought that the flux of potassium ions is influenced by a ring of negatively charged residues 
in the vestibule of the channel. These residues may cause an increase in the local potassium 
concentration, resulting in an increased availability of potassium ions for transit through the 
channel (Salkoff et al 2006).
Calcium sensing domains: The intracellular C-terminal region of BK channels contains 
regions involved in calcium gating. The main sites of calcium sensing are known as the 
calcium bowl and the regulator of conductance for potassium domains, RCK1 and RCK2. The 
calcium bowl was implicated in calcium sensing through the analysis of currents in BK 
channels containing mutations in this region. Deletion of a stretch of three aspartate residues 
results in a reduced calcium sensitivity of the channel, requiring a higher concentration of 
calcium for activation (Schreiber and Salkoff 1997). It is now thought that the calcium bowl 
acts to inhibit voltage activation of BK channels in the absence of calcium. Binding of 
calcium to the calcium bowl overcomes this inhibition (Schreiber et al 1999). This was 
demonstrated through the analysis of currents in BK channel chimeras. Chimeras were 
generated in which portions of the calcium bowl in BK channels were replaced with sequence 
from a non-calcium-activated homologous channel. Chimera channels lacking all endogenous 
calcium bowl sequence were voltage sensitive but did not require calcium for activation. 
Calcium sensitivity was restored in chimera channels containing specific regions of the 
calcium bowl, suggesting a role in inhibition of voltage activation in the absence of calcium 
(Salkoff 2006). 
The RCK1 domain has a role in calcium sensing. Mutations affecting the RCK domains were 
examined by patch clamp analysis of BK channel currents in Xenopus oocytes. Mutations of 
conserved residues in the RCK1 domain (D362A and D367A) were found to reduce calcium 
sensitivity (Xia et al 2002). A triple mutant of D362A, D367A and a mutation abolishing 
calcium bowl function lack almost all calcium sensitivity, suggesting these two regions 
account for the majority of calcium sensing function of BK channels. Analysis of the crystal 
structure of the RCK domains of the MthK channels from bacteria Methanobacterium 
thermoautotrophicum revealed how these RCK domains link to channel gating. In the 
tetramer of subunits it is proposed that the RCK domains form an intracellular gating ring. On 
the binding of calcium between adjacent RCK domains in the tetramer, there is a widening of 
the gating ring. This widening causes the channel to open through a pulling of the linkers that 
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connect the gating ring to the channel (Jiang et al 2002). Figure 1.11 shows a cartoon of how 
the BK channel is envisaged based on these studies.
Figure 1.11. BK channel activation via RCK domains. Each of the four BK channel α 
subunits are coloured (red, green, blue and purple). Binding of calcium between adjacent 
RCK domains results in a conformational change that pulls on the linkers and opens the 
channel. (After Salkoff et al 2006).
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1.18 C. elegans BK channels
slo-1: It has been demonstrated that slo-1 is involved in the regulation of neurotransmitter 
release (Wang et al 2001). slo-1 mutants were isolated based on their ability to relieve the 
block in neurotransmitter release of an unc-64(e246) syntaxin reduction-of-function mutant. 
The unc-64(e246) mutant has defects in its locomotion, only moving briefly when prodded. 
They are described as lethargic (Saifee et al 1998). unc-64 are resistant to the acetylcholine 
esterase inhibitor aldicarb but have wild type sensitivity to the nicotinic agonist levamisole. 
Aldicarb resistance is indicative of a reduction in ACh release. Aldicarb blocks the hydrolysis 
of ACh by ACh esterase resulting in a build up of ACh and paralysis. Reduced ACh release
therefore results in a reduction in sensitivity to aldicarb. No change in levamisole sensitivity 
indicates that that this is not a post-synaptic effect. slo-1 alleles were found to suppress the 
lethargic phenotype of unc-64(e246), indicating slo-1 also has a role in regulating 
neurotransmitter release or mediating its response. slo-1(js379) was able to rescue the aldicarb 
resistance of unc-64(e246) and defects in pharyngeal pumping. EPG traces for unc-64(e246) 
show reduced inhibitory activity, which can be rescued by slo-1(js379).  
SLO-1 potentially has a role in either neurons or muscle in suppressing unc-64 phenotypes. 
Wang et al (2001) looked at the expression pattern of slo-1 using both gfp reporter constructs 
and a polyclonal antibody with specificity for the calcium bowl. Both reporter construct and 
antibody showed expression in the nerve ring, nerve cords, body wall muscle and vulval 
muscle. Tissue specific expression of wild type slo-1 in an unc-64(e246), slo-1(js379) double 
mutant was used to determine the tissue in which expression of slo-1 restores the unc-64 
lethargic phenotype. Expression of wild type slo-1 in neurons, but not body wall muscle, 
restored the lethargic phenotype in the double mutant. This indicates SLO-1 acts to regulate 
neurotansmitter release, rather than the response of the muscle to neurotransmitter release. 
The effects of slo-1 and unc-64 mutations on neurotransmitter release were also assessed by 
recording excitatory post synaptic currents (EPSC) from the body wall muscle using whole 
cell patch clamp. The unc-64(e246), slo-1(js379) was found to have an increased duration of 
EPSC as well as an increased frequency of mEPSC compared to unc-64(e246). This supports 
the idea that SLO-1 acts as a brake to neurotransmitter release. From this screen, several 
genes previously implicated in the regulation of neurotransmitter release were identified, as 
well as the potassium channel SLO-1. Interestingly, only SLO-1 potassium channels were 
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pulled out of the screen, suggesting that it differs from other K+ channels in its ability to 
regulate neurotransmitter release. The activity of BK channels has been shown to be closely 
coupled to voltage-gated Ca2+ channels (Marrion and Travalin 1998). It is thought that this 
close interaction may be the mechanism by which SLO-1 K+ channels regulate transmitter 
release.
The SLO-1 BK channel has also been shown to be important in the behavioural response of 
C. elegans to ethanol (Davies et al 2003). Ethanol acts to inhibit locomotion, egg laying, 
pharyngeal pumping and development (Davies et al 2003, Mitchell et al 2007). Thirteen 
ethanol resistant strains, which mapped to the slo-1 locus, were identified through a 
mutagenesis screen. These mutants were resistant to ethanol’s effects on locomotion and egg 
laying. Davies et al. performed rescue experiments using slo-1 constructs with neuronal and 
muscle promoters to determine if ethanol resistance was due to lack of expression in neurons 
or body wall muscle. Expression of SLO-1 in neurons was shown to fully restore ethanol 
sensitivity in mutant slo-1(js118). Expression of SLO-1 in the muscle of slo-1(js118) caused 
no significant restoration of ethanol sensitivity. It was also shown that the effect of ethanol on 
SLO-1 was specific, rather than an indirect suppression of the depressive effects by 
hyperactive neurotransmission. In vivo patch clamp recordings identified a SLO-1-dependent 
current in C. elegans neurons (CEP). Ethanol was shown to selectively and reversibly 
increase the amplitude of the outward-rectifying current in neurons in N2 animals. This action 
should in turn inhibit neuronal excitability and reduce transmitter release. Ethanol had no 
effect on currents in slo-1 mutants, indicating a direct mechanism of ethanol resistance. In 
addition, SLO-1 gain-of-function mutants displayed depression of locomotion and egg laying 
frequency in a similar way to that of ethanol treated worms. This similarity suggests that 
SLO-1 activation is a major cause of ethanol intoxication in C. elegans (Davies et al., 2003).
Figure 1.12 illustrates a mechanism by which ethanol may have its intoxicating effect in C. 
elegans. An action potential arrives at the nerve terminal. There is a Ca2+ influx through 
voltage-dependent Ca2+ channels, which stimulates transmitter release. The increase in the 
Ca2+ concentration in the nerve terminal increases the probability of the SLO-1 channel being 
in the open confirmation. There is an outward flow of K+, and repolarisation of the cell, which 
produces a feedback inhibition on the voltage-dependent Ca2+ channel, thereby reducing 
neurotransmitter release. Ethanol potentiates SLO-1 activity, leading to an inhibition of 
transmitter release (Crowder, 2004). However, the ethanol sensitivity of slo-1(js379) has been 
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shown not to be significantly different from that of N2 (personal communication with Phillipa 
Mitchell). Subtle differences in assay techniques may account for these observations or 
genetic differences between slo-1(js379) and the slo-1 alleles isolated in the ethanol resistance 
screen may exist. It is possible that mutations tightly linked to slo-1 may be required in 
combination with mutations in slo-1 to cause ethanol resistance. 
Figure 1.12. Ethanol activation of SLO-1. Ethanol is thought to activate SLO-1 either 
directly or indirectly activate SLO-1. This results in potentiation of feedback inhibition on the 
voltage-dependent calcium channels (VDCC) and a reduction in neurotransmitter release. 
(from Davies et al 2003).
The BK channel SLO-1 also has a role in mediating the effects of volatile anaesthetics. The 
slo-1(js380) loss-of-function mutant is resistant to the effects of volatile anaesthetics (Hawalsi 
et al 2004). The mechanism by which slo-1(js380) confers resistance is thought to be indirect. 
It has been postulated that an increase in the level of ACh, as described by Wang et al (2001), 
acts to counteract the effect of the volatile anaesthetics.
SLO-1 has also been shown to have a role in regulating muscle cell excitability. SLO-1 in the 
body wall muscle of C. elegans acts to reduce cell excitability. Carre-Pierrat et al (2006) 
identified hypercontraction and hyperactive head bending phenotypes in slo-1 mutants. These 
mutants were also found to cause muscle degeneration when in a hlh-1 sensitised background. 
hlh-1 is a transcription factor involved in control of skeletal muscle myogenesis (Chen et al
1994). All of these phenotypes could be rescued by the expression of slo-1(+) in the body 
wall muscle but not in the neurons.
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slo-2: The second of the C. elegans BK channel homologues is encoded by the gene slo-2. 
The overall sequence identity between SLO-1 and SLO-2 is relatively low at 10% (Lim et al 
1999). The SLO-1 and SLO-2 channels are, however, structurally similar in that they both 
consist of a multi-transmembrane domain and a large cytoplasmic C-terminal domain. The 
membrane topology of SLO-2, predicted by hydropathy analysis, is like that of SLO-1, except 
for the lack of a S0 transmembrane domain in SLO-2. The most striking differences between 
SLO-1 and SLO-2 are the absence of several features in SLO-2 that are critical to normal 
SLO-1 function. The S4 domain of SLO-2 lacks the sequence of positively charged amino 
acids that comprise the voltage sensor in SLO-1. The calcium sensing region in SLO-1 is 
known as the calcium bowl and consists of a series of negatively charged residues. It is absent
in SLO-2 and replaced by a series of positively charged residues (Lim et al 1999, Yuan et al 
2000). The absence of these domains indicates that the mechanism of activation of SLO-2 
must differ from that of SLO-1. SLO-2 has a mammalian homologue known as Slack. The rat 
homologue of SLO-2 has an identity of 35% with C. elegans SLO-1 (Lim et al 1999), much 
higher than the percentage identity between C. elegans SLO-1 and SLO-2. SLO-2 channels 
have been identified in mammalian cardiomyocytes (Kameyama et al 1984) and neurons 
(Dryer 1994). They have been shown to be activated by sodium and are thought to be 
important under ischaemic conditions (Kameyama et al 1984). Factors involved in the 
activation of C. elegans SLO-2 have been studied by Yuan et al (2000), who found these 
channels to be calcium and chloride sensitive. With SLO-2 expressed in Xenopus oocytes, 
large currents could not be evoked in the absence of either calcium or chloride. However, in 
the presence of both calcium (100 M) and chloride (50 mM), macroscopic currents were 
observed. These currents were also found to be voltage dependent, although the source of this 
dependence is unknown (Yuan et al 2000). Yuan et al (2003) further studied the sensitivity of 
the mammalian SLO-2, rSLO-2. As well as being sensitive to sodium (Dryer et al 1994), 
mammalian rSLO-2 has been shown to have sensitivity to chloride (Yuan et al 2003). The 
rSLO-2 chloride dependence was only seen in the presence of sodium, similar to the situation 
observed in C. elegans SLO-2 (Yuan et al 2000). The observed calcium dependence of C. 
elegans SLO-2, rather than sodium, is likely to reflect the greater reliance on voltage 
dependent calcium channels for inward currents.
It is thought that the mechanism for chloride sensing may be located in a region of SLO-2 that 
is equivalent to the SLO-1 calcium bowl. This region of slo-2 contains many positively 
charged residues, rather than the series of negatively charged residues present in the SLO-1 
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calcium bowl. Mutation of these positively charged residues to negative or neutral residues 
results in either a reduction or loss of chloride sensitivity, supporting the theory that this 
region is important for chloride sensing (Yuan et al 2003). 
SLO-2 has been shown to be expressed in the body wall muscle, vulval muscle, nerve ring 
and motor neurons through the use of a slo-2:gfp fusion construct (Yuan et al 2000). This 
expression pattern is comparable to that of slo-1. The similar expression patterns of slo-1 and 
slo-2 raise the possibility that the two subunits may have overlapping function or form 
heteromultimers. This was investigated using a dominant negative slo-2 mutant expressed in 
Xenopus oocytes. Co-expression of N2 slo-2 and the slo-2 mutant resulted in a thirteen fold 
reduction in the amplitude of currents compared with N2 slo-2 alone. Co-expression of N2
slo-1 and the slo-2 mutant resulted in a five fold reduction in the amplitude of currents 
compared with N2 slo-1 alone. The dominant negative effect of the slo-2 mutant on slo-1
suggests that the formation of heteromultimers is occurring.
The role of SLO-2 in vivo has been investigated by Santi et al (2003). Through the use of 
deletion mutants and RNAi, it was demonstrated that, under normal physiological conditions, 
the majority of the outward current in body wall muscle cells was made up from the gene 
products of the voltage gated potassium channels shl-1 and shk-1. No SLO-2 component of 
the outward current was identified with intracellular calcium and chloride at physiological 
concentration (10 nM and 4 mM, respectively). However, under conditions where 
intracellular calcium and chloride were raised above physiological concentrations (200 M 
and 128 mM, respectively), a greatly increased outward current was observed. SLO-2 
represented 87% of the total outward current (Santi et al 2003). It may be the case that SLO-2 
only becomes active under such conditions, which can occur during hypoxia, remaining 
dormant under normal conditions.
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1.19 The role of BK channels in cell excitability
BK channels are strongly implicated in the regulation of cell excitability. The studies of slo-1
mutants in C. elegans strongly suggest that it acts to put a brake on neurotransmitter release 
(Wang et al 2001) as well as reducing body wall muscle cell excitability (Carre-Pierrat et al 
2006). However, voltage-sensitive calcium-activated BK channels have been implicated in 
both increasing and decreasing cell excitability and neurotransmitter release. 
Warbington et al (1996) performed electrophysiological experiments in which they measured 
excitatory junctional potentials (EJPs) and excitatory junctional current (EJCs) from D. 
melanogaster abdominal muscle cells. BK mutants were shown to have decreased EJPs size at 
external Ca2+ concentrations ranging between 0.1 and 1.0 mM. The largest EJP inhibition 
(70%) was seen at 0.15 mM. This reduced EJP size suggests that a reduction in transmitter 
release has occurred. At higher concentrations of Ca2+ it was shown that the slo-1 EJPs had an 
increased duration. The broadening of the EJP can either be due to presynaptic effects in 
which there is a slower repolarisation, leading to an increased duration of Ca2+ influx. 
Alternatively it may be due to a post-synaptic delay in repolarisation of the EJP. Warbington
et al tested this by looking at EJCs, which would be expected to be broader if the slo-1
mutation acts exclusively presynaptically, or the same if acting exclusively postsynaptically 
(with the muscle cell held under voltage clamp to prevent activation). The EJC was shown not 
to be broader, suggesting that the broadening of the EJP that occurs at higher Ca2+
concentrations is due to BK channel inactivity in the muscle. BK mutants were also shown to 
partially suppress increased transmitter release seen with application of 4-aminopyridine (4-
AP) and in shaker mutants as well as the enhanced effect of 4-AP in eag (ether a go go). The 
BK shaker double mutant was shown to have a six fold decrease in EJP amplitude compared 
with shaker alone. This study shows that mutation of BK confers a reduction in transmitter 
release, rather than an increase (Warbington et al 1996).
Xu et al (2005) have also provided evidence for SLO-1 having a function that facilitates 
transmitter release. In the salamander rod synapse light evoked EPSCs can be recorded. In the 
light, the rod hyperpolarizes, inhibiting glutamate release. In post-synaptic off bipolar and 
horizontal cells this results in a hyperpolarisation and in on bipolar cells this results in a 
depolarisation (Hensley et al 1993, Wu 1985). This mechanism is shown in figure 1.13. BK 
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channel block suppresses the amplitude of EPSC, suggesting there is a reduction in 
neurotransmitter release. This reduction in EPSC is not thought to reflect block of BK in post-
synaptic cells, which were held at –60 mV, therefore making activation of BK unlikely. Also, 
in the off bipolar and horizontal cells and on bipolar cells, changes in the dark holding 
currents had opposite polarities. I.e. BK block results in an increase in dark holding current in 
horizontal and off bipolar cells and a decrease in on bipolar cells. If the effect of BK block in 
post-synaptic cells was being recorded, the dark holding current would increases in all post-
synaptic cells. A possible mechanism by which transmitter release is reduced is that BK block 
reduces the light response of the rods. However, BK block had little effect on the light 
response of the rods, suggesting this is not the mechanism. BK block was found to suppress 
the inward calcium current in the rods. Xu et al (2005) therefore hypothesised that BK block 
was having a local effect at the rod synapse. They proposed a mechanism where by an 
increase in the local potassium concentration in the synapse, through activation of BK, 
resulted in activation of calcium channels and an increase in neurotransmitter release. The 
confined structure of the ribbon synapse is thought to limit the diffusion of potassium ions, 
allowing its accumulation. In isolated rods the calcium current was not suppressed, supporting 
this hypothesis.
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Figure 1.13. Salamander rod synapse. In the dark the rod is depolarised and releases 
glutamate. In the light the rod hyperpolarizes inhibiting glutamate release. Off bipolar (Off 
BP) and horizontal (H) cells depolarise in response to glutamate. On bipolar (On BP) 
hyperpolarize in response to glutamate. (After Hensley et al 1993, Wu 1985)
The fact that SLO-1 is required for emodepside sensitivity suggests that emodepside signals 
through SLO-1. Although there is evidence that knocking out slo-1 can result in a decreased 
transmitter release in certain cases (Warbington et al 1996 and Xu et al 2005), it seems likely 
that in C. elegans it results in an increase in transmitter release (Wang et al 2001). If this is 
the case then one would expect that the action of emodepside is to reduce transmitter release, 
contrary to the evidence produced by Willson et al (2004) which outlined a latrophilin 
signalling pathway resulting in transmitter release. Emodepside induces a flaccid paralysis in 
C. elegans. This is consistent with the role of SLO-1 in the C. elegans body wall muscle, 
which appears to be to reduce cell excitability (Carre-Pierrat et al 2006).
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1.20 Project aims
The overall aim of the project was to further understand the mode of action of emodepside, in 
particular, the relative role of latrophilin and SLO-1 in emodepside’s inhibitory effects on C. 
elegans locomotion. This was achieved through a number of inter-related objectives as 
follows: Amliwala (2005) demonstrated that targeting of lat-1 and lat-2 with RNAi resulted in 
a reduction in emodepside sensitivity. The suggestion is that LAT-1 and LAT-2 are receptors 
for emodepside. If all of emodepside’s effects are associated with these receptors, knock 
down of them would be expected to result in a high level of resistance. The level of resistance 
observed by Amliwala (2005) is not consistent with this. This could be due to an incomplete 
effect of the RNAi and/or could indicate that there is redundancy between lat-1 and lat-2. 
Alternatively it may indicate the presence of another mechanism by which emodepside acts, 
e.g. SLO-1. Available mutants of the lat-1 and lat-2 genes will be used to investigate the roles 
of these receptors in emodepside’s mode of action. A double lat-2, lat-1 mutant will be 
constructed in order to investigate the possibility of redundancy.
In order to investigate whether further genes regulate the response to emodepside, forward 
genetic screens were conducted to generate mutant C. elegans that have high level resistance 
to the effects of emodepside. The genes carrying mutations that confer resistance to 
emodepside would be characterised. 
To confirm the role of SLO-1 in emodepside’s mode of action and to more precisely define its 
role, expression of wild type slo-1 in a slo-1 mutant background will be used, as well as the 
use of complementation tests. The mechanism of slo-1 involvement will be investigated using 
tissue specific expression of wild type slo-1 in a slo-1 mutant background. Analysis of mutant 
phenotypes will be conducted in order to relate SLO-1 function to the level of emodepside 
resistance. Pharmacological studies will be conducted in order to investigate the effect that 
emodepside has on neurotransmitter release.
Finally, the project aims to investigate whether or not SLO-1 is an emodepside receptor. The 
potential effect of emodepside on BK channel currents will be investigated using a 
heterologous expression system and electrophysiological analysis. The C. elegans BK channel 
slo-1 and the human BK channel kcnma1 will be investigated.
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Chapter 2
Methods
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2.01 Nematode growth medium plates
C. elegans are maintained on nematode growth medium (NGM). NGM consists of 15g NaCl, 
12.5g peptone and 85g Agar per 5L H2O. This autoclaved solution is supplemented with 
sterile aqueous solutions of 1 M CaCl2 (5 ml), 1 M MgSO4 (5 ml), 1 M KPO4 (125 ml) and an 
ethanol solution of 5 mg/ml cholesterol (5ml) (Brenner 1974). Plates were poured using 
Jencons perimatic gp pump to a consistant volume (13 ml). Plates were dried for a minimum 
of 24 hours before seeding with 50 μl of a fresh E. coli OP50 culture. OP50 was cultured on 
NGM plates for minimum of 24 hours before use. Plates were stored at room temperature for 
up to two weeks before use.
2.02 C. elegans bacterial food source
The food source for C. elegans is E. coli OP50. E. coli OP50 were grown on 9 cm LB agar 
containing plates. To maintain the OP50, bacteria from the lawn were streaked onto fresh LB 
plates and grown overnight (~16 hours) at 37oC. Single colonies were then selected and 
grown in 10 ml of LB media overnight (~16 hours) at 37oC and 225 rpm in a platform shaker. 
2.03 Drug containing NGM plates
Drug-containing plates were made up fresh for each assay. 150 ml of NGM was prepared and 
cooled to 50oC in a water bath following autoclaving. Drugs were added to the warm liquid 
NGM. Serial dilutions of stock solutions were made before addition to NGM. 1 in 200 
dilutions of the stock solutions were made in NGM. Emodepside stock solutions were 100% 
ethanol, whereas all other stock solutions were aqueous. The 1 in 200 dilution of emodepside 
stock solutions would have given a 0.5 % (86 mM) ethanol concentration in the plate, not 
allowing for evaporation. Ethanol vehicle control plates were made in the same way as for 
emodepside-containing plates with the omission of emodepside. After addition of drug the 
media was mixed robustly to enable even distribution of the drug. 
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2.04 NGM ethanol concentration
Ethanol affects C. elegans behaviour (Morgan and Sedensky 1995, Davies et al 2003). For 
this reason the ethanol concentration of the emodepside-containing plates was tested using the 
“NAD-ADH Reagent Multiple Test Vial” kit from Sigma. This kit contains nicotinamide 
adenine dinucleotide (NAD) and alcohol dehydrogenase (ADH). ADH calalyses the following 
reaction.
ADH
Ethanol + NAD Acetaldehyde + NADH
The consequent increase in absorption at 340 nm due to the production of NADH is directly 
proportional to the ethanol concentration. The following reaction mixture was set up to 
generate a calibration curve (Table 2.01). NAD/ADH was dissolved in 0.5 M glycine buffer 
pH9.
5 M Glycine buffer pH9: 500 nM glycine, 1 M NaCl
Reagent Volume / 620 μl reaction
NAD / ADH (≥ 0.625 mM / ≥ 53 units/ml) 600 μl
Ethanol (5, 10, 20, 50 or 100 mM) 20 μl
Table 2.01. Reaction mixture for ethanol oxidation reaction.
The reaction was incubated at 25 oC for ten minutes. Absorbance was measured at 340 nm. A 
calibration curve was generated. Figure 2.01 shows the absorbance of NADH produced in a 
reaction with NAD and 5, 10, 20, 50 and 100 mM ethanol.
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Figure 2.01. Ethanol assay calibration curve for. Absorbance of NADH at 340 nm 
produced in ethanol oxidation reaction. Absorbance of NADH produced in a reaction with 
NAD and 5, 10, 20, 50 and 100 mM ethanol.
To test the concentration of ethanol in drug-containing NGM plates, chunks (~ 0.5g) of agar 
were sonicated in 1ml of H2O for 1 hour. This allows the ethanol in the agar to equilibrate 
with the H2O. A reaction with a sample of this H2O was set up and the absorbance measured. 
The average absorbance of three readings from three replicates was found to be 0.406. 
Reading off the curve, this equates to 13.9 mM ethanol. The concentration of ethanol in the 
agar was calculated to be 40 mM. This is below the concentration where effects of ethanol on 
locomotion become apparent (Davies et al 2003) and is substantially lower than the 86 mM 
that was added. Never-the-less, ethanol vehicle controls were included for all emodepside 
assays.
2.05 Emodepside solubility
Emodepside stocks are made up in ethanol due to its low solubility in aqueous solution. These 
are then diluted in M9, Dent’s saline or NGM to obtain emodepside at the required 
concentrations. Therefore, assays were conducted to test whether at assay concentrations, 
emodepside remains in aqueous solution or is held in a suspension. Spectrophotometry of 
emodepside in ethanol and aqueous solutions (0.5 % ethanol) at assay concentrations was 
conducted to determine which the case was. It was established that peak absorbance of 
emodepside is at 256 nm. Emodepside solutions were made up in triplicate. Using an 
Eppendorf BioPhotometer spectrophotometer, the absorbance of 10 μM emodepside in 100 % 
ethanol and aqueous solution (0.5 % ethanol) was measured. Solutions were then spun in 1.9 
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ml Eppendorf tubes at 16000 x g for 15 minutes. Solution was carefully removed from the top 
of the tube to avoid taking any undissolved emodepside. The absorbance was the measured, 
again (Figure 2.02.). The Eppendorf BioPhotometer spectrophotometer is limited to reading 
absorbance at 260, 280 and 320 nm. 
A) B)
Figure 2.02. Analysis of emodepside solubility. Spectrophotometric analysis of emodepside 
solubility in either 100 % ethanol or 0.5 % ethanol aqueous solution. A) Absorbance of 10 
μM emodepside in 100 % ethanol () and 10 μM emodepside in 0.5 % ethanol (). B)
Absorbance of 10 μM emodepside in 100 % ethanol () and 10 μM emodepside in 0.5 % 
ethanol () after a 15 minute spin at 16000 xg. Each point is the average of 9 readings (from 
3 samples)  SEM.
Absorbance at 260 nm is close to the peak absorbance of emodepside (256 nm). Absorbance 
of 10 μM emodepside at 260 nm is 0.364 when dissolved in 100 % ethanol and 0.145 when in 
0.5 % ethanol. This suggests there is less dissolved emodepside in the 0.5 % ethanol solution. 
After spinning at 16000 x g for 15 minutes the absorbance of emodepside in the 100% ethanol 
solution remained approximately the same, 0.379 at 260 nm. Absorbance in the 0.5 % ethanol 
solution dropped to 0.019 at 260 nm. This suggests that the emodepside precipitates in the 0.5 
% ethanol solution and is pelleted during the spin step. The absorbance of emodepside in the 
0.5 % ethanol solution at 280 nm and 320 nm appears to be higher than in the 100 % ethanol 
solution. This is probably pseudo-absorbance, resulting from light scattering due to the 
presence of insoluble particles. Indeed, absorbance at these wavelengths is greatly reduced 
after centrifugation, indicating these particles have been pelleted. Both batches of 
emodepside, MK400022 and KP00JFT, behaved identically in this assay.
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Due to the insolubility of emodepside in aqueous solutions at assay concentrations, plate 
assays are the most suitable way to investigate emodepside’s effects on locomotion. The set 
NGM will allow for even dispersal of emodepside throughout the plate.
2.06 Locomotion assays: Plate assay
As a measure of locomotion, the number of wave forms a worm traces out in a given time can 
be counted. The definition of a single body bend is the path traced out by a worm where the 
head, or tail depending on direction of travel, returns to the same point in the wave form from 
which it started. Body bends are counted from the head of the worm if it is moving forwards 
and the tail of the worm if it is moving backwards. The wave form traced out by the worm 
may vary in shape in different strains or with different treatments, but the same definition is 
applied for this study.
Locomotion was assayed on NGM agar plates. In these assays, worms at L4 stage were 
selected and exposed to drug-containing plates for 24 hours on food. Worms were then 
individually transferred to unseeded drug-containing plates for 1 minute. The purpose of this 
step is to deposit OP50 that adheres to the worm and prevent transfer of OP50 to the assay 
plate. The presence of food impacts on locomotion. Worms move more freely in the absence 
of food and this allows for shorter assay times. Finally worms were individually transferred to 
a drug-containing assay plate and left for 1 minute before body bend were counted for 1 
minute. At each step worms were transferred using 0.2 mm diameter pins to reduce the 
transfer of E. coli OP50.
Inter-assay variability in the rate of locomotion was observed. Inter-assay variability may 
arise due to slight variations in temperature at which the assay is conducted. Intra assay 
variability did not occur. All assays were therefore conducted in parallel with controls. The 
inter-assay variability and inter assay consistency is demonstrated in figure 2.03. This shows 
the rate of locomotion of N2 animals on 100 nM emodepside from assays conducted on A) 
separate days and B) in parallel. Each bar represents the average rate of locomotion of a 
population of worms from individual NGM plates.
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Figure 2.03. Inter-assay variability. A) The mean rate of locomotion of N2 worms on 100 
nM emodepside. Each bar represents an independent population assayed on different days. B) 
The mean rate of locomotion of N2 worms on 100 nM emodepside. Each bar represents an 
independent population assayed in parallel with each other. For each bar n≥7 +/- SEM.
2.07 Locomotion assays: Reversal assay
Worms move in a stereotyped fashion, forward movement being interspersed with reversals. 
When worms are removed from food the frequency of reversal increases. This increase in 
reversal is a foraging behavior (Gray and Bargmann 2005, Zhao et al 2003, Zheng et al
1999). Worms were assayed off food so that foraging behavior would be initiated and reversal 
frequency increased, thereby reducing the assay time required. Worms were selected at L4 
stage and kept on food for 24 hours. Worms were then individually transferred to an unseeded 
plate to reduce the amount of E. coli OP50 transferred to the assay plate. After 1 minute each 
worm was then transferred to an unseeded assay plate. After five minutes of acclimatization, 
the number of reversals the worm made in 1 minute was recorded. 
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2.08 Locomotion assays: Aldicarb assay
Aldicarb is an anticholinesterase (ACE) inhibitor. ACE metabolises ACh in the synaptic cleft 
to control the duration of response to ACh. Aldicarb blocks ACE, resulting in a build up of 
ACh and spastic paralysis of the muscle. Figure 2.04 illustrates this mechanism. The 
sensitivity of mutant or drug treated worms to aldicarb can be used to provide an indication of 
the level of ACh release (Miller et al 1996).
Figure 2.04. Aldicarb mechanism of action. Aldicarb inhibits ACE in the neuromuscular 
junction, preventing the break down of ACh. ACh continues to activate post-synaptic 
receptors, leading to spastic paralysis of the muscle.
To test aldicarb sensitivity, L4 worms were selected  24 hours prior to the assay. Fifteen 24 
hour post L4 worms were exposed to aldicarb on a seeded 0.5 mM aldicarb-containing plate. 
This was defined as a single trial. At 30 minute intervals the number of paralysed worms on 
the plate were recorded. Worms were defined as paralysed if a single prod with a platinum 
wire pick failed to elicit forward or backward movement. Paralysed worms were removed 
from the plate. All trials were done blind.
For experiments looking at the effect of emodepside on aldicarb sensitivity, L4 worms were 
selected and pre-exposed to either emodepside or vehicle (0.5 % ethanol) for 24 hours. They 
were then exposed to either 0.5 mM aldicarb and 100 nM emodepside or 0.5 mM aldicarb and 
vehicle (0.5 % ethanol) or 100 nM emodepside alone. The number of paralysed worms was 
ACh ACE
Aldicarb
Neuron
Muscle
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recorded every 30 minutes until all worms were paralysed. Paralysed worms were removed 
from the assay plate.
2.09 Locomotion assays: Levamisole assay
Levamisole is a nicotinic ACh receptor agonist (Lewis et al 1980). It causes hyper-contraction 
and paralysis of the body wall muscle through activation of post-synaptic nicotinic ACh 
receptors (Lewis et al 1980, Fleming et al 1997, Culetto et al 2004). The post-synaptic 
sensitivity of mutants and emodepside treated worms was investigated using levamisole. 
For experiments looking at the effect of emodepside on levamisole sensitivity, L4 worms 
were selected and pre-exposed to either emodepside or vehicle (0.5 % ethanol) for 24 hours.
They were then exposed to either 100 μM levamisole and 100 nM emodepside or 100 μM 
levamisole and vehicle (0.5 % ethanol) or 100 nM emodepside alone. The number of 
paralysed worms was recorded every 30 minutes until all worms were paralysed. Paralysed 
worms were removed from the assay plate.
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2.10 C. elegans genomic DNA extraction
DNA was extracted from both populations of worms and from single worms. To extract DNA 
from a population, worms were washed off a 5 cm plate with 1 ml of M9. Plates contained 
populations of several hundred worms at various stages of development. The worms were 
then transferred to a 1.9 ml Eppendorf tube and incubated at 5 oC for 5 minutes to pellet the 
worms. The supernatant (containing OP50) was removed leaving a worm pellet. Extra wash 
steps were conducted when necessary to ensure OP50 were removed. 100 μl of worm-lysis 
buffer/proteinase K (100 μg/ml) mix was added to the worm pellet. This was incubated at -80 
oC for 15 minutes followed by an incubation at 65 oC for 1 hour (vortexing every 15 minutes), 
resulting in cell lysis and digestion of protein. A final incubation of 95 oC for 15 minutes was 
used to denature the proteinase K. DNA was diluted with 400 μl 10 mM Tris (pH 8.1).
To extract DNA from single worms, they were first cleaned by transferring to a non-seeded 
plate for ~ 2 minutes. They were then picked into 3 μl of worm-lysis buffer/proteinase K mix 
(100 μg/ml) in a well of a PCR plate. The same procedure for DNA extraction from a 
population was then followed. PCR reaction mix was added directly to the lysed worm. 
M9 Buffer: KH2PO4 22 mM, Na2HPO4 42 mM, NaCl 85 mM, MgSO4 1 mM
Lysis buffer: Tris HCl 10 mM pH 8.3, KCl 50 mM, MgCl2 2.5 mM, NP40 0.45 %, 
Tween 20 0.45 %, Gelatine 0.01 %.
2.11 C. elegans RNA extraction
RNA was extracted from five 5 cm plates of worms (as described for DNA extraction). 
Worms were washed from each plate with 1 ml of M9 and transferred to 1.9 ml Eppendorf 
tubes. These were incubated at 5 oC for 5 minutes to pellet the worms. The supernatant was 
removed leaving a worm pellet and 100 l of supernatant. Extra wash steps were conducted 
when necessary to ensure OP50 were removed. Worms from the 5 plates were pooled in a 
single 1.9 ml Eppendorf tube. This was incubated at 5 oC for five minutes to pellet the worms. 
The supernatant was removed leaving the worm pellet. 
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1 ml of Trizol was added and incubated at room temperature for 1 hour, vortexing every 10 
minutes. It was then spun at 16000 x g for 10 minutes at 4 oC to pellet insoluble material. The 
supernatant was transferred to a fresh tube. 200 μl of chloroform was added and the tube was 
vortexed for 15 seconds. This was centrifuged at a RCF of 16110 x g for 15 minutes at 4 oC. 
The upper aqueous phase was transferred to a fresh tube and 500 μl of isopropanol was added. 
This was incubated at room temperature for 10 minutes and then spun at 14 g at 4 oC to pellet 
the RNA. The supernatant was removed and the pellet washed in 100 μl 75 % ethanol (made 
up in diethylpyrocarbonate (DEPC) treated H2O). A further spin at a RCF of 16110 x g for 10 
minutes was done and supernatant removed, followed by a second wash with 100 μl of 100 % 
ethanol. The supernatant was removed and the pellet allowed to air dry. The pellet was then 
re-suspended in 50 μl of DEPC treated H2O.
Reverse transcription was carried out immediately to avoid loss of RNA due to RNAse 
degradation. RNA was frozen at -80 oC in DEPC treated H2O. 
2.12 Polymerase chain reaction
Polymerase chain reaction (PCR) was used for a variety of applications. Deletions in genomic 
DNA were detected using PCR. This allowed the confirmation of the genotype of deletion 
mutants as well as the tracking of deletions during out-crossing. Genomic DNA was PCR 
amplified for sequencing of point mutations in mutant strains. PCR was used to confirm the 
presence of plasmids in transfected worms. slo-1 cDNAa was PCR amplified in order to 
generate a vector for slo-1 expression in HEK293 cells. Regions around snip-SNPs were PCR 
amplified for snip-SNP mapping.
Primer design – Gene specific primers were used for all PCR. Primers sequences were 
designed to be between 18 and 30 nucleotides long, and to have a GC content of between 40 
and 60 %. The following rules were followed when designing primers: avoid runs of 3 or more 
G or C at the 3` end, avoid a T at the 3` end, avoid complementary sequences within and 
between primers. The following equation was used to determine an annealing temperature for 
primers.
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Annealing temperature = (2oC x (A + T)) + (4oC x (C+G))
Primer pairs were designed to have similar annealing temperatures where possible. An 
average of annealing temperatures was taken for primer pairs. A list of primers used is shown 
in the appendix.
PCR mixture – Expand long template PCR system (Roche) was used for all PCR. dNTPs 
from Invitrogen were used for all PCR. Table 2.02 shows the reaction mixture used for PCR. 
PCR were optimised through variation of the Mg2+ concentration in the PCR buffer and 
variation of annealing temperature.
Table 2.02. Components of the PCR reaction mixture.
10 X PCR buffer: 17.5 mM to 27.5 mM MgCl2, 500 mM KCl, 100 mM Tris HCl 
pH 8.3, gelatine 200 μg/ml
Reagent Volume / 25 μl reaction
dNTPs 25 mM 0.25 μl
DNA 3 μl 
Expand long template PCR system 5 Units/μl 0.125  μl
PCR buffer 10 X 2.5  μl
Sense primer 10 μM 5  μl
Anti-sense primer 10 μM 5  μl
ddH2O (DEPC) 9.125
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PCR conditions – Table 2.03 shows the cycling conditions used for PCR. Annealing 
temperature varied depending on the primers being used. Elongation time varied depending 
on the size of the DNA template. Expand long template PCR system (Roche) elongates at a 
rate of 1 kb per minute. Cycle number varied depending on the quantity of PCR product 
required.
Table 2.03. PCR cycle conditions.
PCR were run using an M J research PTC-200 Peltier thermal cycler. Expand long template 
PCR system (Roche) can amplify DNA fragments up to 20 kb in size. It has proof-reading 
activity and copies DNA threefold more accurately than Taq DNA polymerase.
Reverse Transcription PCR - Reverse Transcriptase PCR (RT-PCR) reactions were carried 
out using the SuperScript III One-Step RT-PCR system with Platinum Taq DNA Polymerase 
(Invitrogen). RT-PCR was used to amplify slo-1 cDNA from slo-1(js379) non-
complementing strains. Table 2.04 shows the reaction mixture for the RT-PCR. Table 2.05 
shows the conditions for the RT-PCR. RT-PCR were run using an M J research PTC-200 
Peltier thermal cycler.
Step Temperature Duration Cycles
Initial denaturation 94 oC 2 minutes 1 X
Denaturation
Annealing 
Elongation
94 oC
50 - 60 oC
68 oC
30 seconds
30 seconds
1 minute / Kb
10-30 X
Final elongation 68 oC 7 minutes 1 X
58
Table 2.04. Components of the RT-PCR reaction mixture.
2 X reaction mix: 0.4 mM of each dNTP, 3.2, mM MgSO4
Table 2.05. RT-PCR cycle conditions
Reagent Volume / 25 μl reaction
2 X reaction mix: 25 μl
RNA 5 μl 
SuperScript III RT / Platinum Taq mix 2 μl
Sense primer 10 μM 1 μl
Anti-sense primer 10 μM 1 μl
ddH2O (DEPC) 16 μl
Temperature Time Cycle number
cDNA synthesis 60 oC 30 minutes 1 x
Initial denaturation 94 oC 2 minutes 1 x
Denaturation
Annealing
Elongation
94 oC
55 oC
68 oC
15 seconds
30 seconds
3.5 minutes
40 x
Final elongation 68 oC 7 minutes 1 x
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2.13 PCR purification
PCR products were purified when required for use in further enzymic reactions. PCR 
purification was carried out using a QIAquick PCR Purification Kit as per instructions. The 
purification process removes: primers and nucleotide less than 100 bp, enzymes, oil and salts.
2.14 Gel electrophoresis
Agarose gels of between 0.8 and 1.5 % were used depending on the size of the DNA fragment 
being run. Agarose was dissolved by heating in TBE buffer. Ethidium bromide (10 mg/ml) 
was added to the dissolved agarose and the solution was set in a casting tray. 5x loading 
buffer was added to DNA. Gels were run at 120 V (200 ml and 140 ml gels) or at 90 V (50 ml 
gels) in TBE buffer. All gels were run with a 1kb ladder (MBI Fermentas) (Figure 2.05). 5 μl 
of ladder were run making the 1.6 kb band 50 ng. DNA was visualised using AlphaImager
transilluminator and digitally photographed.
Figure 2.05. 1 kb ladder used in gel electrophoresis. Invitrogen 1 kb DNA ladder 
(www.invitrogen.com). 1636 bp band was loaded at 50 ng.
TBE: 45 mM Tris-borate, 1 mM EDTA
5 X loading buffer: 5 % bromophenol Blue 250 μl, Glycerol 30 %, H2O 70% ml
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2.15 Transformation of chemically competent cells
Subcloning Efficiency DH5α (Invitrogen) chemically competent cells were used. 25 μl 
aliquots (1.9 ml Eppendorf tubes) of DH5α were thawed on ice. 1-10 ng of DNA was gently 
mixed with DH5α cells and incubated on ice for 30 minutes. Cells were then heat shocked at 
42oC for 20 seconds, followed by a further 2 minute incubation on ice. 200 μl of SOC 
(GIBCO BRL) was added to the cells and incubated at 37oC and at 225 rpm in a platform 
shaker for 1 hour. 50 μl and 150 μl of DH5α culture was spread on antibiotic containing LB 
plates. Ampicillin was used at 50 ng/μl and kanamycin at 50 ng/μl. The plates were incubated 
for 16 hours at 37oC.
2.16 Plasmid / Cosmid preparation
Plasmids and cosmids were extracted from DH5α cells. The antibiotics ampicillin (50 ng/l) 
and kanamycin (50 ng/l) in LB media and LB agar were used for selection.
Plasmids (pPD118.33, pBK3.1 and pBK4.1) for use in C. elegans transfection were isolated 
using the QIAprep Spin Miniprep Kit (Qiagen). Single colonies were picked from a freshly 
streaked selective plate. 5 ml of LB media, containing the appropriate antibiotic, was 
inoculated and incubate for 16 h at 37C and at 225 rpm in a platform shaker. Bacterial cells 
were harvested by centrifugation at 16000 x g for 1 minute. LB media supernatant was 
removed and DNA was extracted. DNA yield using QIAprep Spin Miniprep Kit was in 
general approximately 15 μg. 
Plasmids (pCMV4-XL6 and pIRES2-EGFP) for HEK293 cell transfection were isolated using 
QIAGEN Plasmid Mini Kits (Qiagen). Single colonies  were picked from a freshly streaked 
selective plate. 5 ml of LB media, containing the appropriate antibiotic, was inoculated and 
incubated for 16 h at 37C and at 225 rpm in a platform shaker. Bacterial cells were harvested 
by centrifugation at 16000 x g for 1 minute. LB media supernatant was removed and DNA 
was extracted. DNA yield with QIAGEN Plasmid Mini Kits was in general approximately 15 
μg. QIAGEN Plasmid Mini Kits yields transfection grade plasmid DNA.
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The BO457 cosmid for use in C. elegans transfection was isolated using Sigma microprep 
(Sigma). Single colonies were picked from a freshly streaked selective plate. 2 ml starter 
cultures were set up and incubated for 8 hours at 37 oC and at 225 rpm in a platform shaker. 
50 l of starter culture was used to inoculate 25 ml of LB media, containing the appropriate 
antibiotic. This was incubated for 16 h at 37C and at 225 rpm in a platform shaker. Bacterial 
cells were harvested by centrifugation at 6000 x g for 15 minute. LB media supernatant was 
removed and DNA was extracted.
2.17 Restriction Endonucleases
Restriction digest banding patterns were used to confirm the identity of plasmids and cosmids. 
Restriction digests were used for the identification of N2 and CB4856 DNA in snip-SNP 
mapping. Restriction enzymes were also used to generate sticky ends on slo-1 cDNAa for 
insertion into pIRES2-EGFP. Restriction enzymes from New England Biolabs Ltd were used. 
Table 2.06 shows the reaction mixture used in restriction digests. 1 unit of restriction enzyme 
completely digests 1 g of DNA in 1 hour. All enzymes used were incubated at 37 oC for a 
minimum of 1 hour to ensure a complete digest. Enzymes were either heat inactivated (65 oC 
for 15 minutes) or removed using PCR purification (QIAquick PCR Purification Kit).
Reagent Volume / 20 μl reaction
DNA (~500 ng/ μl) 1 μl
Buffer 10 X (1, 2, 3 or 4) 2 μl
BSA (1 μg/μl) if required 2 μl
Enzyme (1 unit) 1 μl
ddH2O 14 μl
Table 2.06. Reaction mixture for restriction digests.
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Optimal conditions for digests were achieved using the following NEB buffers. NEB 
recommended buffers were used for double digests.
10X Buffer 1: 100 mM Bis-Tris-Propane-HCl, 100 mM MgCl2, 10 mM Dithiothreitol
10X Buffer 2: 500 mM NaCl, 100 mM Tris-HCl, 100 mM MgCl2, 1 mM Dithiothreitol
10X Buffer 3: 1 M NaCl, 500 mM Tris-HCl, 100 mM MgCl2, 10 mM Dithiothreitol
10X Buffer 4: 500 mM potassium acetate, 200 mM Tris-acetate, 100 mM Magnesium 
Acetate, 10 mM Dithiothreitol
2.18 Shrimp alkaline phosphatase (SAP)
SAP (USB) was used in the construction of pIRES2-EGFP + slo-1 cDNAa vector. PCR 
purified digested (EcoRI and NheI) pIRES2-EGFP was treated with SAP to prevent 
religation. The following reaction mixture was used (Table 2.07). One unit of SAP catalyses 
the hydrolysis of 1 mol of 5’-phosphates in one minute. Reactions were incubated at 37 oC 
for one hour. SAP was inactivated by incubation at 65oC for 15 minutes.
Reagent Volume / 20 μl reaction
10 X SAP reaction buffer 2 μl
DNA 15 μl (75 ng, ~ 0.0214 pmoles)
ddH2O 2 μl
SAP (0.1 unit / μl) 1 μl (0.1 units)
Table 2.07. Shrimp alkaline phosphatase reaction mix.
10 X SAP Reaction Buffer: 200mM Tris-HCl (pH 8.0), 100mM MgCl2.
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2.19 T4 DNA ligase
T4 DNA ligase (NEB) was used in the construction of pIRES2-EGFP + slo-1 cDNAa vector. 
slo-1 cDNAa was ligated into pIRES2-EGFP in EcoRI and NheI restriction sites. slo-1 
cDNAa was mixed with pIRES2-EGFP in a three fold molar excess. The following reaction 
mixture was set up (Table 2.08). Reactions were incubated overnight at 15 oC.
Reagent Volume / 20 μl reaction
pIRES2-EGFP (5 ng/μl ) 10 μl (~50 ng)
slo-1 cDNAa insert (17 ng/μl) 6 μl (~100 ng)
T4 DNA Ligase 1 μl
10 x T4 DNA Ligase reaction buffer 2 μl
ddH2O 1 μl
Table 2.08. T4 DNA Ligase reaction mixture.
10 X T4 DNA Ligase reaction buffer: 500 mM Tris-HCl, 100 mM MgCl2, 10 mM 
ATP, 100 mM Dithiothreitol
Subcloning Efficiency DH5α (Invitrogen) were inoculated with ligation product in the way 
previously described.
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2.20 Sequencing
Sequencing was done by MWG Biotech. Dry DNA (20 ng/100bp) samples and primers (10 
mM) were sent. MWG Biotech “value read” service was used, which can sequence up to a 
900 bp stretch.
2.21 C. elegans genetic nomenclature
Strain names: Strains have non-italicised names consisting of two uppercase letters followed 
by a number.
Genotypes: Genes have italicised names in the format of three lower case letters, hyphen, 
number. Alleles have italicised names in the format of one or two lower case letters followed 
by a number. When gene and allele names are written together they are in the format 
gene(allele). Mutants with more than one mutation are written by listing the gene and allele 
in left-right order on the genetic map. Different linkage groups are separated by a semicolon 
and given in the order I, II, III, IV, V, X. Heterozygotes are designated by separating mutations 
on the two homologous chromosomes with a slash. wild-type alleles are designated by a plus 
sign. 
Transgenes: Extrachromosomal arrays are given italicised names consisting of the laboratory 
allele prefix, the two letters Ex, and a number. Integrated transgenes are designated by 
italicised names consisting of the laboratory allele prefix, the two letters Is, and a number. 
Both Ex and Is can optionally be followed by genotypic or molecular information describing 
the transgene, in square brackets. Gene fusions incorporated in transgenes that consist of a C. 
elegans gene fused to a reporter are indicated by the C. elegans gene name followed by two 
colons and the reporter, all italicised.
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2.22 Chemical mutagenesis screen
N2 worms were mutagenised with the chemical mutagen ethlymethanesulphonate (EMS) at a 
concentration of 0.05 M, using the method described by Sulston and Hodgkin (1988). The 
average mutation frequency of EMS is 5x10-4 per gene. About 13 % of mutations produced by 
EMS are deletions, the rest are point mutations (Anderson 1995). This procedure was carried 
out in a fume cupboard and double gloves were worn due to the toxic nature of EMS. 1M 
NaOH was used for rinsing gloves and 4M NaOH is used for cleaning contaminated plastic. A 
dedicated Gilson was used.
5 cm plates containing N2 animals at various growth stages were washed off with 1 ml of M9 
buffer and transferred to a 20 ml tube (Sterilin). The worms were left to settle for 15 minutes 
before the majority of the supernatant was removed, leaving 2ml. In a separate tube 2 ml of 
M9 buffer was mixed with 20 l of EMS, giving a concentration of 0.1 M. This was then 
added to the 2ml of M9 containing the worms, giving a final EMS concentration of 0.05 M. 
The tube was placed on its side for 4 hours, mixing every  hour by gently rocking it. The 
worms were then put through 5 wash steps. The volume up was made up to 20ml with M9, 
left for 15 minute to allow the worms to settle, before removing the supernatant and repeating 
the wash. After the final wash the supernatant was removed, leaving 2 ml of M9 containing 
the worms. 0.5 ml of this was then pipetted to the edge of 4 seeded NGM plates. L4 worms 
that were healthy enough to reach the bacterial lawn within half an hour were selected and 
placed on individual plates. 
Most mutations are likely to be recessive (Brenner 1974). Mutated worms must therefore be 
propagated in order to select homozygous mutants (F3). 120 L4 F1 worms exposed to the 
mutagen were picked to individual plates. These were incubated for 4 to 5 days at 20 oC. 
Once the F1 had laid eggs that had matured to gravid F2 adults the F3 eggs were extracted in 
the following process. The worms were washed off each plate with 1 ml of M9 buffer and 
transferred to separate 1.9 ml Eppendorf tubes. They were allowed to settle for 5 minutes 
before the supernatant was removed, leaving a pellet of worms. 100 μl of the following 
solution, 1.25 % NaOCl, 2 M NaOH, was added to the Eppendorf and left for 2 minutes to 
break up the F2 worm. 1 ml of M9 buffer was added and then spun for 20 seconds at 16000 x 
g before removing the supernatant. Another 1 ml of M9 buffer was added and the spin 
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repeated. The majority of the supernatant was removed, leaving ~ 100 μl. The extracted eggs 
were then pipetted on a 1 μM emodepside NGM plate and screened for resistance. This 
concentration of emodepside slows development and inhibits movement of adult worms. The 
screen selected animals that 1) reached adulthood within N2 time frame, 2) retained N2
sinusoidal patterns of movement. The mutagenesis screen is estimated to be of ~ 7500 
genomes.
2.23 Out-crossing
EMS produces random mutations. Therefore a strain containing a desired mutation will also 
contain many other unwanted mutations. These mutations can be removed through a process 
of out-crossing. This process allows mutant DNA to be replaced with N2 DNA whilst 
retaining the desired mutation. Mutant strains are mated with N2 to produce heterozygous 
progeny (F2). F3 progeny homozygous for the desired mutation are then selected. These 
worms are said to be 1 x out-crossed. This process can be repeated to further reduce the 
number of mutations. Homozygous progeny are detected either through a phenotype linked to 
the mutation of interest, by PCR amplification of a deletion or sequencing of a point mutation. 
Males were generated through heat-shock of L4 hermaphrodites for 7 hours at 30 oC. This 
increases the proportion of male progeny to ~2 %. F1 Mutant L4 males were then picked and 
crossed with N2 hermaphrodites. The cross was set up at L4 stage to reduce self-fertilization. 
L4 F2 progeny resulting from the first cross were then placed on individual plates and selfed. 
F3 progeny were then screened for the mutation of interest, either by phenotype, PCR or 
sequencing. Populations were then established from worms homozygous for the mutation. 
Multiple crosses were set up at each step to ensure the desired genotypes were obtained. 
Figure 2.06 shows the process of out-crossing. Strains were out-crossed between 3 to 5 times.
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F1 F2
A/A        X   +/+ A/+ or   A/+
F2 F3
A/+         X   A/+                     A/A or   A/+   or   +/+
Figure 2.06. Out-crossing of mutant worm strains. This process is repeated multiple times 
to remove unwanted mutations. “A” represents the mutant allele and + represents N2. 
Selection of, A/A is based on phenotype or on PCR or sequencing of the mutation.
2.24 lat-2 lat-1 double mutant
The strains VC965, carrying lat-1(ok1465),  and XA3727, carrying lat-2(tm463), were used to 
generate lat-2 lat-1 double mutants. lat-1(ok1465) has a developmental defect and is therefore 
balanced. lat-1(ok1465) was balanced using the mIn1 balancer (Edgely and Riddle 2001). 
mIn1 is an inversion of a large central portion of chromosome II, extending from lin-31 to 
rol-1, that includes most of the genes on the chromosome. lat-1 and lat-2 are both covered by 
mIn1. mIn1 has integrated GFP and dpy-10(e128). dpy-10(e128) is recessive and gfp is semi-
dominant. Figure 2.07 highlights the key features of mIn1.
Figure 2.07. mIn1 balancer. mIn1 is an inversion of a large central portion of chromosome 
II, extending from lin-31 to rol-1, that includes most of the genes on the chromosome (Edgely 
and Riddle 2001). lat-1 and lat-2 are both covered by mIn1. The strain VC965 carries the 
Chromosome II balancer mIn-1 and lat-1(ok1465). mIn1 has GFP integrated and dpy-
10(e128). Genetic map positions of the above mention genes are marked (www.wormbase.org 
08/01/08).
II
II
0.94 cM
lat-1
-4.78 cM
lat-2
lin-31
-6.01 cM
rol-1
6.65 cM
dpy-10(e128)   GFP
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The following crosses were set up in order to obtain a lat-2, lat-1 double mutant (Figure 
2.08).
Cross 1)
+ lat-1 II  / mIn1 II       X   lat-2 + II / lat-2 + II                     
Select non-gfp, non-dumpy
+ lat-1 II / lat-2 + II     
Cross 2)
+ lat-1 II / lat-2 + II         X   + lat-1 II / mIn1 II
Select non-dumpy, gfp expressing      
lat-2 lat-1 II / mIn1 II    or     + lat-1 II / mIn1 II
or    lat-2 + II/ mIn1 II   or   + + II / mIn1 II
Figure 2.08. Construction of lat-2 lat-1 II / mIn1 II. Only genotypes of the selected cross 
progeny are show. Selection is based on dumpy and gfp phenotypes. Progeny from cross 2 
were selected and screened for the presence of both lat-2(tm463) and lat-1(ok1465). Progeny 
of the desired phenotype are shown in bold.
Non-dpy, gfp expressing worms were selected from cross 2 progeny. They were then screened 
for worms carrying both lat-2(tm463), lat-1(ok1465) using PCR to detect deletions. The 
probability of recombination between lat-2 and lat-1 is 1/17.48 as they are 5.72 cM apart on 
chromosome II. The probability of obtaining lat-2, lat-1 // mIn1 from cross 2 is 1/34.96.
2.25 Snip-SNP mapping
Mutations conferring resistance to emodepside were mapped using a technique known as 
snip-SNP (single nucleotide polymorphisms) mapping. This technique exploits the SNPs that 
exist between N2 C. elegans and the Hawaiian strain CB4856. SNPs can result in the creation 
or destruction of restriction enzyme sites across the genome. There are predicted to be 6222 
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SNPs in CB4856 with reference to N2, with 3457 of these modifying restriction sites (snip-
SNPs). 493 of these have been confirmed experimentally (Wicks et al 2001). These snip-
SNPs are used as markers for mapping. A fragment of genomic DNA containing the snip-
SNP is PCR amplified and then digested with the appropriate restriction enzyme.
In order to map using this technique a visible marker mutation was first introduced into the 
emodepside resistant (ER) mutant background. The dpy-20(e1282) was used for this purpose. 
dpy-20(e1282) results in the dumpy appearance of the worm. The following crosses, shown in 
figure 2.09, were set up in order to obtain ER, dpy-20(e1282) double mutants. 
Cross 1)
dpy-20 IV / dpy-20 IV X    ER / ER                           
Select non-dumpy
dpy-20 IV; + / + IV; ER
Cross2) 
dpy-20 IV; + / + IV; ER       X    dpy-20 IV; + / + IV; ER        
Select dumpy worms
dpy-20 IV; ER / dpy-20 IV; ER  or  dpy-20 IV; ER / dpy-20 IV; +
or  dpy-20 IV; + / dpy-20 IV; +
Figure 2.09. Introduction of dpy-20 in mutant background. Crosses set up in order to 
obtain dpy-20 IV; ER / dpy-20 IV; ER. Only genotypes of the selected cross progeny are 
show. Selection is based on dumpy phenotypes. Progeny from cross 2 were selected and 
screened for resistance to 1 μM emodepside. Progeny of the desired phenotype are shown in 
bold.
Selection of dpy-20 IV; ER / dpy-20 IV; ER was based on dumpy phenotype. Progeny from 
these worms were screened for emodepside resistance using the same screening method as 
described for the mutagenesis screen.
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Worms with the dpy-20 IV; ER / dpy-20 IV; ER genotypes were used to set up the crosses 
with CB4856 shown in figure 2.10. These crosses allow for the introduction of CB4856 DNA 
whilst retaining the mutation that confers resistance. The dpy-20 marker was used to confirm 
that the cross was successful.
Cross 1)
dpy-20 IV; ER / dpy-20 IV; ER         X    CB / CB
Select non-dumpy
dpy-20 IV; ER / CB; CB
Cross 2)
dpy-20 IV; ER / CB; CB          X    dpy-20 IV; ER / CB; CB          
Select emodepside resistant
dpy-20 IV; ER / dpy-20 IV; ER      or dpy-20 IV; ER / CB IV; ER
or     CB IV; ER / CB IV; ER
Figure 2.10. Crosses set up in order to introduce CB DNA into ER / ER. Non-dumpy 
progeny were selected from cross 1 to ensure the cross was successful. Progeny resistant to 1 
μM emodepside were selected from cross 2 irrespective of their dumpy phenotype. Progeny 
of the desired phenotype are shown in bold.
All progeny were selected from cross 2 in figure 2.10, and individually placed on 1 μM 
emodepside plates. Populations were established from individual progeny and screened for 
emodepside resistance using the method previously described for the mutagenesis screen. 
Genomic DNA was then extracted from these populations as previously described. Cross 2 in 
figure 2.10 follows Mendelian genetics. i.e.  will be CB / CB,  will be CB / + and  will 
be + / +. However, due to the selection based on resistance to 1 μM emodepside, the region of 
the mutation conferring resistance will always be N2 DNA. Recombination events allow CB 
DNA to be introduced to the chromosome that carries the mutation conferring resistance. 
These recombination events become increasingly less frequent nearer the mutation. Using the 
DNA from the strains generated in the cross in figure 2.10, the mutation conferring resistance 
can be mapped using the snip-SNPs.
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2.26 Complementation tests
Complementation tests are genetic tests that can be used to determine if mutation of a 
particular gene is responsible for a certain phenotype. This test requires a candidate gene and 
a strain with an appropriate mutation within this gene. slo-1(js379) was used for this purpose. 
The following cross was set up (figure 2.11).
dpy-20 IV; ER / dpy-20 IV; ER          X     slo-1 V / slo-1 V
Select non-dumpy
dpy-20 IV; ER / slo-1 V
Figure 2.11. Cross set up in order to generate heterozygous slo-1(js379) and ER. The 
progeny from this cross were then tested for sensitivity to 1 μM emodepside in the body 
bends assay.
slo-1(js379) are resistant to emodepside. If dpy-20 IV; ER / slo-1 V are resistant, then the 
emodepside resistant strain is said to be a non-complement of slo-1(js379). This suggests it is 
an allele of slo-1. Complementation tests were conducted on all emodepside resistant strains. 
Emodepside resistance was tested on 1 μM emodepside in the body bends assay as previously 
described.
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2.27 Transgenic worms
Transgenic worms were generated by micro-injection of DNA vectors into the syncytium of 
young adult worms (1 day post L4). Vectors were co-injected with the injection marker 
pPD118.33. pPD118.33 contains gfp behind the myo-2 pharyngeal muscle promoter. The 
technique used is illustrated in figure 2.12.
Figure 2.12. Micro-injection of C. elegans. The distal part of the gonad was injected with 
the vectors to be expressed. These become incorporated as extra chromosomal arrays in the 
progeny of the injected worm. (After White et al 1988)
To obtain needles for micro-injection, 1mm diameter aluminosilicate glass capillaries were 
pulled using the P-2000 Sutter Instrument electrode puller. DNA solutions were made up in 
ddH2O at concentrations of 50 ng/μl for injection marker vectors and at 25 ng/μl for all other 
vectors. DNA solutions were spun for 10 minutes at 16000 x g to pellet any debris and then 
transferred to a fresh tube. Micro-injection needles were placed in the tube containing the 
DNA solution and filled by capillary action for 10 minutes. The needle was then mounted on 
a micro-manipulator (Eppendorf TransferMan NK2). Viewing the needle under X40 
magnification, it was then broken against the edge of a cover slip immersed in oil. This 
creates a jagged edge suitable for injection.
2 % agarose pads were used to stick the worms in position. These were made by pipetting 50 
μl of molten 2 % agarose in ddH2O onto a microscope slide. This was then flattened using a 
cover slip and dried at 60 oC for 1 hour. Worms were picked to these pads, and a drop of oil 
was placed on them to prevent them drying out. Worms were then injected with DNA solution 
under X40 magnification. They were recovered by pipetting 10 μl of M9 buffer on to them. 
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Worms were transferred onto NGM plates. Transgenic progeny were selected using the 
pPD118.33 gfp marker and stable lines established these worms.
2.28 Cell culture
Cell culture - HEK293 cells (Graham et al 1977) were cultured at 37oC and 5% CO2. 25 cm2
flasks (Greiner bio-one) were routinely used, as was Dulbecco’s Modified Eagle Medium 
(DMEM) + Glutamax (Gibco). DMEM was supplemented with Foetal Calf Serum (10%) 
(Gibco) and penicillin/streptomycin (100 units/ml /100 μg/ml) (Gibco). Medium was replaced 
every two days.
Passaging cells - Cells were passaged when at approximately 80% confluence. Culture media 
was aspirated form the flask. 2 ml of Phosphate buffered solution (PBS) (Gibco) pH7.4 was 
added to rinse the cells. The PBS was aspirated and 1 ml of trypsin (2.5 g/l) versene (2g/l) 
mix was added. This was then incubated at 37 oC for three minutes. 10 ml of DMEM was 
added to dilute the trypsin. This was then spun at 1000 x g for two minutes to pellet the cells. 
DMEM was aspirated and the cells were re-suspended in fresh DMEM. The volume of 
DMEM cells were re-suspended in depended on the percentage confluence required. 0.5 ml of 
re-suspended cells was then added to 4.5 ml DMEM in 25 cm2 flasks. Alternatively, re-
suspended cells were added to 6 well plates (Greiner bio-one) containing cover slips for 
transfection and patch clamp experiments. 13 mm cover slips (Raymond A Lamb) were 
washed in 100 % ethanol and then air dried. Covers slips were placed in six well plates 
(Greiner bio-one). 2 ml of DMEM and 0.5 ml of re-suspended cells were added to each well. 
Cells were added at approximately 20 percent confluence and grown for a minimum of 24 
hours before transfection. 
2.29 HEK293 transfection
HEK293 cells were transfected when approximately 20 percent confluent. Cells must not be 
too confluent as single cells are required for patch clamp experiments. 6 μg of DNA was 
mixed with 1500 μl of Opti-MEM (with GlutaMAX) (Gibco). 12 μl of Lipofectamine 2000 
(Invitrogen) was mixed with 1500 μl of Opti-MEM. These two mixes were incubated at room 
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temperature for five minutes and then combined and incubated for 20 minutes at room 
temperature.
DMEM was aspirated from the six well plate and replaced with 2 ml of Opti-MEM. 0.5 ml of 
the DNA, Lipofectamine 2000 mix was added per well. Plates were incubated at 37 oC for six 
hours before Opti-MEM was replaced with DMEM. Cells were used in patch clamp 
experiments 24 hours after transfection.
Transfected cell were identified by gfp expression. C. elegans slo-1 cDNAa was cloned into 
pIRES2-EGFP which contains gfp driven by pCMV. Human Kcnma1 variant 2 cDNA was 
cloned in pCMV6-XL4, which contains no marker for eukaryote transfections. It was 
therefore co-transfected with pIRES2-EGFP in a 3:1 molar ratio. Transfection efficiency was 
estimated to be between 20 % and 50 %.
2.30 Patch clamp analysis
Whole cell patch clamp experiments were conducted on HEK293 cells. HEK293 cells 
attached to cover slips were transferred to a bath containing an external solution. These were 
stuck down using silicone grease (ACE Silicones) Cells were viewed using a Zeiss Axioskop2 
under x 10 and x 40 water immersion lens. Patch pipettes containing internal solution were 
manoeuvred towards the membrane single cells. The patch pipette was held at -80 mV. 
Positive pressure sufficient to form a slight depression (~1 μm) in the cell membrane was 
applied through the patch pipette. This positive pressure was then turned off, creating a 
backflow sufficient to suck the cell membrane onto the patch pipette. Stable seals generally 
formed instantaneously. Attempts to open cells were made when seal resistance was more 
than 1 GΩ. Cells were opened using a combination of suction and voltage pulse (1.5 V for 0.5 
ms). Recordings were taken from open cells with a seal resistance of more than 1 GΩ.
External solution: 137 mM NaCl, 5.9 mM KCl, 2.2 mM CaCl2, 1.2 mM MgCl2, 14 mM 
glucose, 10 mM HEPES. pH 7.4 (with NaOH)
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Internal solution: 140 mM KCl, 1 mM MgCl2, 10 mM HEPES, 2 mM Na2ATP, 5 mM 
EGTA, 300 μM CaCl2. pH 7.2 (with KOH)
Equipment and software – The Axopatch 200B (Axon Instruments) patch clamp amplifier 
was used in combination with CU203BU headstage (Axon Instruments). Digidata1322A was 
used for conversion of analogue to digital data and interface with a PC. Clampex version 
9.2.0.09 was used for recording of data.
Patch pipettes – Patch pipettes were made from 1.3 mm melting point capillaries (CAP-MPO-
75 Bilbate). They were pulled in a Narishige vertical puller in two steps. Patch pipettes of 
between 3.5 and 5 MΩ resistance were used. Electrode resistance was obtained using 
Clampex 9.2 seal test function, which applies a 5 mV step to calculate resistance.
Electrodes – A silver chloride coated silver wire recording electrode was used. The reference 
electrode was a silver chloride pellet electrode connected to the recording chamber via an agar 
bridge containing bathing solution. This was used to minimise junction potentials and to 
prevent changes in the ionic composition of the bath solution.
Voltage step protocol – A voltage step protocol was set up using Clampex version 9. From a 
resting potential of -80 mV, voltage steps were made to: -90, -80, -70, -60, -50, -40, -30, -20, -
10, 0, +10, +20, +30, +40 and +50 mV. Each step lasted 100 ms. Current required to maintain 
the potential at each voltage step was recorded. Leak subtraction was routinely applied using 
the P/N leak subtraction facility of Clampex. Four sweeps were automatically applied prior to 
execution of the step protocol in the opposite polarity. The average leak was automatically 
subtracted.
Pharmacology – Drugs were applied to the bath. 0.5 ml of external solution was removed 
from the bath and replaced with 0.5 ml of drug dissolved in bath solution. 4-AP, IBTX and 
emodepside were added to a final concentration of 10 mM, 100 nM, and 100 nM respectively.
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Chapter 3
The role of latrophilin receptors in 
emodepside’s mode of action
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3.1 Introduction
Evidence has previously been put forward for a role of the latrophilins in the mode of action 
of emodepside (Saeger et al 2001, Wilson et al 2004). This evidence is based on expression 
cloning of latrophilin from H. contortus and RNA interference studies in C. elegans. 
In all RNAi studies targeting latrophilins (Willson et al 2003, Amliwala 2005), the effect was 
to cause a reduction in sensitivity to emodepside rather than complete resistance. There are 
several possible explanations for this. It may be that the knock down of the LAT-1 and LAT-2 
receptors by RNAi is incomplete and therefore they are only partially resistant to 
emodepside’s effects. Alternatively, redundancy between LAT-1 and LAT-2 may exist. This 
would mean that the action of emodepside can be directed through either LAT-1 or LAT-2. If 
LAT-1 is knocked down then emodepside’s effects go through LAT-2, and if LAT-2 is 
knocked down then emodepside’s effects go through LAT-1. Therefore latrophilin RNAi 
targeted worms would not show a high level of resistance. Another possibility is that there is a 
tissue limited affect of the RNAi. Effective silencing of genes by RNAi in neurons has been 
shown to be variable (Esposito et al 2007). Inefficient silencing of latrophilin receptors in 
some tissues would result in partial resistance. Alternatively, the effects seen with RNAi 
targeting the latrophilins may only modulate emodepside’s effects and a distinct mechanism 
of action may exist.
The availability of deletion mutants for both lat-1 and lat-2, during the course of this project,
provided the opportunity for a more robust analysis of the role of the latrophilins in the mode 
of action of emodepside. Investigation of the effects of emodepside on these mutant strains 
was undertaken. In this chapter, characterisation and phenotypic analysis of these mutants is 
described. A double lat-2 lat-1 mutant was generated to address the question of  functional 
redundancy between lat-1 and lat-2 in terms of emodepside resistance.
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3.2 Developmental defect of the latrophilin mutant strain VC965 
The strain VC965 carries lat-1(ok1465) balanced by the insertion mIn1. The mIn1 balancer 
has an inverted region that carries dpy-10(e128) and gfp (see methods, page 66). lat-
1(ok1465) is balanced in this way as development of homozygous lat-1(ok1465) arrests. A 
small proportion of lat-1(ok1465) are able to escape this developmental arrest. Homozygous 
lat-1(ok1465) are identifiable in a population of VC965 as they lack expression of gfp. In 
order to obtain a homozygous lat-1(ok1465) population, 75 larvae not expressing gfp were 
selected, one of which developed to adult. It was possible to establish a homozygous 
population through propagation of this single worm. The developmental defect was defined 
more precisely using this population. The development of synchronised N2 and lat-1(ok1465) 
eggs was observed over a 96 hour period. Figure 3.01 shows the proportion of animals at each 
stages of development. Worms were staged, based on vulva appearance under a dissecting 
microscope (x 63 max).
94 % of the synchronised N2 had developed to adult at 72 and 96 hours. The 6 % that failed to 
develop are likely to have been damaged during transfer of the eggs. At 72 hours, 98.4 % lat-
1(ok1465) remained at L1 stage, 0.8 % were eggs, 0.4 % were L2 and 0.4 % were L3. At 96 
hours, 98.4 % lat-1(ok1465) remained at L1 stage, 0.8 % were eggs, 0.4 % were L4 and 0.4 % 
were adult. There were significantly fewer lat-1(ok1465) adults (P<0.001) and significantly 
more lat-1(ok1465) L1 (P<0.001) at 72 and 96 hours compared to N2. These groups were 
compared using Fisher’s exact test.
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A) 
B) 
Figure 3.01. Quantification of lat-1(ok1465) growth defect. Percentage of homozygous lat-
1(ok1465 ) (■) and N2 (□) worms at each growth stage at A) 76 hours B) 94 hours after 
synchronised eggs were selected. Larval stage was determined by stage of vulva development. 
For lat-1(ok1465) (■) n=250, for N2 (□) n=100. Differences between N2 and lat-1(ok1465) 
were compared at each stage using a two-tailed Fisher’s exact test. ** indicates P<0.01 and 
*** indicates P<0.001.
Twenty of the lat-1(ok1465) identified as L1 were observed under x 1000 power to more 
stringently analyse the stage of vulva development. All twenty proved to be at the L1 stage of 
development. Figure 3.02 shows an example of the vulva at L1. Four vulva precursor cells are 
visible, Z1, Z2, Z3 and Z4. The vulva of N2 worms is at this stage of development in the L1 
moult.
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A)
B)
Figure 3.02. Vulval development of lat-1(ok1465). Homozygous lat-1(ok1465) after 94 
hours development at x 1000 magnification. The vulva precursor cells are marked. A) Shows 
the lateral view of Z3 and Z4. B) Shows the lateral view of Z1 and Z2. This stage of vulva 
development occurs during L1. 
Attempts to rescue the developmental defect of lat-1(ok1465) were made. The cosmid BO457 
was co-injected with the genetic marker pmyo-2::GFP (pPD118.33). Transgenic F1 progeny 
from injected animals were obtained but the developmental defect did not rescue. 
Z3 Z4
Z1 Z2
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3.3 lat-1(ok1465) contains a 2209 bp deletion
The strain VC965 carries lat-1(ok1465), which has a 2209 bp deletion. The presence of this 
deletion in the VC965 strain was confirmed using PCR. Primers either side of the deletion 
were used to amplify lat-1(+) DNA fragments of 3604 bp and lat-1(ok1465) DNA fragments 
of 1395 bp. PCR was also used to demonstrate that VC956 animals not expressing gfp were 
homozygous for lat-1(ok1465). Primers within and either side of the deletion were used. A 
lat-1(ok1465) DNA fragment of 1395 bp was amplified. The primer within the deletion 
results in the amplification of a 732 bp fragment in lat-1(+). The lack of this product from 
DNA of worms not expressing gfp confirms that they are homozygous for lat-1(ok1465). 
Figure 3.03 shows a gene model of lat-1 with the ok1465 deletion marked (adapted from 
www.wormbase.org), as well as gel electrophoresis for the PCR described.
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A)
B) C)
D)
Figure 3.03. Genotypic analysis of the strain VC965. A) lat-1 gene model 
(www.wormbase.org). The three splice variants have been identified. The allele ok1465 has a 
2209 bp deletion spanning exons 3, 4 and 5 of splice variants a and b and exons 3 and 4 of 
splice variant c. B) PCR of genomic DNA from N2 and lat-1(ok1465) / lat-1(+) using primers 
either side of the deletion. N2 gives a band of 3604 bp and lat-1(ok1465) / lat-1(+) gives 
bands of 3604 bp and 1395 bp. C) PCR of genomic DNA from N2 and lat-1(ok1465) / lat-
1(ok1465) using primers within and either side of the deletion. N2 gives a band of 732 bp and 
lat-1(ok1465) / lat-1(ok1465) gives a band of 1395 bp. D) lat-1(ok1465) model highlighting 
regions PCR amplified. Bold arrows mark regions amplified by PCR. Faint arrow denote 
primers.
2209 bp
11796 bp
ok1465//+ -ve            N2
3604 bp 
1395 bp 
 3604 bp
2209 bp
3604 bp
732 bp
a ba + b = 1395 bp
ok1465
 1395 bp
 732 bp
-ve    N2  ok1465
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Three splice variants of lat-1 have been identified. ok1465 results in the loss of regions coding 
for 41 % of the galactose binding lectin domain in splice variant a and 10 % in splice variant 
b, the hormone receptor domain, the GPCR proteolytic site domain and the first 
transmembrane domain in splice variant a. In splice variant a the deletion is in frame. In splice 
variant b, exon 3 reads in intron 5 and encounters a stop codon. In splice variant c, ok1465
results in the loss of 25 % of the galactose binding lectin domain, its only domain. Figure 3.04 
shows the amino acid sequence for splice variant a with the ok1465 deletion and domains 
highlighted. 
MRRNKTTYSLLQTILVACLLTVTPTFASNKPTTDESGTISHTICDGEAAE
LSCPAGKVISIVLGNYGRFSVAVCLPDNDIVPSNINCQNHKTKSILEKKC
NGDSMCYFTVDKKTFTEDPCPNTPKYLEVKYNCVVPATTTTTTTTTSTTT
TDSSLIVDEEEEAQKDALNSDVIKPVKKKEDVFCSATNRRGVNWQNTKSG
TTSSAPCPEGSSGKQLWACTEEGQWLTEFPNSAGCESNWISSRNSVLSGV
ISSEDVSGLPEFLRNLGSETRRPMVGGDLPKVLHLLEKTVNVIAEESWAY
QHLPLSNKGAVEVMNYMLRNQEIWGSWDVTKRKEFASRFILAAEKAMVAS
AKGMMTSAESNVIVQPAITVEISHKIKMSSQPTDYILFPSAALWNGQNVD
NVNIPRDAILKINKDETQVFFSSFDNLGAQMTPSDVTVAIAGTDQTEVRK
RRVVSRIVGASLIENGKERRVENLTQPVRITFYHKESSVRHLSNPTCVWW
NHHELKWKPSGCKLSYHNKTMTSCDCTHLTHFAVLMDVRGHDLNEIDQTL
LTLLTYVGCIISIICLLLTFFAYLIFSRNGGDRVFIHENLCLSLAIAEIT
FLAGITRTEDSLQCGIIAVALMYMFLSALTWMLLEGYHIHRMLTEVFPSD
PRRFTYLLVGYIPPAIITLVAYLYNSDGFGTPDHCWLSTQNNFIWFFAGP
ACFIFCANSLVLVKTLCTVYQHTSGGYLPCRHDVDSGRSIRNWVKGSLAL
ASLLGVTWIFGLFWVEDSRSIVMAYVFTISNSLQGLFIFLFHVVFAEKMR
KDVGHWMYRRGCGGSSNSSPNHKRHNVQRDLMSPGVNSSTGSDFLYNTND
KYLTNSDTTNRLVYNGIMNHPNQMSVYQQHPHHQIYEQQPGTYDYATIAY
GDMMPGHRVAAPPAYQRLAVAEGRYGSQHQLYQGWHHRPPPEFSPPPPPL
STGPPNSRHYGTGSSGRRPPSSKMSDDSAYSDGSSSMLTTEVTPQGQTVL
RIDLNKPSMYCQDL
Figure 3.04. LAT-1 amino acid sequence. Amino acid sequence of lat-1 splice variant a. 
The underlined section highlights the deleted region in lat-1(ok1465). Yellow highlights the 
galactose binding lectin domain. Blue highlights a domain present in hormone receptors. 
Purple highlights G-protein-coupled receptor proteolytic site domain. Green highlights a 
seven transmembrane domain.
It has been proposed that emodepside binds to the amino terminus of HC110-R (Saeger et al 
2001). In lat-1(ok1465) the majority this region is deleted. It therefore seems unlikely that 
LAT-1 would be functional with regard to emodepside’s proposed mode of action. It would 
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also be predicted that the loss of the first transmembrane domain would result in the protein 
being incorrectly orientated in the membrane. It would be expected that loss of function of 
LAT-1 would prevent activation of the vesicle release pathway by emodepside and therefore 
result in resistance.
The deleted region in lat-1(ok1465) reported on Wormbase was confirmed by sequencing of
genomic DNA. The break point was found to be at 6585 bp from the start codon. This lies in 
intron 2 in splice variants a and c and in exon 3 in splice variant b. The deletion finishes in 
intron 5 at 8794 bp. Figure 3.05 shows the sequencing of lat-1(ok1465).
CTTCTTCGTCGATACGTTTCTGTTCGATGACGCGTGTCCAATGATGAGCAAA
2209 bp deletion
AAACAAAAAATTTTTGGTCGAAATTTGGACCAAAAACCAAAAAATCGAAATTTTCCTTAAAAA
Figure 3.05. lat-1(ok1465) sequence. Sequencing of a PCR amplified fragment of genomic 
DNA from homozygous lat-1(ok1465). The deleted portion of lat-1 is between 6585 bp and 
8794 bp of the lat-1 gene. There is an AT insertion in this region. The deleted region is 2209 
bp. 
bp 6533 Break point 
at 6585 bp
Insertion
Break point 
at 8794 bp
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3.4 lat-1(ok1465) are not resistant to emodepside’s effects on locomotion
The sensitivity of lat-1(ok1465) to emodepside’s effect on locomotion was tested using the 
body bends assay. Animals were exposed to emodepside for 24 hours and then assayed off 
food. The inhibition of locomotion in N2 and lat-1(ok1465) by emodepside at 1 nM, 10 nM, 
100 nM, 1 μM and 10 μM was not significantly different. Figure 3.06 shows a dose response 
for N2 and lat-1(ok1465). N2 have an IC50 of 100 nM, 95 % confidence limits 68 nM to 146, 
compared with a lat-1(ok1465) IC50 of 230 nM, 95 % confidence limits 96 nM to 552 nM.
Figure 3.06. lat-1(ok1465) dose response. Dose response for emodepside on homozygous 
lat-1(ok1465) (●) and N2 (▲). For each point n≥7 and is the mean  S.E.Mean. 
In contrast to the RNAi studies (Wilson et al 2003, Almliwala 2005), lat-1(ok1465) displayed 
a similar sensitivity to emodepside as N2. To further investigate the role of the latrophilins in 
emodepside’s mode of action, lat-2 was investigated. 
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3.5 lat-2 deletion mutants
Two strains with lat-2 deletions were available, VC158 which carries lat-2(ok301) and 
TM463 which carries lat-2(tm463). Neither strain displayed any obvious behavioural or 
developmental phenotype. PCR was used to confirm the presence of the deletions in these 
strains. For lat-2(ok301), primers either side of the deletion were used to amplify lat-2(+) 
DNA fragments of 3159 bp and lat-2(ok301) DNA fragments of 2076 bp. For lat-2(tm463),  
primers either side of the deletion were used to amplify lat-2(+) DNA fragments of 2908 bp 
and lat-2(tm463) DNA fragments of 1530 bp. PCR was also used to confirm that both strains 
were homozygous using primers within and either side of the deletion. For lat-1(ok301), a 
DNA fragment of 2076 bp was amplified and for the N2 control, a DNA fragment of 1100 bp 
was amplified. The lack of the 1100 bp band in lat-1(ok301) demonstrates it is homozygous. 
For lat-1(tm463), a DNA fragment of 1530 bp was amplified and for the N2 control, a DNA 
fragment of 852 bp was amplified. The lack of the 852 bp band in lat-1(tm463) demonstrates 
it is homozygous. Figure 3.07 shows a gene model for lat-2 with ok301 and tm463 deletions 
highlighted as well as gel electrophoresis for the PCR described.
Two lat-2 splice variants have been identified (www.wormbase.org). The deletion in lat-
1(tm463) cover exons 4, 5, 6, 7, 8 and 9 of splice variant a. This results in the loss of coding 
sequence for 20 % of the C-type lectin-like domain and the galactose binding lectin domain in 
splice variant a. The deletion in lat-2(tm463) begins in exon 4 and reads into intron 9, 
subsequently encountering a stop codon in splice variant a. The product of splice variant b, 
which consists of a 15 amino acid amino terminal region, a seven transmembrane domain and 
a 200 amino acid C-terminal tail, is not covered by this deletion. The deletion in lat-2(ok301) 
covers part of 3’ un-translated region of lat-2. Figure 3.08 shows the amino acid sequence for 
lat-2 splice variant a with the tm463 deletion and domains highlighted.
The deletion in lat-2(tm463) covers a large portion of the amino terminal which is proposed to 
be the binding site for emodepside in HC110-R (Seager et al 2001). It would therefore be 
expected that emodepside would be unable to bind. The deletion also results in the 
introduction of an early stop codon, which is likely to truncate the protein. 
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A)
B) C)
D) E)
F)
9200 bp
1378 bp 1083 bp
 2076 bp
 1100 bp
ok301 -ve  N2
 1530  bp
 852 bp
tm463 -ve     N2
1378 bp
 2908 bp
 1530 bp
N2 -ve   tm463
N2 -ve        ok301
 3159 bp
 2076 bp 1083 bp
2908 bp
852 bp
a ba + b = 1530 bp
ok301tm463
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G)
Figure 3.07. Genotypic analysis of lat-2(ok301) and lat-2(tm453). A) lat-2 gene model 
(www.wormbase.org). The two splice variants are shown. The allele tm463 has a 1379 bp 
deletion spanning exons 4, 5, 6, 7, 8 and 9 of splice variant a. The allele ok301 spans part of 
the 3’ UTR of splice variant a. B) PCR of genomic DNA from N2 and lat-2(tm463) using 
primers either side of the deletion. N2 gives a band of 2908 bp and lat-2(tm463) gives a bands 
of 1530 bp. C) PCR of genomic DNA from N2 and lat-2(tm463) using primers within and 
either side of the deletion. N2 gives a band of 852 bp and lat-2(tm463) give a band of 1530 
bp. D) PCR of genomic DNA from N2 and lat-2(ok301) using primers either side of the 
deletion. N2 gives a band of 3159 bp and lat-2(ok301) gives a band of 2076 bp. E) PCR of 
genomic DNA from N2 and lat-2(ok301) using primers within and either side of the deletion. 
N2 gives a band of 1100 bp and lat-2(ok301) give a band of 2076 bp. F) lat-2(tm463) model 
highlighting regions PCR amplified. Bold arrows mark regions amplified by PCR. Faint 
arrow denote primers. G) lat-2(ok301) model highlighting regions PCR amplified. Bold 
arrows mark regions amplified by PCR. Faint arrow denote primers.
3159 bp
1100 bp
a ba + b = 2076 bp
ok301
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MAKQLKYPFLIFIISLAQCQVSNQNVNLCQSNICQNGGTCLVASSVPATA
TCPKNSIYYMGSCYVFDTTLRNWNDAALYCNNMNSATLPLVESAEDQAFF
AGYLQAMIPSNPPADMRPPPDGIWTAVRGVNNVTRASWVYYPGSFLVTDT
FWAPQEPNIYVNYNDVCVALQSDSFYREWTTALCTILKYTVCKVAPTQIQ
AKYVAQCSCPNGYGGQTCETQSTTNQQASTQRTCGSNDFQFSCPNDQTIT
VDFASFGAQESSMCNQASQSREQTCSNVNSLQTVINACQGLQSCEIRNLT
STFSNTPCPVPQEQYLETRMRCETAQQPSCLSGLIQFDSRCYSMTIETNE
KKQRTMEDAQTYCSQSGGSIITSPPDALLQQIVQKVNAETKKTVNFWIGT
PNNCQLLMVTGSSTSYSQCPSSPSSTANVICSTVPQSTASVSARPTQSAP
VDPVSQTMARREVYTGVQPPSVPDSINKPRYCKKEKKDGITYEQTRACML
HEQPCPDPQNVEGTVTRYCNCQTAKWETPDTTNCTHRWVAEMETAIKDNQ
PVEDISSTVNRQLKSTIERTLFGGDITGTVRLSNDMLSLARNQFSVLNDR
NLRENKARNFTENLGGSGDQLLSPVAATVWDQLSSTIRIQHASKLMSVLE
QSVLLLGDYMTDQKLNLQYINWAMEVERSEPEVQTFGAAASPNVQDDMGM
MRVMAAAPPAPQPETNTTIMFPSLKLSPTITLPSASLLSSLASPTPVAGG
GPSILSSFQDDTPVGMASTPNLNRNPVKLGYYAFAGFGQLLNNNNDHTLI
NSQVIGASIQNATQSVTLPVDHPVTFTFQHLTTKGVSNPRCVYWDLMESK
WSTLGCTLIATSSNSSQCSCTHLTSFAILMDISGQVGRLSGGLASALDVV
STIGCAISIVCLALSVCVFTFFRNLQNVRNSIHRNLCLCLLIAELVFVIG
MDRTGNRTGCGVVAILLHYFFLSSFCWMLLEGYQLYMMLIQVFEPNRTRI
FLYYLFCYGTPAVVVAISAGIKWEDYGTDSYCWIDTSTPTIWAFVAPIIV
IIAANIIFLLIALKVVLSVQSRDRTKWGRIIGWLKGSATLLCLLGITWIF
GFLTAVKGGTGTAFAWIFTILNCTQGIFIFVLHVVLNEKVRASIVRWLRT
GICCLPETSSAAYNSRSFLSSRQRILNMIKVNGHSYPSTASTDDKEKQLT
PITKTTDWLSRLPNQDSVSIPESNFNNLNGTLENSNLNSAEIKEEDEIPE
LRRRVTVDLNPMIVSNNEIERMSHASSDPRGSQIIEVTAVEKKAPVKRIK
FPLGAKQSERGSQHRTKAKVIAPPESPVSESGSKDYRF
Figure 3.08. LAT-2 amino acid sequence. Amino acid sequence of lat-2 splice variant a. 
The underlined section highlights the deleted region in lat-2(tm463). Red highlights a C-type 
lectin-like domain. Yellow highlights a galactose binding lectin domain. Blue highlights a 
domain present in hormone receptors. Purple highlights a G-protein-coupled receptor 
proteolytic site domain. Green highlights a seven transmembrane domain.
In order to confirm the sequence of lat-2 in lat-2(tm463) reported on Wormbase, sequencing 
of genomic DNA across the deleted region was done. The break point was found to be at 1423 
bp from the start codon. This lies at the beginning of exon 4. The deletion finishes in intron 9 
at 2801 bp. Figure 3.09 shows the sequencing of lat-2(tm463).
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ACCGTTTTTCGACAGAAAGAT ACAAATTGCACCAGTTACCTAAATTTTTAATATTTTAGACGT
1378 bp deletion
CTGCG
TGTGCAAGTTGGATGGAGCTCGGAGCCGGGTTAAGAAAAAATATTTTTAATTTAAAAAAAGCGA
Figure 3.09. lat-2(tm463) sequence Sequencing of a PCR amplified fragment of genomic 
DNA from homozygous lat-2(tm463). The deleted portion of lat-2 is between 1423 bp and 
2801 bp of the lat-2 gene. There is a TAGAA insertion in this region. The deleted region is 
1378 bp. 
Although lat-2(ok301) may produce a functional LAT-2, the effect of emodepside on both 
deletion mutants was investigated as lat-2(ok301) had previously shown decreased sensitivity 
(Amliwala 2005). Both lat-2(ok301) and lat-2(tm463) were out-crossed five times prior to 
analysis of emodepside sensitivity. Both alleles were followed by PCR during out-crossing 
(see methods, page 65). Out-crossed strains lat-2(ok301) and lat-2(tm463) were designated 
strain names XA3726 and XA3727 respectively.
Break point at
2801 bp
Break point at 
1423 bp Insertion
bp 1355
91
3.6 Emodepside sensitivity of lat-2(ok301) and lat-2(tm463)
The sensitivity of lat-2(ok301) and lat-2(tm463) to emodepside’s affect on locomotion was 
tested using the body bends assay. Animals were exposed to emodepside for 24 hours and 
then assayed off food. The inhibition of locomotion in N2, lat-2(ok301) and lat-2(tm463) by 
emodepside at 1 nM, 10 nM, 100 nM, 1 μM and 10 μM was not significantly different. Figure 
3.10 shows a dose response for N2, lat-2(ok301) and lat-2(tm463). N2 have an IC50 of 163 
nM, 95 % confidence limits 57 nM to 460 nM, compared with a lat-2(ok301) IC50 of 320 nM, 
95 % confidence limits 100 nM to 849 nM and a lat-2(tm463) IC50 of 244 nM, 95 % 
confidence limits 74 nM to 804 nM.
Figure 3.10. lat-2 dose response. Dose response curves for emodepside on lat-2(tm463) (), 
lat-2(ok301) (■) and N2 (▲). Each point is the mean  S.E.Mean of 7 determinants (except at 
1x10-5 M where n=5). 
Neither lat-2(ok301) nor lat-2(tm463) showed a significant decrease in sensitivity to 
emodepside. In order to investigate the possibility of redundancy between lat-1 and lat-2 a 
double mutant was constructed.
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3.7 lat-2 lat-1 double mutant
Figure 3.11 A) shows the crosses set up in order to generate the lat-2 lat-1 double mutant. The 
mIn1 balancer provided useful dumpy and GFP markers for selecting the correct progeny. 
mIn1 also covers both lat-1 and lat-2 and could therefore be used to balance the double 
mutant once it was obtained. lat-1 and lat-2 are both on chromosome II, 5.64 cM apart. The 
probability of a recombination event resulting in both lat-1(ok1465) and lat-2(tm463) alleles 
being carried on the same chromatid is 1/17.7. The odds of recovering lat-2 lat-1 on the same 
chromatid balanced by mIn1 are 1/35.5. The process of generating the lat-2 lat-1 double 
mutant is described in the methods in greater detail.
Figure 3.11 B) shows gel electrophoresis of the PCR products resulting for amplification lat-1 
and lat-2 from genomic DNA (extracted from single worms) of gfp expressing progeny from 
cross 2. Primer flanking the lat-1(ok1465) and lat-2(tm463) were used to amplify DNA 
fragments of 1395 bp and 1530 bp, respectively, in the way previously described. 1/48 
progeny selected from cross 2 carried both lat-1(ok14165) and lat-2(tm463). 
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A)
Cross 1) + lat-1 II / mIn1 II        lat-2 + II / lat-2 + II                   + lat-1 II // lat-2 + II
Cross 2) + lat-1 II / lat-2 + II        + lat-1 II / mIn1 II                   lat-2 lat-1 II / mIn1 II
B)
Figure 3.11. lat-2 lat-1 double mutant construction. A) Crosses set up in order to obtain lat-
2 lat-1 II / mIn1 II. B) PCR of genomic DNA from 48 single worms resulting from cross 2. 
Primers flanking the deletions in lat-1(ok1465) and lat-2(tm463) were used to generate 1395 
and 1530 bp fragments, respectively. Each bracket encloses PCR products generated using 
lat-1 and lat-2 primers from genomic DNA of a single worm. The circled bands are generated 
from genomic DNA carrying both lat-1(ok1465) and lat-2(tm463).
A population was established from the single animal carrying lat-2 lat-1 II / mIn1 II generated 
in cross 2. The developmental defect linked to lat-1(ok1465) was retained. In order to 
generate a homozygous lat-2 lat-1 population, approximately 200 L1 not expressing gfp were 
selected. A homozygous population was established from a single animal that reached adult.
Although the chromosomal location of lat-1 and lat-2 makes the chance that non gfp animals 
selected from the balanced strain do not carry both ok1465 and tm463 extremely unlikely, the 
genotype of this population was confirmed using PCR. Primers within and either side to the 
lat-1(ok1465) and lat-2(tm463) were used in the way described previously. A DNA fragment 
lat-1
lat-2
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of 1395 bp was generated in lat-2(tm463) lat-1(ok1465) and of 732 bp in N2, using lat-1 
primers. The lack of the 732 bp band in lat-2(tm463) lat-1(ok1465) confirms it is homozygous 
for lat-1. A DNA fragment of 1530 bp was generated in lat-2(tm463) lat-1(ok1465) and of 
852 bp in N2. The lack of the 852 bp band in lat-2(tm463) lat-1(ok1465) indicates it is 
homozygous for lat-2(tm463). Figure 3.12 shows a gel for the above mentioned PCR 
reactions. 
Figure 3.12. Confirmation of lat-2 lat-1 genotype. PCR of genomic DNA from homozygous 
lat-2(tm463)lat-1(ok1465) using primers flanking and within the deletions in lat-2(tm463) and 
lat-1(ok1465). PCR using primers flanking and within the deletion of lat-2(tm463) produces 
lat-2(tm463) and N2 products of 1530 bp and 852 bp, respectively. PCR using primers 
flanking and within the deletion of lat-1(ok1465) produces lat-1(ok1465) and N2 products of 
1395 bp and 732 bp, respectively. The contrast has been increased in the bottom right hand 
corner of this gel due to the low intensity of some bands.
852 bp →
l2l1 N2 -ve       l2l1 N2 -ve      
lat-2 primers           lat-1 primers
1530 bp →
← 1395 bp
← 732 bp
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3.8 Emodepside sensitivity of lat-2(tm463) lat-1(ok1465)
The sensitivity of lat-2(tm463) lat-1(ok1465) to emodepside’s affect on locomotion was 
tested using the body bends assay. Animals were exposed to emodepside for 24 hours and 
then assayed off food. The inhibition of locomotion in N2 and lat-2(tm463) lat-1(ok1465) by
emodepside at 1 nM, 10 nM, 100 nM, 1 μM and 10 μM was not significantly different. Figure 
3.13 shows a dose response for N2 and lat-2(tm463) lat-1(ok1465). N2 have an IC50 of 14 nM, 
95 % confidence limits 9 nM to 19, compared with a lat-2(tm463) lat-1(ok1465) IC50 of 19 
nM, 95 % confidence limits 11 nM to 33 nM.
Figure 3.13. lat-2 (tm463) lat-1(ok1465) dose response. Dose response curves for 
emodepside on lat-2(tm463)lat-1(ok1465) (●) and N2 (▲). For each point n=10 and is the 
mean  S.E.Mean. 
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3.9 Discussion
Saeger et al (2001) demonstrated binding of emodepside to the amino terminal of the 
latrophilin receptor of Haemonchus contortus, HC110-R. HEK293 cells transfected with 
HC110-R  showed a decreased response to αLTX in the presence of emodepside, indicating 
there is a competitive interaction with HC110-R. Wilson et al (2004) proposed that 
emodepside acts though LAT-1 in neurons, to cause vesicle release and paralysis of the 
pharyngeal muscle. Components of a latrophilin vesicle-mediated neurotransmitter release 
pathway (Davletov et al 1998) were knocked down, using either mutant C. elegans strains or 
RNAi, resulting in decreases in sensitivity to emodepside. Amliwala (2005) demonstrated that 
RNAi targeting of lat-1 and lat-2 in C. elegans resulted in a deceased sensitivity to 
emodepside. The lat-2(ok301) mutant strain VC158 was also shown to have reduced 
sensitivity to emodepside. These decreases in sensitivity to emodepside have not been 
observed in the locomotion assays conducted on lat-1(ok1465) and lat-2(tm463). There are a 
variety of possible reasons for these inconsistencies. There may be a non specific effect of the 
RNAi that resulted in a decrease in emodepside sensitivity. Alternatively, variability in the 
emodepside thrashing assay may have given misleading results with regard to the effect of 
lat-1 and lat-2 RNAi on emodepside sensitivity.
The studies investigating the effects of RNAi targeting of lat-1 and lat-2 on emodepside 
sensitivity were conducted in liquid. These assays look at the thrashing rate of worms over the 
course of one hour. They are exposed to 10 M emodepside during this time period. Attempts 
to use these assays to investigate the sensitivity of lat-2(tm463) and lat-2(ok301) were made. 
However, these assays produced inconsistent results. lat-2(tm463) was tested in three 
independent assays. In one assay lat-2(tm463) was found to be significantly less sensitive to 
emodepside than N2. In two further assays lat-2(tm463) was found to be as sensitive as N2 to 
emodepside. lat-2(ok301) was found to be as sensitive as N2. These results are shown in the 
appendix. 
The inconsistency seen with the thrashing assay may be explained by the low solubility of 
emodepside at 10 M concentrations (see methods) as well as the relatively short exposure 
period. Attempts to keep the suspension of emodepside well mixed prior to the assay were 
made. However, there is the potential for animals to be exposed to varying amounts of 
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emodepside. For this reason an alternative assay was used. A 24 hour exposure period on 
NGM plates followed by analysis on NGM plates was used (see methods, page 49). Although 
there was inter assay variability in the NGM plate assays, results were consistent relative to 
controls when performed in parallel (see methods, page 50).
lat-2(ok301) was previously shown to have decreased sensitivity to emodepside’s effect on 
locomotion in the body bends assay (Amliwala 2005). However the out-crossed lat-2(ok301) 
was not found to have decreased sensitivity to emodepside. Out-crossing results in the loss of 
many mutations present in strains generated by random mutagenesis. The differences in 
sensitivity between out-crossed and not out-crossed strains may be explained by the loss of a 
mutation(s) during out-crossing. The un-out-crossed lat-2(ok301) was re-tested in the body 
bends assay and was found to have a slight but significant decrease in emodepside sensitivity 
(see appendix).
As no reduction in emodepside sensitivity was seen in lat-1(ok1465) or lat-2(tm463), it was 
postulated that a redundancy might exist between the two genes with regard to emodepside’s 
mode of action. In order to investigate this possibility, a double lat-2 lat-1 mutant was 
constructed. The lat-2 lat-1 double mutant showed no decrease in sensitivity to emodepside in 
the locomotion assay. The data indicate that the latrophilins do not play a role in 
emodepside’s mode of action with regard to its effect on locomotion.
The developmental arrest phenotype of lat-1(ok1465), which was also observed in the lat-
2(tm463) lat-1(ok1465) double mutant, could not be rescued by expressing lat-1(+) in the lat-
1(ok1465) background. However, any rescue may have been masked due to the presence of 
the genetic marker pmyo-2::GFP (pPD118.33). It has been observed that pPD118.33 can 
cause developmental arrest, similar to that observed in lat-1(ok1465), when expressed with no 
other vectors present. It may be that very high levels of gfp expression in the pharyngeal 
muscle inhibit pumping, resulting in developmental arrest. The presence of the developmental 
arrest phenotype in the lat-2(tm463) lat-1(ok1465) double mutant illustrates its tight genetic 
linkage to lat-1(ok1465).
Analysis of the effects of emodepside on lat-1(ok1465), lat-2(tm463) and lat-2(t,463) lat-
1(ok1465) in the electropharyngeogram assay were performed by Kate Bull. lat-2(tm463) was 
not found to have a significantly different sensitivity to emodepside than N2. lat-1(ok1465) 
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and lat-1(ok1465) lat-2(tm463) were both found to be significantly less sensitive to 
emodepside compared with N2, consistent with findings by Willson et al (2003). This 
indicates there is a role for lat-1 in the response of the pharynx to emodepside.
The lack of any reduction in sensitivity to emodepside’s effects on locomotion in the 
latrophilin mutants demonstrate that other genes must be involved in it’s mechanism of 
action. The following chapters investigate the role of SLO-1 in emodepside’s effects on 
locomotion.
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Chapter 4
Forward genetic screens for 
emodepside resistance: 
characterisation of resistant strains 
identifies slo-1 as a major 
determinant of emodepside’s action
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4.1 Introduction
Forward genetic approaches in C. elegans have been successfully used to identify molecular 
targets for anthelmintic drugs and other compounds. The technique was initially used by 
Sidney Brenner in 1974. He isolated mutants that were resistant to the effects of the ACh 
esterase (ACE) inhibitor, lannate, and the anthelmintic, levamisole. Using complementation 
tests he was able to assign genes to a number of these resistant strains. With the sequencing of 
the C. elegans genome and the advancement of mapping techniques, forward genetic 
approaches are now widely used. Forward genetics has the great advantage of being an un-
biased approach with the potential to generate and select mutant animals that are highly 
resistant to the effects of emodepside.
This approach was taken in an earlier study (Amliwala 2005). A mutagenesis screen identified 
seven emodepside resistant strains (Amliwala 2005). Five of these had linkage to 
chromosome V. Of these five, two (pd18 and pd20) were mapped to a locus at ~16.8 cM. slo-
1(js379), which lies in this region of chromosome V, was found to be highly resistant to 
emodepside (Amliwala 2005). SLO-1 is a calcium-activated voltage sensitive potassium 
channel. It is one of two BK channels in C. elegans, SLO-1 and SLO-2. The role of a 
calcium-activated potassium channel was previously suggested as a possible reason for an 
emodepside-induced calcium-dependent hyperpolarisation of Ascaris suum muscle strip 
(Willson et al 2003).
The aim of this chapter is to produce further emodepside resistant strains and identify the 
mutations conferring resistance. Snip-single nucleotide polymorphism (SNP) mapping, 
complementation tests and sequencing are used in the identification of mutations that cause 
high level resistance to emodepside.
Ethlymethanesulphonate is a chemical mutagen that is routinely used for mutagenesis of C. 
elegans. Figure 4.01 shows the process by which emodepside resistant mutants were 
generated as selected. The majority of mutations produced are point mutations (~87 %), the 
rest are deletions (~13 %) (Anderson 1995). Generally the mutations produced are recessive 
(Brenner 1974). Therefore the F3 progeny were screened for emodepside resistance (Figure 
4.01). 
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Figure 4.01. C. elegans mutagenesis. EMS mutagenesis of C. elegans. L4 C. elegans are 
mutagenised using the chemical mutagen EMS. F3 progeny are selected and screened for 
emodepside resistance. Most mutations are recessive and F2 progeny are unlikely to display 
resistance.
Snip-SNPs (single nucleotide polymorphisms) are SNPs that alter restriction sites. There are a 
predicted 6222 SNPs in the C. elegans strain CB4856, of which 3457 are predicted be snip-
SNPs (Wicks et al 2001). These snip-SNPS can be used for the mapping of experimentally 
derived mutations. Snip-SNPs can be easily detected using restriction fragment length 
polymorphisms (RFLP). These are amplified using PCR and digested with the appropriate 
restriction enzyme. By analysis of snip-SNPs in the DNA of progeny resulting from crosses 
between CB4856 and emodepside resistant N2 animals (see methods), mutations can be 
mapped.
Complementation tests are a genetic test that can be used to show if mutations are alleles of 
the same or different genes (Brenner et al 1974). These tests allow for mutations in genes to 
be identified without a lengthy mapping process. The test relies on the mutation being 
recessive in nature. Different emodepside-resistant strains are crossed with each other and the 
progeny are tested for emodepside resistance. If the progeny are resistant, the strains are said 
to be non-complements. This indicates that they are alleles of the same gene.
Emodepside resistance screen
F1 F2 F3
EMS
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4.2 Mutagenesis screen
A screen of approximately 7500 genomes was conducted. The selection of resistant mutants 
was based on the ability to develop from eggs to adult on 1 M emodepside within 96 hours 
as well as an ability to move in a sinusoidal pattern. Three emodepside-resistant mutants were 
isolated from this screen. In total, seven emodepside-resistant mutants from this screen and 
the previous screen (Amliwala 2005) were investigated. The following allele names were 
assigned to the emodepside resistant mutants: pd19, pd23, pd21, pd17, pd24, pd47 and pd46.
4.3 Snip SNP mapping
pd19 was isolated by Amliwala (2005) but had not been decisively mapped to a chromosome. 
Initial indications suggested linkage to chromosome I. The appropriate crosses were set up in 
order to obtain resistant animals carrying CB DNA (see methods). DNA was extracted from 
the progeny of 51 emodepside resistant carrying CB and N2 DNA. 14 of these DNA extracts 
were used for the initial mapping steps to determine chromosomal linkage. Three snip-SNPs 
on chromosome I were used at – 27.45 cM, -6.15 cM and 8.84 cM. DNA was N2 homozygous 
in 36, 21 and 14 percent of samples at -27.45 cM, -6.15 cM and 8.84 cM respectively. These 
values are close to what would be expected with Mendelian segregation, indicating that pd19
is not linked to chromosome I. Figure 4.02 A) shows digested PCR products for the three 
snip-SNPs on chromosome I. Control digests for N2 and CB are shown for each snip-SNP. 
Figure 4.02 B) shows the proportion of N2, CB and N2 / CB in each DNA sample at the three 
snip-SNPs. 
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A)
B)
pd19 Chromosome 1 Chromosome I Chromosome I
SNP location
Cosmid:nucleotide F53G12:8422 WO3D8:34384 ZK1025:21353
Genetic map 
position (cM) -27.45 -6.15 8.84
CB H N2
N2 N2 H
H H H
H H H
H H H
H CB H
H N2 N2
H H CB
N2 N2 H
N2 H H
H H H
N2 H H
N2 H ?
H H H
% N2 36 21 14
Figure 4.02. Chromosome I mapping data for pd19. A) Restriction digest of PCR 
fragments generated from genomic DNA containing SNPs. SNPs at the following genetic 
map positions on chromosome I were used; -27.45, -6.15 and 8.84. Dde1 cuts at SNP 
F53G12:8422 in N2 to give fragments of 220bp and 220 bp. Dra1 cuts at SNP WO3D8:34384 
in N2 to give fragments of 334 and 175. Nde1 cuts at SNP ZK1025:21353 in CB to give 
fragments of 251 bp and 149 bp. B) Percentage of resistant F2 progeny with N2 DNA at SNPs 
F53G12:8422, WO3D8:34384 and ZK1025:21353 (see text for details).
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Figure 4.03. Chromosome V data for pd19. A) Restriction digest of PCR fragments 
generated from genomic DNA containing SNPs. SNPs at the following genetic map positions 
on chromosome V were used; 2.53 and 16.92. Dra1 cuts at SNP AC3:3025 in N2 to give 
fragments of 105 and 387. Dra1 cuts at SNP Y51A2d in CB to give fragments of 273 and 121. 
B) Percentage of resistant F2 progeny with N2 DNA at SNPs AC3:3025 and Y51A2d:92865 
(see text for details).
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Possible linkage of pd19 to chromosome V was tested using snip-SNPs at 2.53 cM and 16.92 
cM. DNA was N2 homozygous in 71 and 100 percent of samples at 2.53 cM and 16.92 cM 
respectively. These values do not reflect Mendelian segregation, indicating that pd19 is linked 
to chromosome V. Figure 4.03 A) shows digested PCR products for the two snip-SNPs on 
chromosome V. Control digests for N2 and CB are shown for each snip-SNP. Figure 4.03 B) 
shows the proportion of N2, CB and N2 / CB in each DNA sample at the two snip-SNPs. 
Mapping revealed linkage to chromosome V in all alleles tested. This indicated that all were 
alleles of the same gene. This was confirmed through the use of complementation tests.
4.4 Complementation tests
Complementation tests allow genes containing mutations that result in a phenotype to be 
rapidly identified. The test relies on the mutations being recessive. The strain NM1968, which 
has the js379 mutation in slo-1, was used in complementation tests with emodepside resistant 
strains. The dpy-20(e1282) mutation was introduced into the background of the emodepside 
resistant mutants for use as a marker when generating cross progeny for complementation 
tests. Initially the sensitivity of slo-1(js379), slo-1(js379) / slo-1(+) and N2 to 1 M 
emodepside was tested using the body bends assay. The locomotion of emodepside treated 
animals is shown as a percentage of the locomotion on vehicle containing plates. Figure 4.04 
shows the percentage control response of worms with these genotypes. The locomotion of slo-
1(js379) / slo-1(+) and N2 is significantly inhibited compared with slo-1(js379), with 
P<0.001. slo-1(js379) / slo-1(+) is as sensitive to 1 M emodepside as N2. This demonstrates 
that a single copy of slo-1(+) is sufficient to confer emodepside sensitivity. The recessive 
nature of slo-1(js379) makes it suitable for use in complementation tests.
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Figure 4.04. slo-1(js379) is recessive. % control response (body bends) of js379/js379, 
js379/+ and N2 after 24 hour exposure to 1 μM emodepside. “% control response” is the 
number of body bends per minute after exposure to emodepside as a percentage of the number 
of body bends on vehicle for each strain. For each bar n≥7 and is the mean  S.E.Mean. ***
indicates P<0.001.
Emodepside-resistant strains were crossed with either slo-1(js379) or alleles that were shown 
to be non-complements of slo-1(js379). Cross progeny that carry non-complementing 
emodepside resistant alleles would be expected to be resistant to emodepside. Emodepside 
resistant strains were crossed with N2 to check that mutations causing emodepside resistance 
were recessive, as a dominant mutation may falsely indicate non-complementation.
0
20
40
60
80
100
120
js379//js379 js379//+ WT
%
co
nt
ro
lr
es
po
ns
e
***
***
NS
N2
107
Complementation of pd19
Figure 4.05 shows the percentage control response of pd19 / pd19, pd19 / + and pd19 / js379
on 1 M emodepside. The locomotion of  pd19 / + is significantly more inhibited by 1 M 
emodepside than pd19 / pd19 (P<0.001). This demonstrates that pd19 is recessive. The 
locomotion of pd19 / + is also significantly more inhibited than pd19 / js379 (P<0.001). This 
demonstrates that pd19 and js379 are non-complements, indicating that they are alleles of the 
same gene.
Figure 4.05. pd19 is a non-complement of slo-1(js379). % control response (body bends) of 
pd19//pd19, pd19//+ and pd19//js379 after 24 hour exposure to 1 μM emodepside. “% control 
response” is the number of body bends per minute after exposure to emodepside as a 
percentage of the number of body bends on vehicle for each strain For each bar n≥5 and is the 
mean  S.E.Mean. *** indicates P<0.001.
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Complementation of pd23
Figure 4.06 shows the percentage control response of pd23 / pd23, pd23 / + and pd23 / js379
on 1 M emodepside. The locomotion of  pd23 / + is significantly more inhibited by 1 M 
emodepside than pd23 / pd23 (P<0.001). This demonstrates that pd23 is recessive. The 
locomotion of pd23 / + is also significantly more inhibited than pd23 / js379 (P<0.001). This 
demonstrates that pd23 and js379 are non-complements, indicating that they are alleles of the 
same gene.
Figure 4.06. pd23 is a non-complement of slo-1(js379). % control response (body bends) of 
pd23//pd23, pd23//+ and pd23//js379 after 24 hour exposure to 1 μM emodepside. “% control 
response” is the number of body bends per minute after exposure to emodepside as a 
percentage of the number of body bends on vehicle for each strain For each bar n≥7 and is the 
mean  S.E.Mean. *** indicates P<0.001.
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Complementation of pd21
Figure 4.07 shows the percentage control response of pd21 / pd21, pd21 / + and pd21 / js379
on 1 M emodepside. The locomotion of  pd21 / + is significantly more inhibited by 1 M 
emodepside than pd21 / pd21 (P<0.001). This demonstrates that pd21 is recessive. The 
locomotion of pd21 / + is also significantly more inhibited than pd21 / js379 (P<0.001). This 
demonstrates that pd21 and js379 are non-complements, indicating that they are alleles of the 
same gene.
Figure 4.07. pd21 is a non-complement of slo-1(js379). % control response (body bends) of 
pd21//pd21, pd21//+ and pd21//js379 after 24 hour exposure to 1 μM emodepside. “% control 
response” is the number of body bends per minute after exposure to emodepside as a 
percentage of the number of body bends on vehicle for each strain For each bar n≥5 and is the 
mean  S.E.Mean. *** indicates P<0.001.
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Complementation of pd17
Figure 4.08 shows the percentage control response of pd17 / pd17, pd17 / + and pd17 / js379
on 1 M emodepside. The locomotion of  pd17 / + is significantly more inhibited by 1 M 
emodepside than pd17 / pd17 (P<0.01). This demonstrates that pd17 is recessive. The 
locomotion of pd17 / + is also significantly more inhibited than pd17 / js379 (P<0.001). This 
demonstrates that pd17 and js379 are non-complements, indicating that they are alleles of the 
same gene.
Figure 4.08. pd17 is a non-complement of slo-1(js379). % control response (body bends) of 
pd17//pd17, pd17//+, and pd17//js379 after 24 hour exposure to 1 μM emodepside. “% 
control response” is the number of body bends per minute after exposure to emodepside as a 
percentage of the number of body bends on vehicle for each strain For each bar n≥7 and is the 
mean  S.E.Mean. ** indicates P<0.01 and *** indicates P<0.001.
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Complementation of pd24
Figure 4.09 shows the percentage control response of pd24 / pd24, pd24 / + and pd24 / pd23
on 1 M emodepside. The locomotion of  pd24 / + is significantly more inhibited by 1 M 
emodepside than pd24 / pd24 (P<0.001). This demonstrates that pd24 is recessive. The 
locomotion of pd24 / + is also significantly more inhibited than pd24 / pd23 (P<0.001). This 
demonstrates that pd24 and pd23 are non-complements, indicating that they are alleles of the 
same gene.
Figure 4.09. pd24 is a non-complement of slo-1(pd23). % control response (body bends) of 
pd24//pd24, pd24//+ and pd24//pd23 after 24 hour exposure to 1 μM emodepside. “% control 
response” is the number of body bends per minute after exposure to emodepside as a 
percentage of the number of body bends on vehicle for each strain For each bar n≥6 and is the 
mean  S.E.Mean. *** indicates P<0.001.
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Complementation of pd47
Figure 4.10 shows the percentage control response of pd47 / pd47, pd47 / + and pd47 / pd23
on 1 M emodepside. The locomotion of  pd47 / + is significantly more inhibited by 1 M 
emodepside than pd47 / pd47 (P<0.001). This demonstrates that pd47 is recessive. The 
locomotion of pd47 / + is also significantly more inhibited than pd47 / pd23 (P<0.001). This 
demonstrates that pd47 and pd23 are non-complements, indicating that they are alleles of the 
same gene.
Figure 4.10. pd47 is a non-complement of slo-1(pd23). % control response (body bends) of 
pd47//pd47, pd47//+ and pd47//pd23 after 24 hour exposure to 1 μM emodepside. “% control 
response” is the number of body bends per minute after exposure to emodepside as a 
percentage of the number of body bends on vehicle for each strain For each bar n≥5 and is the 
mean  S.E.Mean. *** indicates P<0.001.
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Complementation of pd46
Figure 4.11 shows the percentage control response of pd46 / pd46, pd46 / + and pd46 / pd23
on 1 M emodepside. The rate of locomotion of  pd46 / + is not inhibited more than the 
locomotion of  pd46 / pd46. This however reflects the low level of resistance of pd46 / pd46
rather than indicating that it has a dominant phenotype. pd46 was defined as resistant based 
on the parameters of the screen, not on its rate of locomotion. A sinusoidal shape of 
locomotion was observed in pd46 / pd46 (6 out 6 of animals) on 1 μM emodepside. This 
sinusoidal shape of locomotion was not observed in pd46 / + (6 out 6 of animals), indicating 
that pd46 is recessive. The rate of locomotion of pd46 / + on 1 M emodepside is not 
significantly different from that of pd46 / pd23. However, pd46 / pd23 (6 out of 6 animals) 
displayed a sinusoidal shape of locomotion whereas pd46 / + did not (6 out of 6 animals). 
This demonstrates that pd46 and pd23 are non-complements, indicating that they are alleles of 
the same gene.
Figure 4.11. pd46 is a non-complement of slo-1(pd23). % control response (body bends) of 
pd46//pd46, pd46//+ and pd46//pd23 after 24 hour exposure to 1 μM emodepside. “% control 
response” is the number of body bends per minute after exposure to emodepside as a 
percentage of the number of body bends on vehicle for each strain For each bar n≥6 and is the 
mean  S.E.Mean. * indicates P<0.05.
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4.5 Sequencing of slo-1 cDNA from emodepside resistant animals
The data from the complementation tests strongly indicates that each strain carries an allele of 
slo-1. In order to identify mutations conferring resistance to emodepside, the cDNA of slo-1
was sequenced in the resistant strains. RNA was extracted from each emodepside-resistant 
strain. slo-1 cDNA was generated from total RNA using the SuperScript III One-Step RT-
PCR system and gene specific primers. Nested primers, located immediately upstream of the 
start codon and downstream of the stop codon, were used for generating slo-1 cDNA from 
pd17, pd19, pd21 and pd24. An alternate 3’ primer with better specificity, 170 bp downstream 
of the stop codon was used for generating slo-1 cDNA from pd24, pd46 and pd47. Figure 
4.12 shows the products produced in RT-PCR reactions using the primers described. DNA 
fragments that appear to be of the predicted N2 sizes (~3400) are generated in pd17, pd19, 
pd21, pd23, pd24, pd46 and pd47. As well as the predicted band size, fainter bands of 
~1600bp were generated in pd17, pd19, pd21 and pd23 and of ~1800 bp in pd24 (see 
appendix, page 206). 
Figure 4.12. Gel electrophoresis of slo-1 cDNA. RT-PCR products for slo-1 from resistant 
strains pd17, pd19, pd21, pd23, pd24, pd46 and pd47. Nested primer upstream of the start and 
downstream of the stop codon were used to generate slo-1 cDNA. N2 fragments are predicted 
to be of either 3423 (primer pair A) or 3593 (primer pair B) for splice variant a.
pd17    pd19     pd21    pd23                      pd24      pd46      pd47
4000 bp
3000 bp
2000 bp
1600 bp
1000 bp
Primer pair A Primer pair B
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cDNA was amplified in two successive rounds of PCR for each allele. slo-1 cDNA 
consistently failed to amplify for pd47 in the second round PCR. This may indicate the 
presence of a mutation in a region complementary to the primers used. 
The cDNA was sequenced. Sequencing primers spaced at 370 bp intervals across the cDNA 
were used. The primers used were complementary to slo-1 cDNA sequences common to all 
identified splice variants. Three splice variants of slo-1 have been identified in C. elegans
(Wei et al 1996, Zhao et al 2001). Figure 4.13 shows a gene model for slo-1
(www.wormbase.org). Splice variant a has 20 exons. Splice variant b lacks exon 13 compared 
with splice variant a. Splice variant c has an alternate exon 9, an extra exon (exon 11a) 
between exons 11 and 12 and lacks exon 13 compared with splice variant a.
Figure 4.13. slo-1 gene model. Adapted from www.wormbase.org. Three splice variants of 
slo-1 have been identified (Wei et al 1996, Zhao et al 2001). Comparing with splice variant a: 
splice variant b lacks exon 13; splice variant c has an alternate exon 9, an extra exon (exon 
11a) between exons 11 and 12 and lacks exon 13.
In some sequencing reactions for slo-1 the presence of a mixture of sequences was observed. 
This was due to the presence of alternate splice variants in the cDNA. By reading off the 
overlapping sequence, both sequences for splice variants a/b and splice variant c could be 
identified. When the sequence produced from sequencing of cDNA was not of sufficient 
quality, individual exons or groups of exons were PCR amplified from genomic DNA and 
sequenced. Table 4.01 shows the sequence coverage of slo-1 for each allele.
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Allele slo-1 cDNAa slo-1 cDNAb slo-1 cDNAc
pd17 93.6 % 95.4 % 89.6 %
pd19 93.8 % 96.0 % 90.6 %
pd21 90.5 % 92.3 % 91.0 %
pd23 78.4 % 80.0 % 79.9 %
pd24 96.4 % 98.0 % 94.7 %
pd46 98.8 % 98.8 % 98.8 %
Table 4.01. slo-1 sequencing coverage. Percentage of sequence covered for alleles pd17, 
pd19, pd21, pd23, pd24 and pd46. Percentage of sequence covered for each splice variant is 
shown. 
Mutations were identified in slo-1 in four of the alleles. The sequencing for the mutated 
regions for each allele are shown in the following section. Mutations identified in the cDNA 
were confirmed through sequencing of genomic DNA for each allele. N2 sequence was 
obtained from www.wormbase.org for alignment with slo-1 from the emodepside resistant 
alleles. 
Figure 4.14 shows sequencing for two regions of slo-1(pd17) cDNA in which mutations were 
identified. C1572T and C2583T result in semi-conservative changes in the amino acid 
sequence. Both nucleotides changes result in alanine to valine substitutions in the amino acid 
sequence at aa 524 and 870.
117
A)
B)
Figure 4.14. Sequencing of pd17 slo-1 cDNA.Mutations A) C1572T and B) C2583T were 
identified in pd17 slo-1 cDNA. These were confirmed through sequencing of the regions in 
pd17 genomic DNA.
Figure 4.15 shows sequencing for a region of slo-1(pd19) cDNA in which a mutation was 
identified. pd19 carries the mutation G1294A. This result in a change in the amino acid 
sequence from glycine to arginine at 432.
Figure 4.15. Sequencing of pd19 slo-1 cDNA.Mutation G1294A was identified in pd19 slo-
1 cDNA. This was confirmed through sequencing of the region in pd19 genomic DNA.
C C G C TA TC T CG AG C AG A T T T ACG C G C C G 
pd17 cDNA
N2 sequence
G G A T T C A T T G C T C A A A G C T G T C T G G C A
pd17 cDNA
N2 sequence
C G A A T T T T T C A C G G G G A C T G T C A T G G
pd19 cDNA
N2 sequence
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Figure 4.16 shows sequencing for a region of slo-1(pd23) cDNA in which a mutation was 
identified. pd23 carries the mutation G1511A. This results in a change in the amino acid 
sequence from tryptophan to a stop at 504. 
Figure 4.16. Sequencing of pd23 slo-1 cDNA.Mutation G1511A was identified in pd23 slo-
1 cDNA. This was confirmed through sequencing of the region in pd23 genomic DNA.
Figure 4.17 shows sequencing for a region of slo-1(pd24) cDNA in which a mutation was 
identified. pd24 carries the mutation C1861T. This results in a change in the amino acid 
sequence from glutamine to a stop at 620. 
Figure 4.17. Sequencing of pd24 slo-1 cDNA.Mutation C1861T was identified in pd24 slo-1 
cDNA. This was confirmed through sequencing of the region in pd24 genomic DNA.
C C C C T C C T G G G A C TG G A A A C G AG G T
pd23 cDNA
N2 sequence
T C A T C   C A G   C   C T C A   A  A CN2 sequence
pd24 cDNA
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Table 4.02 summarises the mapping, complementation and sequencing data for emodepside-
resistant alleles. The region in which these mutations lie are also noted. All alleles on which 
snip-SNP mapping was conducted were found to map to chromosome V, on which slo-1 lies. 
All alleles were found to be non-complements of slo-1 alleles js379 or pd23. All mutations 
identified were found to lie in RCK1 and RCK2 (regulator of potassium conductance) C-
terminal domains. js379 lies in between transmembrane domains 4 and 5.
Table 4.02. Summary of emodepside resistant allele particulars. Chromosomal linkage, 
complementation data, slo-1 mutation and region of alleles isolated in screens for emodepside 
resistance. Particulars written in grey had previously been identified (Amliwala 2005).
Figure 4.18 shows the amino acid sequence and a model of SLO-1. The three alternate splice 
variants are highlighted. Mutations in pd17, pd19, pd23, pd24 and js379 are marked. 
Mutations in these alleles are present in all three splice variants. The transmembrane domains, 
RCK domains, voltage sensor, pore domain (P loop) and Ca2+ bowl are marked.
Allele Chromosomal linkage
slo-1 non-
complement
slo-1 aa 
change Region of mutation
pd17 V  A524V A870V
RCK1 αF
RCK2
pd19 V  G432R RCK1 βC
pd21 V  - -
pd23 V  W504Stop RCK1 αE
pd24 -  Q620Stop RCK1 βI to βJ
pd47 -  - -
pd46 -  - -
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MGEIYSPSQSKGFNQPYGYPMNCNLSRVFMEMTEEDRKCLEERKYWCFLLSSITTFCASMILVVIWRVVTHLCCQRREKE
FVEPIPAPEAVQINMNGSKHAPSETDPFLKQQEEKHLGWMTEAKDWAGELISGQSLTGRFLVLLVFILSIGSLIIYFYDA
SFQNFQVETCIPWQDSPSQQIDLGFNIFFLVYFFIRFIAASDKVWFLLEMYSWIDFFTIPPSFVAIYLQRNWLGFRFLRA
LRLMTVPDILQ/StopYLNILKTSSSIRLTQLVTIFVAVCLTGAGLVHLLENSGDFFKGFINPHRITYADSVYFVLVTMS
js379
TVGYGDIYCTTLCGRLFMIFFILFGLAMFASYVPEIADLIGNRQKYGGEYKGEHGKKHIVVCGHITYDSVSHFLQDFLHE
DRDDVDVEVVFLHRVVPDLELEGLFKRHFTKVEFFTG/RTVMDSLDLSRVKIGDADACLVLANKYSTNPDAEDAANIMRV
pd19
ISIKNYSSDIRVIVQLMQYHNKAYLLNIPSW/StopDWKRGDDVICLAELKLGFIA/VQSCLAPGFSTMMANLFAMRSFK
pd23 pd17
TSQTTPDWLNLYLCGAGMEMYTDTLSHSFVGMTFPEAVDLLFNRLGLLLLAIELKDEENKECNIAINPGPHIVIQ/Stop
PHTPLWLNDYLRGAGMEMYTESLSPSFANMSFPEAAN pd24
Splice c alternate exon 9
PQTQGFFIAQSADEVKRAFFWCKQCHDDIKDVSLIKKCKCKNLALFRRNTKHSTAAR*************ARATDVLQQF
DYSDFDALFYQND
Splice c exon 11a
QPQAPAGPMGHLGQQVQLRMINQQ***********************PSSGGRRNSMSIPPDGRGVDFSKDFEQQFQDMK
SSTSDTHLNTKSLRFAYEIKKLM
Splice a exon 13
YDSTGMFHWCPSRNLEDCVLERHQAAMTVLNGHVVVCLFADQDSPLIGLRNFIMPLRSSNFHYHELKHVVIVGDLEYLRK
EWKTLYNLPKISILNGSPLSRA/VDLRAVNINLCDMCVIISARVPNTEDTTLADKEAILASLNIKAMQFDDTLGFFPMRH
pd17
QTGDRSPLGSPISMQKKGAKFGTNVPMITELVNDSNVQFLDQDDDDDPDTELYLTQPFACGTAFAISVLDSLMSTTYFND
SALTLIRTLVTGGATPELELILAEGAGLRGGYSTPETLSNRDRCRIAQISLQDNPYDGVVHNTTYGAMFTIALRRYGQLC
IGLYRLHDQDNPDSMKRYVITNPPAELRIKNTDYVYVLEQFDPGLEYEPGKRHF*
B)
Figure 4.18. SLO-1 amino acid sequence and structure. A) SLO-1 amino acid sequence. There are three 
splice variants and the sequence of these are indicated. The location of the slo-1 mutations for: js379, pd19, 
pd23, pd17, pd24 are indicated. The RCK domains are underlined, the voltage sensor is marked with a broken 
line, the pore domain (P loop) is highlighted in black and the Ca2+ bowl is highlighted in grey. B) cartoon of the 
SLO-1 protein showing the location of the mutations. The voltage sensor (S4), the P loop and Ca2+ sensor (Ca2+
bowl) are also marked. (After Wang et al 2001, Salkoff et al 2006 / based on sequence similarity).
js379
pd19 pd23 pd17 pd24 pd17
S0 S1 S2 S3 S5
+
+
S4 S6
NH2
COOH
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4.6 Discussion
This chapter presents evidence that all highly resistant emodepside strains are alleles of the 
same gene, slo-1. The mapping of pd19 shows that it has linkage to chromosome V. All 
mapped emodepside resistant alleles (Amliwala 2005) showed linkage to chromosome V. 
Two alleles, pd18 and pd20, were shown to map to a region close to slo-1 (~16.8 cM) 
(Amliwala 2005). The mapping data suggest that all the emodepside resistant alleles are likely 
to be alleles of the same gene. All alleles were tested in complementation tests. The 
emodepside resistant strains pd19, pd23, pd21, pd17, pd24, pd47 and pd46 are all non-
complements of slo-1(js379) or pd23 (itself a non-complement of js379). The fact that all 
alleles fall into the same complementation group suggests that they are all alleles of the same 
gene.
The fact that all resistant strains carry alleles of slo-1 indicates that it is key to emodepside’s 
mode of action. slo-1(js379), which has a premature stop codon in the S4 domain, is predicted 
to be a loss-of-function mutant. This implies that it is the loss of SLO-1 function that confers 
resistance to emodepside in slo-1(js379). This suggests that emodepside’s effect on the SLO-1 
channel would be to activate it. Of the mutations identified, all five lie in parts of the slo-1 
gene that code for regions known as regulators of conductance of potassium (RCK) domains. 
There are two RCK domains per SLO-1 α-subunit, RCK1 and RCK2. Both pd23 and pd24
result in the generation of premature stop codons in the RCK1 domain. pd19 results in a 
glycine to alanine substitution in RCK1. pd17 results in two alanine to valine substitutions in 
RCK1 and RCK2 domains. A tetramer of SLO-1 α-subunits is required to form a functional 
channel. In this tetramer of subunits it is proposed that the RCK domains (4 x RCK1 and 4 x 
RCK2) form an intracellular gating ring (Jiang et al 2002). It is thought that this gating ring 
changes conformation on ligand binding, resulting in opening of the channel (Jiang et al
2002). Jiang et al (2002) proposed a model whereby calcium binds in clefts between adjacent 
RCK domains in the tetramer, resulting in a widening of the gating ring. This widening causes 
the channel to open through a pulling of the linkers that connect the gating ring to the channel. 
It is thought that different channels can be gated by a variety of different ligands. It is possible 
that emodepside may affect this mechanism either directly of indirectly to open the channel. 
Second round amplification of slo-1 cDNA in pd47 consistently failed. This could indicate 
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that there is mutation at the site of primer annealing. Mutations upstream of the start codon 
could potentially disrupt the promoter and prevent expression.
A BLAST of RCK1 and RCK2 domains from C. elegans slo-1 revealed homology of these 
domains in calcium-activated potassium channels across species. The amino acid identities for 
RCK ranged from 100% in Caenorhabditis briggsae to  22 % in Trypanosoma cruzi. In 
RCK2 the amino acid identity ranged from 100 % in Caenorhabditis briggsae to 22 % in 
Dictyostelium discoidem. Alignment of C. elegans slo-1 RCK domains with the homologues 
revealed that residue glycine 432 was always conserved. In the allele pd19, glycine 432 is 
substituted for arginine. The alanine residues at position 524 and 870, which are substituted 
for valines in pd17, were less conserved. It is interesting that glycine 432 is always conserved 
as it suggests that it may be important for normal function of this RCK domain. The less 
substantial conservation of alanines 524 and 870 suggests they may be less important for 
normal RCK domain function.
The mutations in pd24 and pd23 are also of interest. The stop codon in pd23 lies 
approximately half way through RCK1. It seems unlikely that a channel with a functional 
gating ring would form with this mutation. It has been shown that BK channels truncated after 
the seventh trans-membrane domain can retain their function when expressed in HEK 293 
cells and Xenopus oocytes (Piskorowski et al 2002). It is therefore possible that a functional 
channel that lacks the majority of RCK1 and all of RCK2 is expressed in pd23. If this is the 
case, it would indicate that the RCK domains are required for emodepside’s mode of action. 
However, Piskorowski et al (2002) also showed that the expression level of the truncated BK 
channel was a 1000 fold lower compared with N2. If this is the case with C. elegans slo-1 in 
pd23, the low level of expression could explain the resistance to emodepside, rather than the 
lack of a gating ring. The same can be said of pd24, which has a stop codon in the latter half 
of RCK1.
Understanding the nature of these mutations may help to understand the mechanism of 
emodepside. It may be that in some cases that the mutations that confer resistance to 
emodepside do not affect SLO-1 function, potentially providing an insight to an emodepside 
binding site on SLO-1. This is further investigated in the following chapter.
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Chapter 5
Behavioural analysis of slo-1 alleles
124
5.1 Introduction
The BK channel SLO-1 is a key mediator of emodepside’s effects. The fact that only slo-1
mutants were isolated from the screens for emodepside resistance supports this idea. In order 
to further understand the role of slo-1 in emodepside’s mode of action an investigation of the 
phenotypes of slo-1 mutants has been undertaken. Through a comparison of slo-1 allele 
phenotypes and the nature of the slo-1 mutations, information on emodepside’s mode of 
action can be obtained. 
It might be expected that if emodepside signals through SLO-1, the highest level of drug 
resistance would be seen in those mutants predicted to be functional nulls. If emodepside 
binds to SLO-1, high levels of emodepside resistance may also be seen in SLO-1 mutants that 
retain their function but have mutations in an emodepside binding site. These theories were 
tested by measuring the level of sensitivity to emodepside and two read outs of SLO-1 
function, the reversal frequency of direction of movement and aldicarb sensitivity. The 
emodepside sensitivity, reversal frequency and aldicarb sensitivity of eight slo-1 alleles is 
investigated. slo-1 mutants were reported to have an increased sensitivity to the ACh esterase 
(ACE) inhibitor aldicarb as well as having an increased tendency to reverse (Wang et al
2001). The emodepside sensitivity of two slo-1 gain-of-function alleles, ky399 and ky389, is 
also investigated. If emodepside acts through SLO-1, the gain of function mutants would be 
predicted to have the same level of sensitivity to emodepside as N2. If loss of SLO-1 function 
acts to oppose emodepside’s action then the effect of gain of SLO-1 function and emodepside 
would be predicted to additive. Figure 5.01 shows the two possible mechanisms of SLO-1 
involvement in emodepside’s mode of action.
A) B)
Figure 5.01. Alternative hypothesises for SLO-1 involvement in emodepside’s mode of 
action. A) Emodepside acts directly through SLO-1 resulting in paralysis. B) SLO-1 function 
complements emodepside’s effects.
Emodepside
SLO-1
Behaviour
Emodepside
Behaviour
SLO-1
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The forward movement of C. elegans is interspersed with spontaneous reversals (Chiba and 
Rankin 1990). The neuronal circuit controlling forward and backward movement was first 
described in the context of mechano-sensation (Chalfie et al 1985, White et al 1986). The 
command interneurons AVA, AVB, AVD/E and PVC receive input from a variety of sensory 
neurons and inter-neurons. The output from the command inter-neurons is directed to a subset 
of motor-neurons, initiating either forward or backward movement (Chalfie et al 1895, Zheng 
et al 1999). The command inter-neurons AVA and AVD/E control backward movement and 
AVB and PVC control forward movement. It is thought that the command interneurons have 
an intrinsic activity and that reversal frequency is regulated by the level of neuronal 
depolarisation (Zheng et al 1999). The increased reversal frequency of slo-1(js379) suggests 
that there is an increase in neuronal activity within the command inter-neurons. Increased 
neuronal activity may result from loss of SLO-1 function. If this is the case, reversal 
frequency provides a read-out for the level of SLO-1 function.
Reduced aldicarb sensitivity in C. elegans is thought most likely to reflect defects in synaptic 
transmission (Miller et al 1996). Mutants with hyperactive neurotransmission have been 
shown to be hypersensitive to the effects of aldicarb (Nurrish et al 1999). Wang et al (2001) 
showed that slo-1 loss-of-function mutants were hypersensitive to aldicarb. Davies et al 
(2003) showed that slo-1 gain-of-function mutants had reduced sensitivity to aldicarb. These 
increases and decreases in aldicarb sensitivity are likely to reflect changes in the level of ACh 
release resulting from altered neuronal activity. In this case, aldicarb should also provide a 
read-out for the level of SLO-1 function. However, the apparent effect of SLO-1 loss of 
function on aldicarb sensitivity should be viewed with caution. Rescue of aldicarb sensitivity 
of slo-1 mutants has not been demonstrated and the aldicarb sensitivity of hypomorphic slo-1 
alleles is not consistent (Wang et al 2001). 
Prior to phenotypic analysis, the slo-1 alleles pd17, pd19, pd21, pd23, pd24, pd46 and pd47
were out-crossed three times into the N2 genetic background to remove extraneous mutations. 
slo-1 homozygous outcrossed animals were selected based on resistance to emodepside. The 
parameters used to define emodepside resistance in the mutagenesis screen were used for this 
selection. The slo-1(js379) strain NM1968 was obtained from the CGC, outcrossed five times. 
The strains CX3940 and CX3933, which carry ky399 and ky389, respectively, were obtained 
from the CGC. CX3933 was obtained outcrossed three times. CX3940 was obtained 
outcrossed once and carrying rol-6(e187). In order to assay CX3940, rol-6(e187) was 
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outcrossed. Outcrossed ky399 were selected based on egg laying and locomotion phenotypes 
(Davies et al 2003). Due to the semi dominant nature of ky399, selection of homozygous 
ky399 was confirmed by the absence of N2 like egg laying and locomotion phenotypes in the 
progeny. ky399 retain eggs and have sluggish locomotion.
Out crossed alleles were used in all assays excluding aldicarb assays. This was due to the 
emergence of aldicarb hypersensitivity in the N2 strain propagated in house during the course 
of this project. This aldicarb hypersensitivity is likely to be due to spontaneous mutation. The 
out crossed alleles therefore potentially carry this mutation. This highlights the need for 
caution when interpreting aldicarb sensitivity data. In order to allow for this, un-outcrossed 
slo-1 alleles were compared to an N2 from which they were generated from prior to the 
emergence of aldicarb hypersensitivity. Outcrossed slo-1 alleles were compared to the N2
with which they were outcrossed. N2 and the aldicarb hypersensitive N2 displayed the same 
reversal frequency and emodepside sensitivity as each other. Therefore, the presence or 
absence of the mutation conferring aldicarb hypersensitivity in the out crossed strains will not 
influence the outcome of these assays.
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5.2 slo-1(js379) is emodepside insensitive
Previously, sensitivity of slo-1(js379) to emodepside’s effects on locomotion had been 
assessed using the thrashing assay (Amliwala, 2005). Due to problems with the solubility of 
emodepside, this project adopted the body bends assay was used in order to assess 
emodepside sensitivity. Further more, all assays were performed in parallel with N2 controls. 
Figure 5.02 shows a dose response curve for N2 and slo-1(js379). Animals were exposed to 
emodepside for 24 hours and then assayed off food. Emodepside significantly inhibited the 
locomotion of N2 and at 100 nM, 1 μM and 10 μM. slo-1(js379) was not significantly 
inhibited at these concentrations. N2 have an IC50 of 100 nM, 95 % confidence limits 68 nM 
to 146. No IC50 for slo-1(js379) could be measured as emodepside does not inhibit its 
locomotion. This illustrates the high level of resistance that slo-1(js379) have to emodepside.
Figure 5.02. slo-1(js379) dose response for emodepside. slo-1(js379) (■) and N2 (▲). For 
each point n≥12 and is the mean  S.E.Mean. *** indicates P<0.001.
slo-1(js379) are unaffected by concentrations as high as 10 μM. This high level of resistance 
is also reflected in the lack of effect that emodepside has on the sinusoidal shape of movement 
of slo-1(js379). Figure 5.03 shows the effect of 24 hour exposure to 1 μM emodepside on the 
sinusoidal movement of N2 and of slo-1(js379) on food. Photographs show 24 hour post L4 
worms. N2 lose their sinusoidal shape on 1 μM emodepside and extend their anterior in a 
straight line. slo-1(js379) retain their sinusoidal shape on 1 μM emodepside.
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Figure 5.03. Emodepside’s effects on N2 and slo-1(js379) body posture. All photograph 
show 24 hour post L4 worms. A) N2 exposed to vehicle for 24 hours, B) Two N2 exposed to 
1 μM emodepside for 24 hours, C) slo-1(js379) exposed to vehicle for 24 hours, D) slo-
1(js379) exposed to 1 μM emodepside for 24 hours.
5.3 Quantification of emodepside resistance in slo-1 alleles
The level of resistance to emodepside of slo-1 alleles js379, pd17, pd19, pd21, pd23, pd24, 
pd46 and pd47 was tested in the body bends assay. L4 worms were picked onto 1 M 
emodepside-containing NGM plates for 24 hours on food. They were also picked onto 0.5 % 
ethanol vehicle NGM plates. After 24 hours the young adults were picked onto an un-seeded 
NGM plate for one minute in order to remove any OP50. They were then picked to an un-
seeded assay plate and left to recover for one minute. Finally body bends were counted for 
one minute. Figure 5.04 shows effect of 1 M emodepside on these animals. This illustrates 
that not all slo-1 alleles exhibit the same high level of emodepside resistance observed in 
js379.
A) B)
C) D)
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Figure 5.04. slo-1 allele emodepside sensitivities. The effect of 24 hour exposure to 1 M 
emodepside on locomotion of N2, js379, pd47, pd19, pd23, pd17, pd24, pd46 and pd21. □ 
shows animals exposed to vehicle and ■ shows animals exposed to 1μM emodepside. For 
each bar n≥8 and is the mean  S.E. Mean. * indicates P<0.05, ** indicates P<0.01 and ***
indicates P<0.001
The locomotion of N2, pd17, pd46 is significantly inhibited by 1 M emodepside, with 
P<0.01. pd17 and pd46 appear to be as sensitive to 1 M emodepside as N2 with regard to 
their rate of locomotion. However, they retain a sinusoidal pattern of movement on 1 M 
emodepside as observed in strains with stronger resistance. The locomotion of pd19 and pd21
is significantly inhibited by 1 M emodepside, although to a lesser extent, with P values of 
P<0.05 and P<0.01, respectively. The locomotion of js379, pd47, pd23 and pd24 is not 
inhibited by 1 M emodepside. 
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5.4 Reversal frequency of slo-1 alleles
Worms were assayed off food so that foraging behaviour would be initiated and reversal 
frequency increased, thereby reducing the assay time required. Worms were selected at L4 
stage and kept on food for 24 hours. Worms were then individually transferred to an unseeded 
plate to reduce the amount of E. coli OP50 transferred to the assay plate. After 1 minute each 
worm was then transferred to an unseeded assay plate. After five minutes of acclimatization, 
the number of reversals the worm made in 1 minute was recorded. Assays were performed 
blind and conducted in parallel with N2 controls. 
Figure 5.05. slo-1 allele reversal frequencies. Number of reversals in one minute of N2, 
js379, pd47, pd19, pd23, pd17, pd24, pd46 and pd21 after five minutes off food. For each bar 
n≥10 and is the mean  the S.E. Mean. * indicates P<0.05 and *** indicates P<0.001 
compared with N2.
Figure 5.05 show average reversal frequency of each slo-1 allele compared with the average 
reversal frequency of N2. The reversal frequencies of pd17 and pd21 do not significantly 
differ from that of N2. The reversal frequency of pd46 is slightly but significantly increased 
compared to N2 (P<0.05). The reversal frequencies of pd47, pd19, pd23 and pd24 are 
significantly increased compared with N2 (P<0.001). In general there is a correlation between 
reversal frequency and emodepside sensitivity. However, pd21 has a reversal frequency 
comparable to that of N2 whereas its has strong resistance to emodepside. 
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5.5 Aldicarb sensitivity of slo-1 alleles
L4 worms were selected 24 hours before the assay. The assay was performed blind. Young 
adults were transferred to 0.5 mM aldicarb containing NGM plates seeded with OP50. Worms 
were assayed on food to prevent the worms from moving off the plate. 15 worms were placed 
on each plate. The number of paralysed worms was recorded every 30 minutes. Paralysis was 
assessed through a single prod with a platinum wire pick. Multiple trials were conducted for 
each strain. One trial refers to a single plate of worms assayed. Experiments were run with 
parallel controls. Paralysed worms were removed from the plate.
Figure 5.06 A) shows the average percentage of animals paralysed by 0.5 mM aldicarb from 
16 trials. slo-1(js379) are paralysed by 0.5 mM aldicarb at a quicker rate that N2. A 
significantly higher proportion of slo-1(js379) are paralysed after 60, 90 and 120 minutes on 
0.5 mM aldicarb (P<0.001). This result is similar to that observed by Wang et al (2001). 
Figure 5.06 B) shows the average percentage of animals paralysed by 0.5 mM aldicarb from 
≥10 trials. slo-1(pd24) are paralysed by 0.5 mM aldicarb at a quicker rate that N2. A 
significantly higher proportion of slo-1(pd24) are paralysed after 60, 90 and 120 minutes on 
0.5 mM aldicarb with P<0.05, P<0.001 and P<0.01, respectively. Figure 5.06 C) shows the 
average percentage of animals paralysed by 0.5 mM aldicarb from ≥4 trials. slo-1(pd19) are 
paralysed at the same rate as N2 by 0.5 mM aldicarb. Figure 5.06 D) shows the average 
percentage of animals paralysed by 0.5 mM aldicarb from  ≥4 trials. slo-1(pd23) are paralysed 
at the same rate as N2 by 0.5 mM aldicarb. Figure 5.06 E) shows the average percentage of 
animals paralysed by 0.5 mM aldicarb from  ≥4 trials. slo-1(pd17) are paralysed by 0.5 mM 
aldicarb at a quicker rate that N2. A significantly higher proportion of slo-1(pd17) are 
paralysed after 30, 60 and 90 minutes on 0.5 mM aldicarb with P<0.01, P<0.001 and 
P<0.001, respectively. Figure 5.06 F) shows the average percentage of animals paralysed by 
0.5 mM aldicarb from  ≥3 trials. slo-1(pd47) are paralysed by 0.5 mM aldicarb at a quicker 
rate that N2. A significantly higher proportion of slo-1(pd47) are paralysed after 60 and 90 
minutes on 0.5 mM aldicarb with P<0.05 and P<0.01. Figure 5.06 G) shows the average 
percentage of animals paralysed by 0.5 mM aldicarb from  ≥2 trials. slo-1(pd21) are paralysed 
at the same rate as N2 by 0.5 mM aldicarb. Figure 5.06 H) shows the average percentage of 
animals paralysed by 0.5 mM aldicarb from  ≥2 trials. slo-1(pd46) are paralysed by 0.5 mM 
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aldicarb at a quicker rate that N2. A significantly higher proportion of slo-1(pd46) are 
paralysed after 90 minutes on 0.5 mM aldicarb (P<0.01).
No correlation can be drawn between the level of resistance to emodepside and the sensitivity
to aldicarb. In the cases of js379, pd24 and pd47, strong resistance to emodepside and high 
sensitivity to aldicarb are observed. However, pd23 is strongly resistant to emodepside but its 
sensitivity to aldicarb is not significantly different to that of N2. pd17 and pd46 are weakly 
resistant to emodepside yet both are significantly more sensitive to aldicarb than N2. pd19 and 
pd21 have an intermediate level of resistance to emodepside but are not significantly more 
sensitive to aldicarb than N2. Although mutations present in the background of these strains 
may affect their aldicarb sensitivity, the lack of any correlation suggests an uncoupling 
between emodepside resistance and aldicarb hypersensitivity.
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G) pd21 H) pd46
Figure 5.06. slo-1 allele aldicarb sensitivities. Time until paralysis on 0.5 mM aldicarb of 24 hour post L4 worms on food: A) N2 (■) and js379 
(♦), each point is the mean  S.E.Mean of 16 trials, B) N2 (■) and pd24 (▲), each point is the mean  S.E.Mean of ≥ 10 trials, C) N2 (■) and 
pd19 (), each point is the mean  S.E.Mean of ≥ 4 trials, D) N2 (■) and pd23 (●), each point is the mean  S.E.Mean of ≥ 4 trials, E) N2 (■) 
and pd17 (▼), each point is the mean  S.E.Mean of ≥ 4 trials, F) N2 (■) and pd47, each point is the mean  S.E.Mean of ≥ 3 trials, G) N2 (■) 
pd21 (), each point is the mean  S.E.Mean of ≥ 2 trials, H) N2 (■) and pd46 (), each point is the mean  S.E.Mean of ≥ 2 trials. * indicates 
P<0.05, ** indicates P<0.01 and *** indicates P<0.001.
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5.6 slo-1(ky399) and slo-1(ky389) gain-of-function mutants phenocopy  
emodepside treated N2 and are not emodepside hypersensitive
The slo-1 gain-of-function mutants ky399 and ky389 were previously isolated as nsy-3
mutants in a screen of neuronal symmetry (Tromel et al 1999). Both slo-1(ky389) and slo-
1(ky399) have defects in locomotion and egg laying (Davies et al 2003). 
The sensitivity of slo-1(ky399) and slo-1(ky389) to emodepside’s effect on locomotion was 
tested using the body bends assay. Animals were exposed to emodepside for 24 hours and 
then assayed off food. Most notably, the basal rate of locomotion of slo-1(ky399) and slo-
1(ky389) is significantly lower than that of N2. this is consistent with the suggestion that these 
slo-1 gain of function mutants phenocopy the effects of emodepside. Despite this lower 
locomotion rate, the IC50 for emodepside was not altered. Figure 5.07 shows a dose response 
for N2 and slo-1(ky399) and slo-1(ky389). The IC50 of N2, slo-1(ky399) and slo-1(ky389) are 
not significantly different.. N2 have an IC50 of 52 nM (95 % confidence limits 32 nM to 
84nM). slo-1(ky399) have an IC50 of 130 nM (95 % confidence limits 48 nM to 347 nM). slo-
1(ky389) have an IC50 of 130 nM (95 % confidence limits 62 nM to 273 nM).
Figure 5.07. Emodepside dose response for slo-1 gain-of-function mutants. slo-1(ky399) 
(▲), slo-1(ky389) (▼) and N2 (■). For each point n=10 and is the mean  S.E.Mean. ** 
indicates P<0.01 and *** indicates P<0.001. Comparison are made between N2 vs slo-
1(ky389) (shown above) and N2 vs slo-1(ky399) (shown below).
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A more detailed consideration of the phenotype of slo-1 gain of function showed that both 
slo-1(ky399) and slo-1(ky389) phenocopy the effects of emodepside on N2. As well as the 
effects on its locomotion, egg laying is significantly decreased in both slo-1(ky399) and slo-
1(ky389) (Davies et al 2003). Similarly, emodepside inhibits egg laying and locomotion in N2
(Bull et al 2007, Wilson et al 2003). The appearance of the locomotion of slo-1(ky399) and 
slo-1(ky389) resembles that of N2 exposed to 10 nM or 100 nM emodepside, with shallower 
bends and a tendency to elongate their anterior.
137
5.7 Discussion
The high level of emodepside resistance observed in the putative null slo-1(js379) suggests 
that emodepside activates SLO-1 dependent pathway. If loss of SLO-1 function only acted to 
oppose the paralytic action of emodepside, it would be expected that the resistance would be 
less substantial. However, emodepside appears to have no effect on slo-1(js379) at 
concentrations as high as 10 μM. Effects of emodepside on N2 are apparent at concentrations
lower than 10 nM in the body bends assay.
The phenotypes of the slo-1 alleles are presented in table 5.01. There is a correlation between 
the level of emodepside resistance and reversal frequency, with some exceptions. The alleles 
js379, pd23, pd24 and pd47 confer insensitivity to 1 μM emodepside. js379, pd23, pd24 and 
pd47 all display a frequency of reversal that is significantly increased compared to N2
(P<0.001). pd17 and pd46 confer a low level of resistance to emodepside. The reversal 
frequency of pd17 is not significantly different from that of N2. The reversal frequency of 
pd46 is only slightly increased compared to that of N2 (P<0.05). In general, alleles that show 
the highest resistance have the strongest slo-1 loss of function phenotype.
The exception to this is pd21. pd21 has an intermediate level of resistance but has a reversal 
frequency not significantly different to that of N2. This suggests that SLO-1 function is 
retained in pd21 while emodepside sensitivity is reduced. This may indicate a directed action 
of emodepside on SLO-1. pd19 also has an intermediate level of resistance to 1 μM 
emodepside, although the statistical significance of this is low (P<0.05). The frequency of 
reversal of pd19 is significantly greater than that of N2 (P<0.001). This could suggest that 
loss of SLO-1 acts to oppose emodepside’s effects. Alternatively the mutation in pd19 may 
reduce SLO-1 function to a level sufficient to result in a reversal frequency that is 
significantly different from N2 whilst retaining some emodepside sensitivity. The bulk of the 
evidence suggests an action of emodepside through SLO-1.
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Allele 1) Emodepside resistance level
2) Reversal frequency 
increase – compared 
to N2
3) Aldicarb 
sensitivity at T90
js379 ++++ (High) *** ***
pd23 ++++ (High) *** ns
pd24 ++++ (High) *** ***
pd47 ++++ (High) *** **
pd19 +++ (intermediate) *** ns
pd21 ++ (intermediate) ns ns
pd17 + (low) ns ***
pd46 + (low) * **
Table 5.01. slo-1 allele phenotype summary. 1) Level of resistance to 1 μM emodepside. 
Comparisons made between 1 μM emodepside and 0.5 % ethanol vehicle treated worms. 
++++ indicates ns (most resistant), +++ indicates P<0.05, ++ indicates P<0.01, + indicates 
P<0.001 (least resistant). 2) The statistical significance of increases in reversal frequency for 
each slo-1 allele are shown. 3) The statistical significance of increases in aldicarb sensitivity 
after 90 minutes exposure for each slo-1 allele are shown. . * indicates P<0.05, ** indicates 
P<0.01 and *** indicates P<0.001.
The level of aldicarb sensitivity in these mutants does not correlate well with the reversal 
frequency or emodepside resistance. The lack of any correlation between emodepside 
resistance / reversal frequency and aldicarb hyper-sensitivity might indicate that these 
phenotypes do not originate through the same mechanism. This could either be through a 
different mechanism involving slo-1 or alternatively, a mechanism unrelated to slo-1.
js379 is a putative null mutant that is hypersensitive to aldicarb. However, the relationship 
between slo-1 function and aldicarb sensitivity does not appear to be consistent. Of the two 
mutants that have premature stop codons generated in the emodepside resistance screen, two 
are aldicarb hypersensitive (js379 and pd24) and one is not (pd23). The mutation in pd23
would be expected to result in truncation of slo-1 earlier in the sequence than pd24. If loss of 
SLO-1 function results in aldicarb hypersensitivity, both pd24 and pd23 would be expected to 
be aldicarb hypersensitive. The fact that they are not suggests that the aldicarb hyper-
sensitivity may be un-related to these mutations in slo-1. In a similar way, slo-1 suppressors 
of the unc-64 lethargic phenotype also had large variations in their aldicarb sensitivity (Wang 
et al 2001). The allele md1745 has an early stop codon between the S0 and S1 transmembrane 
domains (Q134Stop), compared with js379 which has an early stop codon in the S4 
transmembrane domain (W850Stop). However, js379 is substantially more sensitive to 
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aldicarb than md1745. Expression of slo-1(+) in aldicarb hypersensitive slo-1 loss of function 
mutants is required to definitively address this question.
The available evidence suggests that greater loss of SLO-1 function result in stronger 
emodepside resistance and reversal frequency phenotypes. Alleles with premature stop 
codons (js379, pd24, pd23) have a high level of emodepside resistance (++++) and a reversal 
frequency highly significantly increased compared to N2 (***). The amino acid change 
G432R in pd19 results in a lower level of emodepside resistance (+++) and a reversal 
frequency highly significantly increased compared to N2 (***). The amino acid changes 
A524V and A870V in pd17 result in a low level of emodepside resistance (+) and a reversal 
frequency not significantly different compared to N2 (ns). It seems likely that reversal 
frequency reflects the level of SLO-1 function. However, if emodepside acts through SLO-1 
directly, it may be possible to generate emodepside resistant alleles that do not affect SLO-1 
function. Mutation of a possible emodepside binding site on SLO-1 could result in a high 
level of resistance whilst leaving SLO-1 function unaffected. It is possible that this is the case 
with pd21. Unfortunately, sequencing of pd21 slo-1 cDNA is yet to identify a mutation.
The slo-1 gain-of-function mutants ky399 and ky389 are not hypersensitive to emodepside. If 
loss of SLO-1 function confers emodepside resistance by indirectly opposing its paralytic 
effects, it would be expected that the effects of SLO-1 gain-of-function and emodepside 
would be additive. The fact that it is not suggests that emodepside acts directly through SLO-
1, or a SLO-1 dependent pathway.
The effect of slo-1 function on aldicarb sensitivity is unclear. The lack of correlation between 
emodepside resistance / reversal frequency and aldicarb sensitivity and the unexplained 
variability in aldicarb sensitivity of slo-1 alleles shows that further investigation is required. 
Importantly, rescue of this phenotype through the generation of slo-1(js379) expressing slo-
1(+) was not demonstrated directly by Wang et al (2001). Therefore the suggestion that SLO-
1 loss of function increases aldicarb sensitivity is in doubt. Attempts to address this are made 
in the following chapter.
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Chapter 6
Tissue specific analysis of the role of 
SLO-1 in emodepside’s mode of 
action
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6.01 Introduction
The genetic evidence suggests that emodepside causes activation of the BK channel SLO-1. 
Activation may result from direct binding of emodepside or activation via a pathway. As BK 
channels provide a mechanism for cell repolarisation, activation of SLO-1 channels would be 
expected to reduce cell excitability. The aim of this chapter is to investigate the effect that 
emodepside has on cell excitability and how this results in inhibition of locomotion. This was 
addressed using two approaches. A pharmacological analysis was used to test whether 
emodepside increases or decreases the activity of cholinergic motor neurons or body wall 
muscle. In addition, cell specific expression of wild type slo-1 in the slo-1(js379) null genetic 
background was used to assess whether emodepside requires slo-1 in neurons and/or muscle 
to inhibit locomotion.
In neurons reduced cell excitability would impact on neurotransmitter release. However, it is 
unclear whether BK channel activation reduces or increases neurotransmitter release. 
Warbington et al (1996) found that loss of function of Drosophila melanogaster SLO channel 
results in a decrease in neurotransmitter release. Xu et al (2005) demonstrated that specific 
block of BK channels in the salamander rod synapse could decrease transmitter release. This 
is possible in the salamander rod synapse as its confined structure prevents diffusion of the 
potassium ions out of the synaptic cleft, resulting in a high local concentration (Towns-
Anderson et al 1985). However, the morphology of C. elegans synapses does not resemble 
that of the salamander rod synapse. In fact, the structure of C. elegans synapses is far simpler. 
Synapses in C. elegans occur en passant. The pre-synaptic specialisations vary in size and 
complexity. The post-synaptic elements have no visible specialisation and are often quite 
ambiguous (White et al 1986). It is hard to imagine that the potassium induced calcium 
currents that occur in the salamander rod synapse could occur by the same mechanism at 
these synapses, where ions could easily diffuse. The most relevant evidence for the role of 
SLO-1 in neurotransmitter release comes from a paper by Wang et al (2001). slo-1 was 
identified in a screen for C. elegans mutants that would suppress the lethargic phenotype of 
the syntaxin hypomorph unc-64. unc-64(e246) has reduced neurotransmitter release, which 
has been demonstrated using the acetylcholine esterase (ACE) inhibitor aldicarb. unc-
64(e246) has a reduced aldicarb sensitivity which can be rescued by slo-1. Although the role 
of slo-1 in aldicarb sensitivity is not clear, slo-1 does rescue the unc-64 lethargic phenotype. 
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Neuronal expression of slo-1(+) in the unc-64, slo-1 double mutant abolished rescue of the 
lethargic phenotype. This suggests the role of SLO-1 in C. elegans is to reduce 
neurotransmitter release. Therefore, it would be expected that emodepside would cause a 
reduction in neurotransmitter release. 
Pharmacological compounds can be used as tools to inform about cell excitability. Aldicarb 
and levamisole have been used in this way in the following chapter. Aldicarb is an ACE 
inhibitor. ACE metabolises ACh in the synaptic cleft to control the duration of its response. 
Block of ACE results in a build up of ACh and paralysis of the muscle. The sensitivity of 
mutants or drug treated worms to aldicarb can be used to provide an indication of changes in 
ACh release (Miller et al 1996). An increased sensitivity to aldicarb indicates there is an 
increase in ACh release. Levamisole is a nicotinic ACh receptor agonist (Lewis et al 1980). It 
cause hyper-contraction and paralysis of the body wall muscle through activation of post-
synaptic nicotinic ACh receptors (Lewis et al 1980, Fleming et al 1997, Culetto et al 2004). 
The sensitivity of a mutant or drug treated worm to levamisole can be used to provide an 
indication of changes in muscle cell excitability. An increased sensitivity to levamisole 
indicates an increase in muscle cell excitability. The mechanisms of action of both aldicarb 
and levamisole are illustrated in figure 6.01.
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Figure 6.01. Aldicarb and levamisole modes of action. Aldicarb inhibits ACE in the 
neuromuscular junction, preventing the break down of ACh. ACh continues to activate post-
synaptic receptors, leading to paralysis of the muscle. Levamisole in an ACh agonist that 
activates post-synaptic nicotinic ACh receptors, leading to paralysis of the muscle. 
In this chapter the effect of emodepside pre-treatment on the sensitivity to aldicarb and 
levamisole has been used to provide an indirect indicator of how it might influence 
neuromuscular transmission.
ACh ACE
Aldicarb
Neuron
Muscle
Levamisole
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6.02 C. elegans transformations
In order to understand the role of SLO-1 in emodepside’s mode of action, tissue specific 
rescue of slo-1 in the neurons or body wall muscle of slo-1(js379) was undertaken. The 
vectors pBK3.1 and pBK4.1 for these experiments were kindly provided by Lawrence Salkoff 
(Wang et al 2001). pBK3.1 contains slo-1 cDNAa under  the control of the neuronal promoter 
psnb-1 (Nonet 1999). pBK4.1 contains slo-1 cDNAa under the control of the body wall 
muscle pmyo-3. These were injected into the syncytium of young adults slo-1(js379) in order 
to generate transgenic progeny. The injection marker pPD118.33 was used. pPD118.33 
contains gfp under control of the pharyngeal muscle promoter pmyo-2. This was co-injected 
with pBK3.1 and pBK4.1. Co-injected vectors that share homology undergo frequent 
recombination reactions. These reactions drive the assembly of large contiguous arrays which 
become heritable if they attain a sufficient size (Mello et al 1991). pBK3.1 and pBK4.1 have 
3168 bp and 3377 bp of identity with pPD118.33, respectively. Transgenic animals that 
express pmyo-2::gfp are therefore likely to carry the co-injected vectors within the extra-
chromosomal array. Once the extra-chromosomal arrays are formed, the frequency of 
recombination is greatly reduced and they are propagated indefinitely with little further 
rearrangement (Mello et al 1991). Stable lines, in which the extra-chromosomal array is 
propagated, were used in all assays. 
Initial control experiments were conducted to confirm that the pPD118.33 marker did not 
confer sensitivity to emodepside in slo-1(js379). Stable lines of slo-1(js379) carrying 
pPD118.33 were established. The sensitivity of worms expressing the marker to 10 M 
emodepside was tested in a locomotion assay. L4 worms expressing the pmyo-2::gfp marker 
were exposed to 10 M emodepside on food containing NGM plates for 24 hours. Body 
bends of the young adult worms were then counted for one minute off food on 10 M 
emodepside NGM plates (see methods). Figure 6.02 shows the rate of locomotion of N2, slo-
1(js379) and slo-1(js379) expressing pmyo-2::gfp with and without exposure to 10 M 
emodepside. 
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Figure 6.02. Transfection marker control assay. Rate of locomotion of N2, slo-1(js379) 
and slo-1(js379) transformed with pPD118.33 (Pmyo-2::GFP). Clear bars show the rate of
locomotion off emodepside (on vehicle) and filled bars show the rate of locomotion on 10 μM 
emodepside. N=6 for slo-1(js379) on emodepside and N=8 for the rest.. Each bar is the mean 
 S.E.Mean. *** indicates P<0.001.
N2 worms are significantly inhibited by 10 M emodepside (P<0.01) compared with  the 
vehicle control. The locomotion of slo-1(js379) on 10 M emodepside is not significantly 
different to locomotion on vehicle control. The locomotion of slo-1(js379) expressing pmyo-
2::gfp on 10 M emodepside is not significantly different to locomotion on vehicle control. 
This demonstrates that the expression of pmyo-2::gfp does not affect the sensitivity of slo-
1(js379) to emodepside. It seems unlikely that expression of gfp in the pharyngeal muscle 
would directly effect sensitivity to emodepside. However, it has been observed that strong 
expression of pmyo-2::gfp can slow development and this could potentially have implications 
for emodepside sensitivity (Bull et al 2007).
Before assays were conducted on the transgenic slo-1(js379) carrying either pBK3.1 or 
pBK4.1, the presence of these vectors was confirmed using PCR. Figure 6.03 shows maps for 
these plasmids as well as the PCR products obtained using DNA extracted from transgenic 
worms, the vector and N2 worms. 
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Figure 6.03. Confirmation of presence of vectors pBK3.1 and pBK4.1 by PCR. A and B
shows 1267 bp PCR amplified fragments from the vectors pBK4.1 and pBK3.1, respectively. 
Primers complementary for sequences in the slo-1 cDNA and terminator sequence of these 
vectors were used. A) Template DNA for this reaction was taken from 3 populations of slo-
1(js379) transformed with pBK4.1 (1, 2 and 3), pBK4.1 (4) and N2 (5). Number 6 is a H2O 
control. B) Template DNA for this reaction was taken from populations of slo-1(js379) 
transformed with pBK3.1 (1, 2 and 3), pBK3.1 (4) and N2 (5). Number 6 is a H2O control. C) 
Shows vector maps for pBK4.1 and pBK3.1. The PCR amplified regions are marked with 
arrow heads.
The vectors were detected in the transgenic animals using primers within the slo-1 cDNA and 
in the unc-54 terminator sequence contained in these vectors (see vector maps figure 6.03). 
DNA was extracted from three populations of worms expressing the pmyo-2::gfp marker for 
both pBK3.1 and pBK4.1 stable lines. The expected size band produced using the primers 
marked in figure 6.03 is 1267 bp. Figure 6.03 A) shows that the expected 1267 bp band is 
produced with DNA extracted from stable lines carrying pBK4.1 and  the pBK4.1 vector but 
is not produced with control N2 DNA or negative water control. Figure 6.03 B) shows that the 
expected 1267 bp band is produced with DNA extracted from stable lines carrying pBK3.1 
js379     js379     js379   pBK3.1 N2 -ve       ladder
pBK3.1  pBK3.1  pBK3.1 vector
1           2            3            4           5           6
1267 bp
ladder js379     js379     js379    pBK4.1   N2 -ve
pBK4.1  pBK4.1  pBK4.1 vector
1            2        3            4           5           6
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and  the pBK3.1 vector but is not produced with control N2 DNA or negative water control. A 
slo-1(js379) expressing pmyo-2::gfp control was also found not to produce the 1267 bp band 
in this reaction (see appendix). These PCRs demonstrate the presence of the pBK3.1 and 
pBK4.1 vectors in the pmyo-2::gfp expressing stable lines.
6.03 Neuronal expression of slo-1 restores emodepside sensitivity to slo-
1(js379)
Locomotion assays were conducted on worms expressing slo-1 cDNAa in neurons. L4 slo-
1(js379), N2 and slo-1(js379) expressing slo-1(+) in the neurons were picked to 1 nM, 10 nM, 
100 nM, 1 M and 10 M emodepside containing NGM plates for 24 hours on food. They 
were also picked to 0.5 % ethanol vehicle NGM plates for 24 hours on food. After 24 hours 
the young adults were picked to an un-seeded NGM plate for one minute in order to remove 
any OP50. They were then picked to an un-seeded assay plate and left to recover for one 
minute. Finally body bends were counted for one minute. Figure 6.04 shows a dose response 
curve for these animals.
Figure 6.04. slo-1 neuronal rescue of emodepside sensitivity. Dose response curves for 
emodepside on N2 (■), slo-1(js379) (♦) and slo-1(js379) expressing slo-1(+) from the neuron 
specific promoter psnb-1 (▲). For each point n is between 6 and 32. Each point is the mean 
S.E.Mean. * indicates P<0.05 and *** indicates P<0.001. Comparisons are made between 
slo-1(js379) (♦) and slo-1(js379) expressing slo-1(+) from the neuron specific promoter psnb-
1 (▲).
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The dose response for slo-1(js379) expressing slo-1(+) in the neurons is pooled data from two 
independent lines. N2 and slo-1(js379) controls were run in parallel with the transgenic lines. 
The IC50 for N2 in this assay is 11 nM. slo-1(js379) are uninhibited at all concentrations of 
emodepside. The IC50 for slo-1(js379) expressing slo-1(+) in the neurons is 109 nM. slo-
1(js379) expressing slo-1(+) in the neurons is significantly inhibited by 100 nM, 1 μM and 10 
μM emodepside compared to slo-1(js379) with P<0.05, P<0.001 and P<0.001, respectively. 
N2 is significantly more sensitive to emodepside than slo-1(js379) expressing slo-1(+) in the 
neurons at 100 nM with P<0.001.
A different phenotype to that of N2 was observed in the slo-1(js379) expressing slo-1(+) in 
the neurons when on 10 μM emodepside. The photographs in figure 6.05 show these 
phenotypes. On 10 μM emodepside slo-1(js379) has a normal sinusoidal pattern of movement 
(Figure 6.05 A). N2 looses the ability to move in a normal sinusoidal manner as emodepside 
causes a flaccid paralysis (Figure 6.05 B). slo-1(js379) expressing slo-1(+) in the neurons 
displayed a coiling phenotype in many cases (Figure 6.05 C).
A) B) C)
Figure 6.05. Neuronal rescue phenotype on emodepside. Strain phenotypes on 10 μM 
emodepside. A) slo-1(js379) on 10 μM emodepside. B) N2 on 10 μM emodepside. C) slo-
1(js379) expressing slo-1(+) in the neurons displays a coiling behaviour not observed in N2 or 
slo-1(js379) on 10 μM emodepside.
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6.04 Body wall muscle expression of slo-1 restores emodepside sensitivity
Locomotion assays were conducted on worms expressing slo-1 cDNAa in body wall muscle. 
L4 slo-1(js379), N2 and slo-1(js379) expressing slo-1(+) in the body wall muscle were picked 
to 1 nM, 10 nM, 100 nM, 1 M and 10 M emodepside containing NGM plates for 24 hours 
on food. They were also picked to 0.5 % ethanol vehicle NGM plates for 24 hours on food. 
After 24 hours the young adults were picked to an un-seeded NGM plate for one minute in 
order to remove any OP50. They were then picked to an un-seeded assay plate and left to 
recover for one minute. Finally body bends were counted for one minute. Figure 6.06 shows a 
dose response curve for these animals.
Figure 6.06. slo-1 body wall muscle rescue of emodepside sensitivity. Dose response 
curves for emodepside on N2 (■), slo-1(js379) (♦) and slo-1(js379) expressing slo-1(+) from 
the body wall muscle specific promoter pmyo-3 (▼). For each point n is between 6 and 34. 
Each point is the mean  S.E.Mean. *** indicates P<0.001. Comparisons are made between 
slo-1(js379) (♦) and slo-1(js379) expressing slo-1(+) from the body wall muscle specific 
promoter myo-3 (▼).
The dose response for slo-1(js379) expressing slo-1(+) in the body wall muscle is pooled data 
from two independent lines. N2 and slo-1(js379) controls were run in parallel with the 
transgenic lines (controls same as in figure 6.05). The IC50 for N2 in this assay is 11 nM. slo-
1(js379) are uninhibited at all concentrations of emodepside. The IC50 for slo-1(js379) 
expressing slo-1(+) in the body wall muscle is 234 nM. slo-1(js379) expressing slo-1(+) in the 
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body wall muscle is significantly inhibited by 1 μM and 10 μM emodepside compared to slo-
1(js379) with P<0.001. N2 is significantly more sensitive to emodepside than slo-1(js379) 
expressing slo-1(+) in the neurons at 100 nM with P<0.001. slo-1(js379) expressing slo-1(+) 
in the body muscle displayed a phenotype similar to that of N2 on 10 μM emodepside. No 
coiling phenotype was observed unlike with expression of slo-1(+) in the neurons.
6.05 Expression of slo-1(+) in neurons and body wall muscle restores 
emodepside sensitivity
Locomotion assays were conducted on worms expressing slo-1 cDNAa in body wall muscle 
and neurons. L4 slo-1(js379), N2 and slo-1(js379) expressing slo-1(+) in the body wall 
muscle and neurons were picked to 1 M emodepside containing NGM plates for 24 hours on 
food. They were also picked to 0.5 % ethanol vehicle NGM plates. After 24 hours the young 
adults were picked to an un-seeded NGM plate for one minute in order to remove any OP50. 
They were then picked to an un-seeded assay plate and left to recover for one minute. Finally 
body bends were counted for one minute. Figure 6.07 shows the response of these animals to 
emodepside.
Figure 6.07. slo-1 body wall muscle and neuron rescue of emodepside sensitivity.
Response to 1 M emodepside of N2 (□), slo-1(js379) (♦) and slo-1(js379) expressing slo-
1(+) from the body wall muscle specific promoter pmyo-3 and neuron specific promoter psnb-
1 (▼). For each point n is between 7 and 34. Each point is the mean  S.E.Mean. *** indicates
P<0.001. Comparisons are made between slo-1(js379) (♦) and slo-1(js379) expressing slo-
1(+) from the body wall muscle specific promoter pmyo-3 and neuron specific promoter psnb-
1 (▼).
-11 -10 -9 -8 -7 -6 -5
0
10
20
30
40
log[emodepside] M
B
od
y
be
nd
s
pe
r
m
in
ut
e
***
0
151
slo-1(js379) expressing slo-1(+) in the body wall muscle and neurons is significantly inhibited 
by 1 μM emodepside compared to slo-1(js379) with P<0.001. The sensitivity of slo-1(js379) 
expressing slo-1(+) in the body wall muscle and neurons is not significantly different to N2 on 
1 μM emodepside. However, slo-1(js379) expressing slo-1(+) in the body wall muscle and 
neurons did not resemble N2 when exposed to 1 μM emodepside but displayed the coiling 
phenotype observed in slo-1(js379) expressing slo-1(+) in the neurons. The phenotype 
produced by expression of slo-1(+) in the neurons has a dominant effect.
6.06 Aldicarb sensitivity assays
The ACE inhibitor aldicarb was used to investigate if emodepside affects ACh release in N2
and slo-1(js379). Aldicarb causes hyper-contraction of C. elegans body wall muscle which 
results in paralysis. It has been previously shown that slo-1(js379) are aldicarb hyper-sensitive 
(Wang et al 2005). In order to investigate the effect of emodepside on aldicarb sensitivity of 
N2 and slo-1(js379), their rate of paralysis on 0.5 mM aldicarb was assayed. L4 worms were 
selected 24 hour before the assay. The assay was performed blind. Young adults were 
transferred to 0.5 mM aldicarb containing NGM plates seeded with OP50. 15 worms were 
placed on each plate. The number of paralysed worms was recorded every 30 minutes. 
Multiple trials were conducted for each strain. One trial refers to a single plate of worms 
assayed. Experiments were run with parallel controls. Data from individual experiments was 
pooled.
6.07 slo-1(js379) is aldicarb hypersensitive
N2 and slo-1(js379) were assayed in the way described above. Figure 6.08 shows the average 
percentage of animals paralysed by 0.5 mM aldicarb from multiple trials. Each trial is for 15 
animals. slo-1(js379) are paralysed by 0.5 mM aldicarb at a quicker rate that N2. A 
significantly higher proportion of slo-1(js379) are paralysed after 60, 90 and 120 minutes on 
0.5 mM aldicarb (P<0.001). This result is similar to what was observed by Wang et al (2001).
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Figure 6.08. slo-1(js379) aldicarb sensitivity. Time until paralysis on 0.5 mM aldicarb for 
N2 (■) and js379 (▲). % paralysed is the average proportion of paralysed animals from 
multiple trials. Each point is the mean  S.E.Mean of 16 trials of 15 animals for N2 and the 
mean  S.E.Mean of 16 trials of 15 animals for slo-1(js379). *** indicates P<0.001 compared 
to N2 control.
6.08 Emodepside decreases N2 sensitivity to aldicarb
To test whether emodepside affects ACh release, the aldicarb sensitivity of emodepside 
treated N2 worms was tested. If emodepside acts to increase ACh release, an increase in 
aldicarb sensitivity would be predicted. L4 worms were placed on NGM plates containing 
either sub-paralysing concentrations of emodepside (10 nM or 100 nM) or 0.5 % ethanol 
vehicle. After 24 hours exposure, treated and un-treated worms were transferred to seeded 0.5 
mM aldicarb containing NGM plates, that also contained either emodepside (10 nM or 100 
nM) or 0.5 % ethanol vehicle. Emodepside treated worms were also assayed on emodepside 
NGM plates to confirm the concentrations used were sub-paralysing. The number of 
paralysed worms was recorded every 30 minutes. Experiments were run with parallel 
controls. Data from individual experiments was pooled.
Figure 6.09 shows the average percentage of animals paralysed by 0.5 mM aldicarb from 
multiple trials. N2 animals pre-treated with 100 nM emodepside paralyse at a significantly 
slower rate than N2 animals pre-treated with vehicle (0.5 % ethanol) on 0.5 mM aldicarb. The 
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percentage of paralysed animals is significantly higher in the control group at 90, 150, 180 
and  210 minutes with P<0.001 and at 120 minutes with P<0.01. The rate of paralysis of N2
with vehicle (0.5 % ethanol) pre-treatment is comparable to that of N2 without vehicle pre-
treatment (compare to N2 in figure 6.08), suggesting this concentration of ethanol does not 
impact on aldicarb sensitivity. N2 animals pre-treated with 100 nM emodepside and assayed 
off aldicarb and on 100 nM emodepside did not paralyse, demonstrating that 100 nM is a sub-
paralysing concentration of emodepside on N2.
Figure 6.09. 100 nM emodepside affects N2 aldicarb sensitivity. Time until paralysis on 
0.5 mM aldicarb. N2 on 0.5 mM aldicarb without pre-exposure to emodepside (■), N2 on 0.5 
mM aldicarb with pre-exposure to 100 nM emodepside (▲) and N2 without exposure to 0.5 
mM aldicarb but with pre-exposure to 100 nM emodepside (▼). Each point is the mean 
S.E.Mean of 8 trials of 15 animals (■), 7 trials of 15 animals (▲) and 3 trials of 15 animals 
(▼). ** indicates P<0.01 and *** indicates P<0.001.
Similar effects were observed when pre-treating with 10 nM emodepside (figure 6.10). N2
animals pre-treated with 10 nM emodepside paralyse at a significantly slower rate than N2
animals pre-treated with vehicle (0.5 % ethanol) on 0.5 mM aldicarb. The percentage of 
paralysed animals is significantly higher in the control group at 90, 120 and 150 minutes with 
P<0.05 and at 180 minutes with P<0.01.
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Figure 6.10. 10 nM emodepside affects N2 aldicarb sensitivity. Time until paralysis on 0.5 
mM aldicarb. N2 on 0.5 mM aldicarb without pre-exposure to emodepside (■), N2 on 0.5 mM 
aldicarb with pre-exposure to 10 nM emodepside (▲) and N2 without exposure to 0.5 mM 
aldicarb but with pre-exposure to 10 nM emodepside (▼). Each point is the mean  S.E.Mean 
of 8 trials of 15 animals (■), 4 trials of 15 animals (▲) and 3 trials of 15 animals (▼). * 
indicates P<0.05 and ** indicates P<0.01.
It was observed that worms co-exposed to 100 nM emodepside and 0.5 mM aldicarb had a 
different morphology to worms co-exposed to vehicle (0.5 % ethanol) and 0.5 mM aldicarb. 
Aldicarb causes hyper-contraction of body wall muscle, resulting in a shortening of body 
length. Figure 6.11 shows photographs of N2 worms co-exposed to emodepside and aldicarb 
or vehicle and aldicarb after 80 minutes. Vehicle and aldicarb co-exposed worms display a 
shortening of body length to a greater extent than emodepside and aldicarb co-exposed 
worms. These results indicate that treatment with emodepside results in a decrease ACh 
release. In emodepside treated worms on aldicarb, it seems likely that the build up of ACh in 
the synaptic cleft is slowed. The onset of paralysis and the hyper-contracted phenotype due to 
aldicarb treatment is therefore slowed.
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A) B)
Figure 6.11. Emodepside affects the onset of aldicarb induce changes in morphology.
Effect of 100 nM emodepside and 0.5 mM aldicarb co-exposure on body length. A) N2
vehicle (0.5 % ethanol) and aldicarb (0.5 mM) co-exposure after 80 minutes, B) N2
emodepside (0100 nM) and aldicarb (0.5 mM) co-exposure after 80 minutes.
6.09 Emodepside does not affect slo-1(js379) aldicarb sensitivity
Assays were conducted to determine if the emodepside induced reduction in aldicarb 
sensitivity observed in N2 also occurs in slo-1(js379). L4 worms were placed on NGM plates 
containing either a sub-paralysing concentration of emodepside (100 nM) or 0.5 % ethanol 
vehicle. After 24 hours exposure, treated and un-treated worms were transferred to seeded 0.5 
mM aldicarb containing NGM plates, that also contained either emodepside (100 nM) or 0.5 
% ethanol vehicle. Emodepside treated worms were also assayed on emodepside NGM plates 
to confirm the concentrations used were sub-paralysing. The number of paralysed worms was 
recorded every 30 minutes. Experiments were run with parallel controls. Data from individual 
experiments was pooled.
1 mm 1 mm
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Figure 6.12. slo-1(js379) aldicarb sensitivity is unaffected by 100 nM emodepside. Time 
until paralysis on 0.5 mM aldicarb. slo-1(js379) on 0.5 mM aldicarb without pre-exposure to 
100 nM emodepside (■), slo-1(js379) on 0.5 mM aldicarb with pre-exposure to 100 nM 
emodepside (▲) and slo-1(js379) without exposure to 0.5 mM aldicarb but with pre-exposure 
to 100 nM emodepside (▼). Each point is the mean  S.E.Mean of 4 trials of 15 animals (■), 
4 trials of 15 animals (▲) and 3 trials of 15 animals (▼).
Figure 6.12 shows the average percentage of animals paralysed by 0.5 mM aldicarb from 
multiple trials. slo-1(js379) animals pre-treated with 100 nM emodepside paralysed at the 
same rate as slo-1(js379) animals pre-treated with vehicle (0.5 % ethanol) on 0.5 mM 
aldicarb. This demonstrates that slo-1 is required for emodepside’s effect on aldicarb 
sensitivity. slo-1(js379) animals pre-treated with 100 nM emodepside and assayed off aldicarb 
and on 100 nM emodepside did not paralyse, demonstrating that 100 nM is a sub-paralysing 
concentration of emodepside on slo-1(js379).
The fact that SLO-1 is required for emodepside sensitivity and for emodepside’s effects on 
aldicarb sensitivity suggests that the mechanisms involved are the same. This therefore 
indicates that emodepside causes paralysis through a reduction in cell excitability.
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6.10 slo-1(js379) expressing slo-1(+) in  neurons are aldicarb hypersensitive
Expressing slo-1(+) in the neurons of slo-1(js379) restores emodepside sensitivity, although in 
a way not resembling N2. The aldicarb hypersensitivity of slo-1(js379) indicates that SLO-1 
negatively regulates ACh release. The emodepside induced reduction in aldicarb sensitivity 
observed in N2 does not occur in slo-1(js379). This suggests that emodepside leads to a 
reduction in ACh release and that it requires SLO-1 for this. Wang et al did not demonstrate 
rescue of the aldicarb hyper-sensitivity observed in slo-1(js379). To further understand the 
role of SLO-1 in ACh release and in emodepside’s mode of action, the aldicarb sensitivity of 
slo-1(js379) expressing slo-1(+) in neurons was investigated.
24 hours post L4 worms were assayed in the way previously described. Figure 6.13 shows the 
average percentage of animals paralysed by 0.5 mM aldicarb from multiple trials. slo-1(js379) 
are paralysed by 0.5 mM aldicarb at a quicker rate that N2 as previously shown. A 
significantly higher proportion of slo-1(js379) are paralysed after 60 and 120 minutes P<0.01 
and 90 minutes P<0.001 on 0.5 mM aldicarb compared with N2. The rate of paralysis on 0.5 
mM aldicarb of slo-1(js379) expressing slo-1(+) in the neurons is not significantly different 
from that of slo-1(js379). 
Figure 6.13. slo-1 neuronal expression does not rescue aldicarb hyper-sensitivity. Time 
until paralysis on 0.5 mM aldicarb. N2 (■), slo-1(js379) (▲), and slo-1(js379) expressing slo-
1(+) from the neuron specific promoter snb-1 (▼). Each point is the mean  S.E.Mean of 7 
trials of 15 animals (■), 7 trials of 15 animals (▲) and 6 trials of 15 animals (▼). ** indicates 
P<0.01 and *** indicates P<0.001. Comparisons marked are between slo-1(js379) and slo-
1(js379) expressing slo-1(+) in neurons (above) and slo-1(js379) and N2 (below).
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Wang et al (2001) demonstrated that slo-1(js379) has an increased duration, amplitude and  
frequency of EPSP indicating it has an increased transmitter release. The aldicarb 
hypersensitivity of slo-1(js379) also indicates it has increased ACh release. Rescue of the unc-
64(e246) lethargic phenotype by slo-1(js379) was reversed when slo-1(+) was expressed in 
the neurons, but not in the muscle, of unc-64(e246); slo-1(js379) double mutants. This 
indicates that the reduced neurotransmitter release in unc-64(e246) is reversed by the loss of 
slo-1 in the neurons. However, it was not directly shown that loss of slo-1 in the neurons 
causes an increase in transmitter release. Rescue of the increase EPSCs duration, amplitude 
and frequency or aldicarb hypersensitivity in slo-1 loss of function mutants was not 
demonstrated by Wang et al (2001). The fact that expressing slo-1(+) in the neurons of slo-
1(js379) does not rescue aldicarb hypersensitivity may indicate that slo-1 in the body wall 
muscle may play a role in slo-1(js379) aldicarb hypersensitivity. Loss of slo-1 in the body 
wall muscle could potentially result in or contribute to increased EPSC duration, amplitude 
and frequency and aldicarb hypersensitivity.
6.11 slo-1(js379) expressing slo-1(+) in  body wall muscle are aldicarb 
hypersensitive
slo-1(js379) expressing slo-1(+) in the body wall muscle were tested in the aldicarb assay in 
order to investigate the role of muscle cell excitability in aldicarb sensitivity. 24 hours post L4 
worms were assayed in the way previously described. Figure 6.14 shows the average 
percentage of animals paralysed by 0.5 mM aldicarb from multiple trials. slo-1(js379) are 
paralysed by 0.5 mM aldicarb at a quicker rate that N2 as previously shown. A significantly 
higher proportion of slo-1(js379) are paralysed after 60, 90 and 120 minutes P<0.001 on 0.5 
mM aldicarb compared with N2. The rate of paralysis on 0.5 mM aldicarb of slo-1(js379) 
expressing slo-1(+) in the body wall muscle is significantly different from that of slo-1(js379) 
at 60 minutes P<0.05. 
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Figure 6.14. slo-1 body wall muscle expression does not rescue aldicarb hyper-
sensitivity. Time until paralysis on 0.5 mM aldicarb. N2 (■), slo-1(js379) (▲), and slo-
1(js379) expressing slo-1(+) from the body wall muscle specific promoter myo-3 (▼). Each 
point is the mean  S.E.Mean of 6 trials of 15 animals (■), 6 trials of 15 animals (▲) and 4 
trials of 15 animals (▼). * indicates P<0.05 and *** indicates P<0.001.
The slight but significant decrease in aldicarb sensitivity of slo-1(js379) expressing slo-1(+) in 
the body wall muscle compared with slo-1(js379) indicates that aldicarb sensitivity is affected 
by the presence of slo-1 in the muscle.
The nature of the aldicarb hypersensitivity of slo-1(js379) is subtle. It may be that the lack of 
rescue observed when expressing slo-1(+) in the neurons and the minimal rescue observed 
when expressing slo-1(+) in the body wall muscle is due to the non-native expression of slo-
1(+). These results do however indicate that aldicarb sensitivity can be affected by SLO-1 in 
the body wall muscle. This suggests that the reduced aldicarb sensitivity of emodepside 
treated worms could stem from its effects on SLO-1 neurons or body wall muscle. The effect 
of the nicotinic ACh receptor agonist levamisole on emodepside sensitivity has therefore been 
investigated. 
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6.12 Emodepside increases levamisole sensitivity
Levamisole is a nicotinic ACh receptor agonist. It causes spastic paralysis of nematode body 
wall muscle (Martin et al 2005). Levamisole was used to investigate the effect of emodepside 
on muscle cell excitability. The sensitivity of N2 pre-treated with 100 nM emodepside or 
vehicle (0.5 % ethanol) to 100 M levamisole was tested. L4 worms were placed on NGM 
plates containing either a sub-paralysing concentration of emodepside (100 nM) or 0.5 % 
ethanol vehicle. After 24 hours exposure, treated and un-treated worms were transferred to 
seeded 100 M levamisole containing NGM plates, that also contained either emodepside 
(100 nM) or 0.5 % ethanol vehicle. Emodepside treated worms were also assayed on 
emodepside NGM plates to confirm the concentrations used were sub-paralysing. The number 
of paralysed worms was recorded every 30 minutes. Experiments were run with parallel 
controls. Data from individual experiments were pooled.
Figure 6.15. 100 nM emodepside affects N2 levamisole sensitivity. Time until paralysis on 
100 μM levamisole. N2 on 100 μM levamisole without pre-exposure to emodepside (■), N2
on 100 μM levamisole with pre-exposure to 100 nM emodepside (▲) and N2 without 
exposure to 100 μM levamisole but with pre-exposure to 100 nM emodepside (▼). Each 
point is the mean  S.E.Mean of 4 trials of 15 animals (■), 4 trials of 15 animals (▲) and 3 
trials of 15 animals (▼). * indicates P<0.05, ** indicates P<0.01 and *** indicates P<0.001.
Figure 6.15 shows the average percentage of animals paralysed by 100 M levamisole from 
four trials. N2 animals pre-treated with 100 nM emodepside paralyse at a significantly faster 
rate than N2 animals pre-treated with vehicle (0.5 % ethanol) on 100 M levamisole. The 
0 30 60 90 120 150 180 210 240
0
20
40
60
80
100
120
Time (minutes)
%
pa
ra
ly
se
d
*
***
***
**
** *
161
percentage of paralysed animals is significantly higher in the emodepside treatment group at 
60 and 210 minutes with P<0.05, 150 and 180 minutes with P<0.01 and 90 and 120 minutes 
with P<0.001. N2 animals pre-treated with 100 nM emodepside and assayed off aldicarb and 
on 100 nM emodepside did not paralyse, demonstrating that 100 nM is a sub-paralysing 
concentration of emodepside on N2.
This result is surprising as levamisole is thought to cause spastic paralysis due to increased 
excitability. If emodepside acts to reduce muscle cell excitability, it would be expected that 
pre-treated worms would have reduced levamisole sensitivity. If emodepside acts to reduce 
excitability only in neurons it might be expected that sensitivity to levamisole would remain 
the same. In order to better understand this result, the sensitivity of slo-1(js379) to levamisole 
was investigated.
6.13 slo-1(js379) has reduced levamisole sensitivity
L4 worms were selected 24 hour before the assay. The assay was performed blind. Young 
adults were transferred to 100 M levamisole containing NGM plates seeded with OP50. 15 
to 20 worms were placed on each plate. The number of paralysed worms was recorded every 
30 minutes. Four trials were conducted for each strain. Experiments were run with parallel 
controls. Figure 6.16 shows the average percentage of animals paralysed by 100 M 
levamisole for four trials. slo-1(js379) are paralysed by 100 M levamisole at a significantly 
slower rate that N2. A significantly lower proportion of slo-1(js379) are paralysed after 60, 
90, 120, 150 and 180 minutes on 100 M levamisole with P<0.001. 
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Figure 6.16. slo-1(js379) levamisole sensitivity. Time until paralysis on 100 μM levamisole. 
N2 on 100 μM levamisole (■) and slo-1(js379) on 100 μM levamisole (▲). Each point is the 
mean  S.E.Mean of 4 trials. *** indicates P<0.001.
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6.14 Discussion
Expression of slo-1(+) in either the body wall muscle or neurons of slo-1(js379) results in 
rescue of emodepside’s inhibitory actions on locomotion. As well as confirming that it is slo-
1 that is required for emodepside sensitivity, it also demonstrates that emodepside can exert 
effects through SLO-1 both in the body wall muscle and the neurons. Endogenous expression 
of slo-1 has been characterised using both immuno-staining and expression of slo-1::gfp. 
Wang et al (2001) demonstrated that slo-1 is expressed in the nerve ring, nerve cords, body 
wall muscle and vulval muscle. This was done using both a mouse polyclonal antibody and a 
slo-1::gfp reporter. Carre-Pierrat et al (2006) found expression of slo-1 in body wall muscle 
using a slo-1::gfp reporter but found the antibody used by Wang et al (2001) to be non-
specific. Expression of slo-1 has also been found in most of the pharyngeal neurons, again 
using a slo-1::gfp reporter (Chiang et al 2006).
The rescue observed in slo-1(js379) expressing slo-1(+) in the body wall muscle and neurons 
is consistent with the expression pattern of slo-1 in N2. The ability of slo-1(+) to rescue 
emodepside sensitivity in both tissues shows that it can act through SLO-1 in body wall 
muscle and neurons to inhibit locomotion. Neither slo-1(js379) expressing slo-1(+) in body 
wall muscle nor in neurons resulted in complete rescue of emodepside sensitivity. As it seems 
likely that SLO-1 plays a role in both the body wall muscle and neurons in emodepside’s 
inhibitory effects on locomotion, it is not surprising that expression in one or the other does 
not completely rescue the phenotype. However, when slo-1(+) was expressed in body wall 
muscle and neurons simultaneously the rescue still did not resemble N2. The coiling 
phenotype observed with the neuronal rescue was still present. 
There are several possible explanations for this incomplete rescue. Genes in extra-
chromosomal arrays can have a patchy expression across the tissue in which it is driven 
(Stinchcomb et al 1985). This is evident with the gfp transfection marker, which sometimes is 
present throughout the pharyngeal muscle and at other times has a patchy expression. Mosaic 
expression of slo-1 could result in incomplete rescue of emodepside’s effects. It is also 
possible that the use of a single slo-1 splice variant (cDNAa) in these rescue experiments 
prevents full rescue of emodepside’s effects. Another possibility is that the use of the snb-1
and myo-3 promoters, rather than the endogenous slo-1 promoter, results in a different level or 
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pattern of expression. This seems most likely as expression of slo-1(+) (cDNAa) using the 
endogenous slo-1 promoter resulted in complete rescue of emodepside effects on locomotion 
(Personal communication with Nina Krger).
Expressing slo-1(+) in the body wall muscle or neurons of slo-1(js379) results in a 
quantitatively similar rescue of emodepside’s inhibitory effect on locomotion, with IC50 of 
234 nM and 109 nM, respectively. There are however qualitative differences between these 
strains when exposed to emodepside. slo-1(js379) expressing slo-1(+) in the body wall muscle 
exhibits a phenotype similar to that of N2. Emodepside causes a flaccid paralysis. The worm 
loses its sinusoidal shape of movement and extends its anterior forward by propelling itself 
through shallow wave-like movement of its posterior. Expression of slo-1(+) in the neurons 
results in a tight coiling not observed in N2 animals when on 10 μM emodepside. Using the 
pan-neuronal promoter snb-1 (Nonet 1999) may have resulted in expression of slo-1 in 
neurons that do not usually express it. Imbalances in neurotransmitter release have been 
shown to result in coiling phenotype (Walthall et al 1993). It is possible that an emodepside-
induced activation of SLO-1 in neurons that do not normally express SLO-1 causes an 
imbalance in neurotransmitter release and a coiling of the worm. 
The rescue of emodepside sensitivity through expression of slo-1 in either body wall muscle 
or neurons suggests SLO-1 is important for emodepside’s effects in both these tissues. The 
emodepside resistance in slo-1 loss-of-function mutants suggests that emodepside causes an 
activation of SLO-1. Activation of SLO-1 would be expected to cause a reduction in cell 
excitability. Levamisole and aldicarb were used in order to indirectly investigate the effect of 
emodepside on the excitability of muscle and neurons.
Reduced aldicarb sensitivity in C. elegans is thought most likely to reflect defects in synaptic 
transmission (Miller et al 1996). slo-1(js379) was shown to be aldicarb hypersensitive in the 
previous chapter and by Wang et al (2001). In the previous chapter, aldicarb sensitivity was 
found to be unaltered in many of the slo-1 mutants. The relevance of slo-1 loss of function in 
increasing aldicarb sensitivity was investigated. Expression of slo-1(+) in the neurons of slo-
1(js379) does not result in rescue of the aldicarb hypersensitivity, suggesting the increased 
aldicarb hypersensitivity is either independent of slo-1(js379) or is due to loss of SLO-1 
function in other tissues. The lack of correlation between aldicarb hypersensitivity and SLO-1 
function highlighted in the previous chapter indicates that it is the former. However, it seems 
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that SLO-1 does play a role in neurotransmitter release as it has that ability to rescue the 
lethargic phenotype of unc-64 in the unc-64, slo-1 double mutant. The unc-64 lethargic 
phenotype is restored by expression of slo-1(+) in the neurons of the double mutant (Wang et 
al, 2001). 
Expression of slo-1(+) in the body wall muscle of slo-1(js379)  results in a slight but 
significant decrease in aldicarb sensitivity. This indicates that slo-1 expression in the muscle 
influences aldicarb sensitivity. This is contrary to what is reported by Wang et al (2001) who 
suggest that the increased aldicarb sensitivity of slo-1(js379) is due to loss of slo-1 in the 
neurons. 
Worms pre-treated with emodepside have a reduced sensitivity to aldicarb. This supports the 
idea that emodepside acts to reduce transmitter release. The aldicarb sensitivity of slo-
1(js379) cannot be influenced by emodepside, demonstrating that this effect is dependent on 
SLO-1. A summary of the changes in the sensitivity of worms to aldicarb and levamisole is 
shown in table 6.01. 
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Table 6.01. Factors affecting aldicarb and levamisole sensitivity. A) Changes in aldicarb 
and levamisole sensitivity of slo-1(js379) and 100 nM emodepside treated N2 compared to N2
sensitivity. B) Changes in aldicarb sensitivity of slo-1(js379) on 100 nM emodepside, slo-
1(js379) + neuronal slo-1(+) and slo-1(js379) + body wall muscle slo-1(+) compared to slo-
1(js379) sensitivity. 
Levamisole was used to investigate the effect of emodepside on the body wall muscle.
Levamisole is a nicotinic receptor agonist and causes spastic paralysis of nematode body wall 
muscle (Aceves et al 1970). Attempts were made to use changes in levamisole sensitivity to 
make predictions about muscle cell excitability. N2 animals pre-treated with emodepside have 
an increased sensitivity to levamisole. slo-1(js379) have a decreased sensitivity to levamisole. 
These results are consistent with each other in that loss of SLO-1 function in slo-1(js379) and 
the hypothesised increase in SLO-1 function in emodepside treated N2 have opposite effects. 
The changes in levamisole sensitivity observed are however contrary to any predicted result. 
If SLO-1 in the body wall muscle has an important role in mediating emodepside’s effects, 
Change in aldicarb and levamisole sensitivities compared to N2
Condition Change in aldicarb sensitivity
slo-1(js379) ↑
N2 on 100 nM emodepside ↓
Change in levamisole sensitivity
slo-1(js379) ↓
N2 on 100 nM emodepside ↑
Change in aldicarb sensitivities compared to slo-1(js379)
Condition Change in aldicarb sensitivity
slo-1(js379) on 100 nM emodepside No change
slo-1(js379) + neuronal slo-1(+) No change
slo-1(js379) + body wall muscle slo-1(+) ↓
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the hypothesised emodepside induced increase in SLO-1 function would be predicted to 
decrease cell excitability and therefore decrease levamisole sensitivity (Salkoff et al 2006, 
Orio et al 2002). Loss of function of SLO-1 would be predicted to result in increased cell 
excitability and therefore increase levamisole sensitivity. If SLO-1 in the body wall muscle 
does not have an important role in mediating emodepside’s effects, it would be predicted that 
no change in levamisole sensitivity would be observed. There are a variety of possible 
explanations for effects opposite to those predicted being observed.
One possibility is that of adaptation. In slo-1(js379) an increase in cell excitability may result 
in a down regulation of nicotinic ACh receptors. This may result in a decrease in levamisole 
sensitivity. Similarly, treatment with emodepside may result in an up regulation of nicotinic
ACh receptors. This may result in an increase in levamisole sensitivity. However, if this type 
of adaptation occurs, one would expect to see similar results in the aldicarb assay, which is 
not the case.
Robertson et al (1993) found levamisole was able to cause a block of nACh receptors at 
concentrations between 30 and 90 M. If levamisole causes nACh receptor block, reducing 
cell excitability, it would be expected that emodepside and levamisole effects would be 
cumulative. However, the paralysis of C. elegans by emodepside and 100 M levamisole do 
not resemble each other. Emodepside causes a flaccid paralysis in which the body of the 
worm loses its sinusoidal wave form, where as levamisole causes spastic paralysis in which 
the body of the worm shortens as the muscle becomes hyper-contracted.
The mechanism by which levamisole causes paralysis in C. elegans is likely to be more 
complex than a simple spastic paralysis through activation of nACh receptors on the body 
wall muscle. nACh receptor subunits are expressed on neurons and muscle of C. elegans
(Flemming et al 1997, Gottschalk et al 2005, Gally et al 2004, Gottschalk and Schafer 2005, 
Culetto et al 2004). Levamisole would be expected to affect transmitter release by acting on 
neuronal nACh receptors. Endogenous cholinergic activity on neuronally expressed nicotinic 
ACh receptors has been shown to modulate release of inhibitory neurotransmitters in a variety 
of systems (Wang et al 2002, Takeda et al 2007). The effects of levamisole on 
neurotransmitter release are likely to contribute to the paralysis, as well as its direct effect on 
the body wall muscle. 
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The effect that emodepside has on cell excitability is unclear. Emodepside reduces N2
sensitivity to aldicarb, suggesting it reduces ACh release and the excitability of cholinergic 
neurons. Alternatively, it may indicate that the response of the body wall muscle to ACh is 
reduced, i.e. muscle cell excitability is reduced. Emodepside increases N2 sensitivity to 
levamisole, suggesting it increases body wall muscle cell excitability. However, this is not 
consistent with the observed emodepside induced flaccid paralysis in C. elegans and in 
Ascaris suum muscle strip (Willson et al 2003). It may be that this interpretation of the 
change in levamisole sensitivity is too simplistic, as previously discussed. Further 
investigation, using direct electrophysiological recording techniques, will be required to 
obtain a fuller understanding of emodepside’s effects on cell excitability. Whatever the 
precise effect of emodepside on cell excitability, it is clear that the ability of slo-1(+) to rescue 
emodepside sensitivity in both neurons and body wall muscle of slo-1(js379) indicates 
emodepside acts through SLO-1 in both these tissues. Indeed, high level of resistance of slo-1 
null mutants and the fact that only slo-1 mutants were recovered from the screens for 
emodepside resistance might suggest a direct action of emodepside on SLO-1. The following 
chapter attempts to address this.
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Chapter 7
Electrophysiological analysis of 
emodepside’s effects on SLO-1
170
7.1 Introduction
There is strong evidence for a key role of SLO-1 in emodepside’s mode of action. The genetic 
evidence indicates that emodepside causes an activation of SLO-1 as loss of SLO-1  function 
mutations cause high level resistance. The physiological effects are consistent with an 
activation of SLO-1 in that the emodepside induced paralysis is flaccid. Emodepside treated 
worms have reduced aldicarb sensitivity, suggesting it either causes a reduction in ACh 
release or a reduction in the response of the muscle to ACh. Activation of SLO-1 in neurons 
or muscle would be expected to reduce cell excitability. Emodepside causes a calcium 
dependent relaxation of the Ascaris suum muscle strip preparation which may indicate 
activation of a BK channel (Willson et al 2003). The fact that slo-1 gain-of-function mutants 
are not hypersensitive to emodepside suggests that it either directly activates SLO-1 or 
activates SLO-1 via a pathway. Only slo-1 mutants were recovered from the screen for 
emodepside resistant strains. This indicates that the action of emodepside on SLO-1 is direct. 
However, if loss of function of components of a SLO-1 activation pathway resulted in a lethal 
phenotype they would not be recovered from the screen.
In order to test if emodepside activates SLO-1, and to see if this activation is through direct 
interaction with SLO-1, a heterologous expression system was used and whole cell currents 
were analysed. A variety of expression systems have been used for expression of BK channels 
from a range of species. The most commonly used systems are Xenopus oocytes and HEK293 
cells. Berns et al (1972) showed that expression of exogenous mRNA in Xenopus oocytes was 
possible. Adelman et al (1992) expressed slo cDNA from Drosophila melanogaster by 
injection of RNA into Xenopus oocytes. Functional analysis using patch clamp showed that 
the channel had a voltage and Ca2+ dependence. Differences between splice variants was also 
observed. The mouse slo (mSlo) and human slo (hSlo) have also both been expressed in 
Xenopus oocytes (McCobb et al 1995, Butler et al 1993) and are voltage and Ca2+ dependent. 
They were also shown to be sensitive to the specific BK channel blocker iberiotoxin. The
single channel conductance of both mSlo and hSlo are 272 and 282 pS respectively, whereas 
the dSlo is only 126 pS. C. elegans slo-1 has also been expressed in Xenopus oocytes (Wang
et al 2001) and is both voltage and Ca2+ dependent. It has a single channel conductance of 
~250 pS. The similarity in the biophysical properties of BK channels between species is not 
surprising as they have a very strong sequence similarity. Table 7.01 shows the amino acid 
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sequence identity of BK channels from Haemonchus contortus, Drosophila melanogaster and 
Homo sapiens compared with C. elegans SLO-1.
Species Sequence accession number % identity 
Haemonchus contortus ABS45068.1 85.4 %
Drosophila melanogaster NP_0010014655.1 61.3 %
Homo sapiens NP_002238.2 50.8 %
Table 7.01. BK channel sequence identity. Amino acid sequence identity of BK channels 
compared to C. elegans SLO-1. Global alignments were conducted using Readseq version 
2.1.24. The following parameters were used: gap open/ext; -14/-4.
Mammalian cell cultures are also commonly used for transient or stable expression of BK 
channels. Strobaek et al (1996) stable expressed the hSlo α subunit in HEK293 cells. They 
showed that hSlo has similar biophysical properties when expressed in HEK293 cells or 
Xenopus oocytes. Its single channel conductance is ~250 pS when expressed in HEK293 cells, 
similar to in Xenopus oocytes. HEK293 cells have also been used to express invertebrate BK 
channels. Shumin et al (2001) expressed dSlo in HEK293, demonstrating the versatility of 
using HEK293 cells.
HEK293 cells have been used to express invertebrate BK channels (Shumin et al 2001) as 
well as other C. elegans genes (Mertens et al 2005). Mertens et al (2005) functionally 
expressed the C. elegans GPCR Y59H11AL.1 in order to determine the ligand for this orphan 
receptor. Due to previous successful expression of invertebrate BK channels and other C. 
elegans gene, HEK293 cells were chosen to express the C. elegans slo-1 gene. Practical 
considerations also made mammalian cell culture the choice heterologous expression system. 
A variety of compounds have been shown to be ligands for BK channels both blocking and 
activating the channel. Commonly used specific blockers of BK channels include iberiotoxin 
(Galvez et al 1990) and charybdotoxin (Miller et al 1985), which are components to scorpion 
venom. Non specific potassium channel blockers include 4-amino-pyridine (Sherratt et al 
1980) and tetraethyl ammonium.
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The human embryonic kidney cell line HEK293 was chosen for this (Graham et al 1977). 
HEK293 cell line has been used extensively for expression of recombinant proteins and is 
amenable to transfection and patch clamp analysis (Thomas and Smart 2005). HEK293 cells 
are able to generate functional mammalian and non-mammalian proteins and have been used 
for expression of C. elegans genes (Mertens et al 2005). HEK293 cells have also been used 
extensively for expression of BK channels form a variety of species, including D. 
melanogaster (Bian et al 2001). A range of compounds have been shown to have activating 
properties of BK channels from a variety of species. These include cannabinoid 
methanandamide, which was shown to increase the outward current in BK-α transfected 
HEK293 cells (Sade et al 2006). The compound NS11021 has been shown to activate BK 
channel currents in KCa1.1 transfected HEK293 cells using the whole-cell patch technique
(Bentzen et al 2007).
7.2 Expression of C. elegans slo-1 in HK293 cells
In order to express C. elegans slo-1 in HEK293 cells the pIRES2-EGFP vector from BD 
biosciences Clontech was used. This vector has several benefits. It contains an internal 
ribosome entry site (IRES) that allows the gene of interest and EGFP to both be generated 
from the same transcript. This avoids the need to generate a slo-1GFP fusion which may 
affect the functioning of the channel. EGFP is a variant of WT GFP but has been optimised 
for higher fluorescence in mammalian cell culture (Cormack et al 1996). This system allows 
cells carrying slo-1 pIRES2-EGFP to be easily identified. However, it does not provide any 
information on whether slo-1 is translated or trafficked to the membrane in the way that a slo-
1 gfp fusion would.
slo-1 cDNAa was PCR amplified from pBK3.1 using primers designed to generate suitable 
restriction sites for ligating into the MCS of pIRES2-EGFP, as well as the Kozak sequence. 
The Kozak sequence is a 5’ non-coding sequence directly upstream of the start codon that is 
required for efficient translation in eukaryotic cells (Kozak 1987). 
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Three rounds of PCR were used to progressively build up the 5’ end to incorporate a Kozak 
sequence and a Nhe-1 restriction site. Five extra nucleotides were incorporated in front of the 
Nhe-1 site to ensure efficient digestion. Attempts to generate a restriction site at the 3’ end 
were made using a variety of different primer designs. These however failed and primers in 
the unc-54 terminator sequence were subsequently used. Figure 7.01 shows the 5’ primers 
used to build up these sequences.
Figure 7.01. Primer design for slo-1 cDNAa amplification. The Kozak sequence and Nhe-1 
restriction site are incorporated onto 5’ end of C. elegans slo-1 cDNAa. These three primers 
were used in subsequent rounds with nested primers downstream of the slo-1 stop codon.
The “Expand Long Template PCR System” was used to amplify slo-1 cDNA. This is a mix of 
Taq DNA polymerase and Tgo DNA polymerase with proofreading activity. It has a 3 fold 
lower error rate than Taq DNA polymerase alone (7.3x10-6 errors per nucleotide per cycle). 
Enzymes with lower error rates were used (PfuUltraTM HF DNA polymerase) with little 
success, resulting in production of multiple fragments. 
In order to reduce the error rate when using the “Expand Long Template PCR System”, 10 
cycle programmes were used for the first two rounds of PCR, followed by a 25 cycles for the 
final round, a total of 45 cycles. The probable number of errors for this process is ~1. Figure 
7.02 A and B show optimisation rounds of PCR using primers slo-1 cDNAa IF and unc-54-
seq-R2 for the first round and kozak+partNhe1 and unc-54 R3 for the second round. Figure 
7.02 C shows the final PCR product, generated using primers Nhe1+Kozak F and unc-54 R4. 
This PCR product was used in further enzymic reactions in preparation for ligation into 
pIRES2-EGFP. 
5’ATGGGCGAGATTTACTCGCCT3’ slo-1cDNA IF
5’AGCCACCATGGGCGAGATTTACTCG3’ kozak+partNhe1
5’CCGAGGCTAGCCACCATGGGCGAGAT3’ Nhe1+Kozak F
KozakNhe1 slo-1
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A) round 1 B) round 2 C) round 3
D)
Figure 7.02. Amplification of slo-1 cDNAa by PCR. PCR products from three consecutive 
rounds. A) Round one PCR using primers slo-1cDNA IF and unc-54-seq-R2, B) Round two 
PCR using primers kozak+partNhe1 and unc-54 R3, C) Round cycle PCR using primers 
Nhe1+Kozak F and unc-54 R4. D) Cartoon of PCR fragment containing slo-1 cDNAa with 
annotated primer sites.
4668 bp
4668 bp
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The final PCR product and the pIRES2-EGFP vector were initially cut with Nhe-1. Cutting 
the slo-1 cDNAa PCR product with Nhe1 produces fragments of 6 and 4668 bp (Figure 7.03 
A), B), and C)). These digests were purified using QIAquick PCR     
Nhe1 vector and insert digest EcoR1 vector and insert digest
A) B) C) D) E)
F)
Figure 7.03. slo-1 cDNA insert and pIRES2-EGFP digest. Gel electrophoresis of A) slo-1 
cDNA PCR fragment Nhe1 digest, B) pIRES2-EGFP Nhe1 digest, C) Uncut pIRES2-EGFP, 
D) slo-1 cDNAa PCR fragment EcoR1 digest, E) pIRES2-EGFP EcoR1 digest. F) Cartoon of 
PCR fragment containing slo-1 cDNAa with annotated primer and restriction enzyme sites.
5308 bp
4668 bp
5308 bp
4663/4584 bp
3533 bp
1044 bp
3533 bp
4584 bp
4663 bp
1044 bp
84 bp
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Purification Kit. The slo-1 cDNAa PCR product and the cut pIRES2-EGFP vector were then 
cut with EcoRI (Figure x D) and E)). The EcoRI digest of the slo-1 cDNA PCR product 
removes the majority of the downstream sequence, leaving only 102 bp after the stop codon. 
EcoRI digest of slo-1 cDNAa PCR product produces fragments of 3533, 1044 and 84 bp. It is 
the 3533 bp product that is required for ligation into pIRES2-EGFP. 
Digested pIRES2-EGFP was treated with shrimp alkaline phosphatase to prevent re-ligation 
of the vector without the insert. The 3533 bp slo-1 cDNAa PCR product was put into a 
ligation reaction in a 3 fold molar excess with pIRES2-EGFP, using T4 DNA Ligase. dh5α 
cells were transformed with the ligation product. Six colonies were isolated and cultured. Due 
to the presence of multiple fragments in the ligation reaction there was the potential to obtain 
vectors containing incorrect inserts. In order to identify colonies containing the correct sized 
inserts, analytical digests were conducted on extracted Plasmid DNA. Of the six extracts, five 
of these displayed the correct digestion pattern (7019 and 1781 bp) when cut with sal1 (Figure 
7.04).
Due to the low proofreading activity of the “Expand Long Template PCR System” many of 
the slo-1 cDNAa cloned into pIRES2-EGFP vector contained errors. The five slo-1 cDNAa 
constructs were therefore sequenced. Table 7.02 shows the mutations generated in the PCR 
for the individual constructs. Only one had no mutations.
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A) B)
1     2    3     4     5 
Figure 7.04. Analytical digest of pIRES2-EGFP with slo-1 cDNA inserted. A) Gel 
electrophoresis of a sal1 digest for five extracts of pIRES2-EGFP with slo-1 inserted. B)
Vector map for pIRES2-EGFP with slo-1 cDNAa inserted. The sal1 restriction sites are 
highlighted in red.
Construct Errors
1
2 A224G
Gln75Gln
T616C
Phe206Ser
C1504T
Pro502Leu
T3165C
Ser1056Pro
3 C593T
Ile198Ile
T1957C
Val653Ala
4 C973T
Thr325Met
C3245T
Tyr1082Tyr
5 C198T
Arg67Stop
A771G
Thr258Ala
A1909G
Lys637Arg
Table 7.02. pIRES2-EGFP slo-1 cDNAa errors. pIRES2-EGFP slo-1 vectors were 
sequenced. Nucleotide changes in slo-1 cDNAa are shown. The resulting amino acid changes 
are shown. pIRES2-EGFP slo-1 vector 1 is the only one without any errors.
1781 bp
7019 bp
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7.3 Patch clamp analysis
Whole cell currents were recorded in HEK293 cells using patch clamp techniques. Single 
cells measuring between 20-30 μm were selected for patch clamp analysis. Figure 7.05 shows 
a typical example of the types of cells used. Initially recordings of endogenous HEK293 cell 
currents were made. HEK293 cells have been reported to have a variety of endogenous 
currents (Kurejova et al 2007, Zhu et al 1998, Jiang et al 2002) and it was therefore important 
to analyse these before looking at currents in HEK293 cells transiently transfected with BK 
channels.
Figure 7.05. Single HEK293 cell. An example of a single HEK293 cell typically used for 
patch clamp recording. The smooth edges of the cell allow for tight seals to be formed 
between the cell membrane and the micro-pipette.
7.4 Endogenous currents in HEK293 cells
Recordings of endogenous currents were made using the whole cell patch clamp technique 
(Hamill et al 1981). Single cells were selected for patch clamp recordings A voltage step 
protocol was used to record currents, clamping at 10 mV intervals between -90 and +50 mV. 
Each voltage step lasted 100 ms before returning to a holding potential of -80 mV. Figure 
7.06 shows currents typically seen when recoding in the whole cell configuration. Due to a 
high level of background noise steps have been separately displayed. 
10 μm
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-90 -10
-70 +10
-50 +30
-30 +50
Figure 7.06. HEK293 endogenous whole cell currents. Endogenous whole cell outward 
currents typically observed in HEK293 cells. 100 ms voltage steps were applied, stepping 
from a holding potential of -80 mV, to between -90 mV and +50 mV. Leak subtraction 
applied.
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50 ms
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100 pA
50 ms
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The cells displayed outward currents, which most likely reflect an outward flow of potassium 
ions. The presence of endogenous potassium currents in HEK293 cells has been previously 
reported (Jiang et al 2002, Zhu et al 1998, Kurejova et al 2007 and Thomas and Smart 2004). 
Figure 7.07 shows the current voltage relationship for endogenous currents in HEK293. The 
average current at +50 mV is 66.4  10.7 pA. The currents did not show inactivation during 
the 100 ms depolarising pulses.
Figure 7.07. IV relationship for whole cell currents from HEK293 cells. 100 ms voltage 
steps were applied, stepping from a holding potential of -80 mV, to between -90 mV and +50 
mV. For each point n=19 and is the mean  the S.E. Mean. Leak subtraction applied.
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7.5 Endogenous currents are 4-AP sensitive 
The effect of 4-AP on the size of the whole cell currents was tested. 4-AP was added to the 
recording chamber to a final concentration of 10 mM. The voltage step protocol was run 
before and 2 minutes after the addition of 4-AP. In four out of four tests 4-AP caused a 
reduction in the amplitude of the outward current at voltage steps between –30 and + 50. 
However, the difference between the currents before and after 4-AP application at each 
voltage step was found not to be significantly different using a paired, two tailed t-test at each 
voltage step (Figure 7.08).
Figure 7.08. IV relationship for whole cell currents from HEK293 cells +/- 4-AP. 100 ms 
voltage steps were applied, stepping from a holding potential of -80 mV, to between -90 mV 
and +50 mV. HEK293 cells pre (■) and post (▼) 4-AP application. For each point n=4 and is 
the mean  the S.E. Mean. Leak subtraction applied.
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7.6 C. elegans slo-1 transfected cells do not have large whole cell currents
HEK293 cells were transfected with pIRES2-EGFP slo-1 using lipofectamine 2000 
(Invitrogen). Cell were transfected when at approximately 20 % confluence. The transfection 
efficiency was estimated to be between 20 % and 50 %. Recordings were made using the 
whole cell patch clamp technique (Hamill et al 1981). Single cells expressing gfp were 
selected for patch clamp recordings. Cells strongly expressing gfp were not used as these were 
generally unhealthy. A voltage step protocol was used to record currents, clamping at 10 mV 
intervals between -90 and +50 mV. Each voltage step lasted 100 ms before returning to a 
holding potential of -80 mV. Figure 7.09 shows the voltage current relationship for un-
transfected HEK293 cells and for HEK293 cells transfected with pIRES2-EGFP slo-1. 
Figure 7.09. IV relationship for whole cell currents from C. elegans slo-1 transfected and 
non-transfected HEK293 cells. 100 ms voltage steps were applied, stepping from a holding 
potential of -80 mV, to between -90 mV and +50 mV. Untransfected HEK293 cells (■) and C. 
elegans slo-1 transfected HEK293 cells (○). For each point n≥6 and is the mean  the S.E. 
Mean. Leak subtraction applied.
The current voltage relationships for both un-transfected cells and for cells transfected with 
pIRES2-EGFP slo-1 was found not to be significantly different using a paired, two tailed t-
test at each voltage step. This indicates that slo-1 is not being functionally expressed. 
Expression of BK channel α subunits in HEK293 cells usually results in whole cell currents 
the nA range at potentials of +50 mV (Sade et al 2005).
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7.7 Homo sapiens kcnma1 transfected cells have large whole cell currents
HEK293 cells were co-transfected with pCMV4-XL6 kcnma1 and pIRES2-EGFP as a marker 
at a ratio of 3:1. Recordings were made using the whole cell patch clamp technique (Hamill et 
al 1981). Single cells expressing gfp were selected for patch clamp recordings. A voltage step 
protocol was used to record currents, clamping at 10 mV intervals between -90 and +50 mV. 
Each voltage step lasted 100 ms before returning to a holding potential of -80 mV. Figure 
7.10 shows the voltage current relationship for un-transfected HEK293 cells and for HEK293 
cells transfected with pIRES2-EGFP slo-1 and cells transfected with pCMV4-XL6 kcnma1. 
Figure 7.10. IV relationship for whole cell currents from H. sapiens kcnma1 transfected, 
C. elegans slo-1 transfected and non-transfected HEK293 cells. 100 ms voltage steps were 
applied, stepping from a holding potential of -80 mV, to between -90 mV and +50 mV. 
Untransfected HEK293 cells (■), C. elegans slo-1 transfected HEK293 cells (○) and H. 
sapiens kcnma1 transfected HEK293 cells (▲). For each point n≥6 and is the mean  the S.E. 
Mean. Leak subtraction applied.
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Figure 7.11 shows the currents typical seen in HEK293 cells transfected with kcnma1. A 
voltage step protocol was used to record currents, clamping at 10 mV intervals between -90 
and +50 mV. Each voltage step lasted 100 ms before returning to a holding potential of -80 
mV.
Figure 7.11. kcnma1 currents in transfected HEK293 cells. Typical currents seen in 
HEK293 cells transfected with pCMV4-XL6 kcnma1. 100 ms 10 mV voltage steps were 
applied, stepping from a holding potential of -80 mV, to between -90 mV and +50 mV. Leak 
subtraction applied.
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7.8 Discussion
Endogenous currents in HEK293 cells were successfully measured. These currents were 
found to be smaller than those reported in the literature. The average size of endogenous 
currents at + 50 mV was found to be 66 pA. Jiang et al (2002) observed outward currents in 
HEK293 cells under whole cell patch configuration. Using internal and external solutions 
similar to those used here, Jiang et al (2002) observed an average outward current of 
approximately 250 pA at + 50 mV. Yu et al (1998) observed an average outward current of 
approximately 350 pA at +50 mV. Variation in the size of endogenous currents observed in 
HEK293 cells has been reported (Kurejov et al, 2007). Over the course of two months, the 
size of whole cell currents was found to progressively decrease. This decrease is thought to 
reflect changes in the expression levels of ion channels. 
The smaller size of currents observed here could result from a different level of ion channel 
expression in the batch of HEK293 cells used. The smaller outward currents observed make 
these cells more suitable for the analysis of BK channel currents. HEK293 cells expressing 
BK channel α subunits typically have currents in the nA range. The endogenous currents 
observed in these cells are in the pA range and would therefore be expected to have a minimal 
impact on whole cell currents observed in HEK293 cells expressing BK channels.
Due to difficulties encountered using the patch clamp technique, a thorough pharmacological 
analysis of whole cell currents could not conducted. Cells in the whole cell patch clamp 
configuration were found to be unstable. The mechanical forces on the cell that resulted from 
the application of pharmacological compounds frequently disrupted the seal between the cell 
and micro-pipette.
10 mM 4-AP was successfully applied to four cells in the whole cell patch configuration. In 
each case this resulted in a decrease of the outward current at potentials between –30 and + 
50. The average size of the outward current was reduced from 147 pA to 72 pA at + 50 mV. 
Although the application of 4-AP did not result in a statistically significant decrease in the 
outward current, the trend suggests that the currents are 4-AP sensitive. This indicates the 
presence of endogenous potassium channels. A 51 % inhibition in the size of the average 
outward currents was observed with application of 10 mM 4-AP. This is similar to what is 
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reported in the literature. Jiang et al (2002) found a 40% inhibition of endogenous whole cell 
currents at + 50 mV using 5 mM 4-AP.
The aim of this chapter was to investigate the possibility of a direct action of emodepside on 
the SLO-1 channel. Unfortunately slo-1 was not functionally expressed in the HEK293 cells. 
There are several possible reasons for this failure to express. HEK293 cells were maintained 
at 37oC. However, C. elegans do not survive at such high temperatures. Lithgow et al (1995) 
reported  that maintaining N2 at 35oC killed 100 % of worms within 500 minutes. In some 
cases it has been reported that by lowering the temperature after transfection, functional 
expression of C. elegans genes that was not possible at 37oC can be achieved (Kubiak et al
2003). This has been shown to be the case for both npr-1 and npr-3 neuropeptide receptors. 
Lowering the temperature of C. elegans slo-1 transfected HEK293 cells to 28oC may result in 
functional expression. However, the lack of functional expression may result from differences 
in the post-translational modifications between H. sapiens and C. elegans. 
Although an effect of emodepside on C. elegans slo-1 currents could not be established, 
attempts to investigate its possible effects on kcnma1 currents were made. There is 50.8 % 
amino acid sequence identity between C. elegans slo-1 and Homo sapiens kcnma1 BK 
channels. The high level of sequence identity suggests that if emodepside binds to C. elegans
SLO-1 to elicit a response, there is a good chance this mechanism would exist in kcnma1. 
Kcnma1 was successfully expressed in HEK293 cells. The average whole cell current size at 
+ 50 mV was 2668 pA. These currents were easily distinguishable from the endogenous 
currents, with the average size of currents in HEK cells expressing kcnma1 being forty times 
larger. The size of the currents seen in HEK293 cells expressing kcnma1 are comparable to 
those reported in the literature (Sade et al 2006; Fukao et al 2001).
However, due to difficulties with the patch clamp technique, pharmacological compounds 
could not be successfully applied to the preparation. Ideally, iberiotoxin would have been 
applied in order to confirm that the observed currents were due to the presence of BK 
channels. Of the two preparations to which emodepside was successfully applied, neither 
displayed changes in the amplitude of the outward current. The expectation is that 
emodepside activates SLO-1, which would be reflected as an increase in the size of the 
outward currents. The fact that this is not observed could be due to a lack of sensitivity of the 
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kcnma1 channel to emodepside due to sequence differences compared to slo-1. Alternatively, 
the absence of components of a BK channel activation pathway may be responsible. 
However, due to the low n number, no solid conclusions can be drawn.
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Chapter 8
Discussion 
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The development of resistance to currently used anthelmintics has led to the requirement for 
anthelmintics with novel mechanisms of action. Emodepside, a member of the cyclo-
octadepsipeptide family of compounds, is one such compound. Its resistance breaking 
properties in a variety of parasitic nematodes initially indicated that emodepside has a novel 
mechanism of action (Harder & Samson-Himmelstjerna, 2002). The aim of this project has 
been to better define the mechanism of action of emodepside. Understanding emodepside’s 
mechanism of action may be beneficial for future drug design and may inform possible future 
applications for emodepside. It may also provide insight into biological mechanisms within C. 
elegans and therefore of parasitic nematodes. The identification of novel targets may prove 
useful for the development of future drugs. These may be new anthelmintics or alternatively 
compounds for treatment of other diseases. Potential applications not previously considered 
may be identified for emodepside. The usefulness of C. elegans as a parasitic model (Geary 
and Thompson 2001) can only be judged on a case by case basis. This project has shown that 
with regard to emodepside, C. elegans provides a representative model for its effects in 
parasitic nematodes. 
This study started with the hypothesis that emodepside activates neuronal latrophilin receptors 
resulting in the release of  neurotransmitters and paralysis of the muscle. The evidence for the 
involvement of the latrophilin receptors comes from studies that demonstrated binding of a 
PF1022A-keyhole limpet haemocyanin (KLH) conjugate to the Haemonchus contortus
latrophilin receptor HC110R. Emodepside was shown to antagonize the LTX-induced influx 
of calcium in HEK293 cells expressing HC110R although it could not induce calcium influx 
itself. Studies in C. elegans also indicated that the latrophilin receptors play a role in 
emodepside’s mode of action. RNAi was used to knock down lat-1. This resulted in a 
decrease in sensitivity of emodepside’s effects on the pharynx and on locomotion (Willson et 
al 2005, Amliwala 2005). RNAi knock down of lat-2 resulted in a decrease in sensitivity to 
emodepside’s effects on locomotion (Amliwala 2005). 
However, the current study demonstrates that neither LAT-1 nor LAT-2 have a role in 
emodepside’s effects on locomotion. The lat-1(ok1465) and lat-2(tm463) alleles both contain 
large deletions that are predicted to result in loss-of-function of the receptor. Regions 
putatively involved in emodepside binding are disrupted. Neither of these alleles displayed 
any reduction in sensitivity to emodepside’s effects on locomotion. The lat-1(ok1465) allele 
was however found to have reduced sensitivity to emodepside’s effects on the pharynx (Bull 
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2007). The reduction in sensitivity of the pharynx of lat-1(ok1465) was similar to that 
observed in animals with RNAi knock down of lat-1. 
Plate assays were used to assess the effect of emodepside on the locomotion of lat-1(ok1465) 
and lat-2(tm463) as opposed to the thrashing assay which was used to investigate the effect of 
RNAi knock down of lat-1 and lat-2 (Willson et al 2004, Amliwala 2005). However, it is 
unlikely that this prevented any difference in emodepside sensitivity being detected. Several 
strains carrying loss-of-function mutations in components of the latrophilin-mediated vesicle 
release pathway were found to have reduced sensitivity to emodepside when assessed using 
the plate assay (Amliwala 2005). Knock out of the emodepside receptor would be expected to 
result in resistance at least as strong as knock out of down stream elements. The lack of 
resistance observed in lat-1(ok1465) and lat-2(tm463) led to the hypothesis of functional 
redundancy between lat-1 and lat-2 with regard to emodepside’s mode of action. However, 
the lack of resistance to emodepside of the lat-2 lat-1 double mutant rules out this possibility. 
This also indicates that previous results obtained with RNAi are not specific to effects on 
either lat-1 or lat-2 genes. There is however a role for the LAT-1 receptor in emodepside’s 
effects on pharyngeal pumping. lat-1(ok1465) was found to result in a similar level of 
resistance to emodepside as knock down of lat-1 by RNAi in the EPG assay. lat-2 has been 
found not to influence the sensitivity of the pharynx to emodepside in the EPG assay. The 
decrease in sensitivity of lat-1(ok1465)  to emodepside’s effects on the pharynx rather than 
complete resistance indicates there must be another mechanism by which emodepside has its 
effects.
The BK channel SLO-1 is key to emodepside’s mode of action. Concentrations of 
emodepside of up to 10 μM failed to inhibit the locomotion of slo-1(js379). slo-1(js379) 
contains an early stop codon in the S4 transmembrane domain. This mutation is predicted to 
cause a loss of function of SLO-1. SLO-1 loss-of-function therefore results in high level 
resistance to emodepside. Restoration of emodepside sensitivity can be achieved through 
expression of slo-1(+) in either body wall muscle or neurons. This confirms that it is SLO-1 
loss-of-function that results in emodepside resistance, rather than a mutation in the 
background of the slo-1(js379) strain NM1968. The genetic evidence suggests that 
emodepside activates SLO-1.
191
All of the emodepside resistant mutants generated through random mutagenesis are alleles of 
slo-1. This has been demonstrated through the use of complementation tests. This, coupled 
with the high level of resistance observed in slo-1 loss-of-function mutants, indicates that 
SLO-1 is the main modulator of emodepside’s effects and is currently the best candidate for 
an emodepside receptor. Although no other genes involved in emodepside’s mode of action 
were identified in the mutagenesis screens, the possibility that emodepside binds to a receptor 
upstream of SLO-1 remains. 
Mutations in slo-1 have been identified in four emodepside resistant strains. pd24 and pd23
contain mutations that result in early stop codons in the RCK1 domain. Mutations in pd17 are 
in the RCK1 (A524V) and RCK2 (A870V) domains. In pd19 there is a mutation in the RCK1 
domain (G432R). The fact that these mutation are clustered in the RCK domains is interesting 
and may indicate that emodepside acts in this region.
The relationship between SLO-1 function and emodepside sensitivity was investigated using 
reversal frequency and aldicarb sensitivity as read outs for SLO-1 activity. slo-1 loss-of-
function mutants have an increased reversal frequency compared to N2. In general, there was 
a strong correlation between reversal frequency and emodepside resistance, indicating that the 
level of SLO-1 function directly relates to the level of emodepside resistance. The exception 
to this is pd21, which has an intermediate level of emodepside resistance but has a reversal 
frequency not significantly different from N2. This may indicate that the mutation in pd21
that confers emodepside resistance does not interfere with SLO-1 function. The identification 
of this mutation would be very useful as it may help to determine a site of interaction,  
possible an emodepside binding site, on SLO-1. This study brings into question the use of
aldicarb sensitivity as a read-out of SLO-1 function. Aldicarb sensitivity does not correlate 
well with emodepside resistance. Although some predicted SLO-1 loss-of-function mutants 
are hypersensitive to aldicarb, other are not. This indicates that it is mutations present in the 
background of some strains that causes aldicarb hypersensitivity, rather than loss of SLO-1 
function itself. Attempts were made to rescue the aldicarb hypersensitivity of slo-1(js379) by 
expressing slo-1(+) in either neurons or muscle. Expression of slo-1(+) in the muscle partially 
rescues the aldicarb hypersensitivity of slo-1(js379). slo-1(ky389) and slo-1(ky399) gain-of-
function mutants have been shown to have reduced aldicarb sensitivity compared to N2 
(Davies et al 2003). These results demonstrate that SLO-1 has the ability to influence aldicarb 
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sensitivity. However, whether or not the decrease in aldicarb sensitivity observed in slo-
1(js379) when slo-1(+) is expressed in the muscle is genuine rescue remains unanswered.
The SLO-1 gain-of-function mutants slo-1(ky399) and slo-1(ky389) have proved valuable in 
understanding the involvement of SLO-1 in emodepside’s mechanism of action. In loss of 
SLO-1 function mutants, emodepside resistance could be due to an indirect opposition of
emodepside’s effects or due to loss of SLO-1 activation by emodepside. If resistance results 
from the former, the effect of a gain of SLO-1 function mutation and emodepside would be 
cumulative. The effect of SLO-1 gain-of-function mutation and emodepside are not 
cumulative, suggesting that emodepside acts directly through SLO-1.
The evidence discussed suggests that emodepside activates SLO-1, resulting in inhibition of 
locomotion. In chapter six the result of SLO-1 activation by emodepside and the tissues in 
which this activation occurs was considered. slo-1 is endogenously expressed in both neurons 
and body wall muscle (Wang et al 2001). By expressing slo-1(+) in either body wall muscle 
or neurons of slo-1(js379) emodepside sensitivity could be restored. Emodepside can 
therefore activate SLO-1 in either neurons or muscle, both of which result in the inhibition of 
locomotion. Emodepside treated slo-1(js379) expressing slo-1(+) in the body wall muscle 
results in an inhibition of locomotion that most closely resembles N2. Emodepside treated slo-
1(js379) expressing slo-1(+) in the neuron results in an inhibition of locomotion that is 
characterized by coiling. There are several possible explanations for the coiling phenotype 
observed when expressing slo-1 in the neurons. The fact that slo-1 expression is not driven by 
the endogenous promoter is likely to influence this. Neuronal expression of slo-1(+) in slo-
1(js379) is driven by the pan-neuronal snb-1 promoter. This may result in expression in 
neurons that do not normally express slo-1. Another factor that might result in the coiling 
phenotype is the fact that only one splice variant of slo-1(+) was expressed. Three splice 
variants have been identified (Wang et al 2001). It may be that the splice variants are 
differentially expressed in different tissues and that non-endogenous expression results in the 
coiling phenotype observed. The coiling phenotype is not a result of a lack of expression in 
the body wall muscle as it is still observed when slo-1(+) is co-expressed in the neurons and 
body wall muscle of slo-1(js379). The coiling phenotype is likely to result from one or more 
of the above mentioned possibilities.
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As slo-1 is normally expressed in body wall muscle and neurons and as slo-1(+) can restore 
emodepside sensitivity to slo-1(js379) when expressed in both tissues, it seems likely that the 
inhibition of locomotion by emodepside in N2 results from an action in both tissues. The fact 
that the inhibition of locomotion in slo-1(js379) expressing slo-1(+) in muscle more closely 
resembles that in N2 may suggest that SLO-1 in the muscle plays a more prominent role in 
locomotion inhibition.
The pharynxes of slo-1(js379) are highly resistant to the effects of emodepside (Bull 2007). 
Interestingly, expression of slo-1(+) in the neurons completely restores emodepside 
sensitivity. Expression of slo-1(+) in the pharyngeal muscle of slo-1(js379) does not restore 
emodepside sensitivity. This suggests that emodepside’s effects on the pharynx are purely 
neuronal. This may also indicate that additional proteins that are not expressed in the pharynx 
are required for emodepside’s effects, as SLO-1 alone is not sufficient to restore sensitivity.
Attempts were made to determine the relative role of emodepside’s effects on 
neurotransmitter release and on muscle cell excitability using the compounds aldicarb and 
levamisole. The sensitivity of emodepside treated N2 and slo-1(js379) to aldicarb was 
assessed to investigate the effect emodepside has on ACh release. N2 worms treated with a 
sub-paralysing concentration of emodepside were found to have a decreased sensitivity to 
aldicarb. The sensitivity of slo-1(js379) treated with a sub-paralysing concentration of 
emodepside was found to be unaltered. This suggests that emodepside causes a reduction in 
ACh release (Miller et al 1996) and that this is dependent on SLO-1. However, this decrease 
in aldicarb sensitivity could reflect a post-synaptic effect of emodepside. To investigate 
whether this is a post-synaptic effect, the nicotinic agonist levamisole was used. If 
emodepside acts post synaptically to reduce muscle cell excitability, it would be predicted that 
N2 worms treated with a sub-paralysing concentration of emodepside would have decreased 
sensitivity to levamisole. slo-1(js379), which are thought to have increased muscle cell 
excitability (Carre-Pierrat et al 2006), would be predicted to by hypersensitive to levamisole. 
In fact the opposite was observed. Pre-treatment of N2 with emodepside resulted in 
hypersensitivity to levamisole. slo-1(js379) were found to have reduced sensitivity to 
levamisole. This suggests that emodepside acts to increase muscle cell excitability via 
activation of SLO-1. However, this interpretation is not consistent with the observed flaccid 
paralysis in C. elegans and the reduction in tension in Ascaris suum muscle strip caused by 
emodepside (Willson 2003). Electrophysiological recording from C. elegans neuromuscular 
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junction muscle would be useful in order to clarify what emodepside’s effect on muscle cell 
excitability are (Richmond 2006). These pharmacological and expression studies overall 
indicate that SLO-1 mediates emodepside’s effects in both neurons and body wall muscles.
The evidence presented in this thesis suggests that a mechanism of action of emodepside 
involving activation of SLO-1 in neurons and body wall muscle exists. The activation of 
SLO-1 leads to a reduction in ACh release, presumably through a decrease in excitability in 
cholinergic neurons. It may be that emodepside’s effect of reducing neurotransmitter release 
in cholinergic neurons is common to all types of neurons. Further investigation is required in 
order to determine what effect emodepside has on muscle cell excitability. Whether or not 
activation of SLO-1 is through a direct interaction with emodepside or is down stream on a 
pathway activated by emodepside remains to be determined. 
Figure 8.01. Proposed mechanism of action for emodepside.
However, such a mechanism is at odds with previous findings by Willson et al (2004) and 
Amliwala (2005) which suggest that emodepside acts to increase neurotransmitter release. 
Mutations in components of the latrophilin vesicle release pathway were found to result in a 
decrease in emodepside sensitivity, supporting the idea that emodepside causes 
neurotransmitter release. The Gαq egl-3 reduction-of-function mutants were found to have 
reduced emodepside sensitivity in both EPG and locomotion assays. Gαq egl-30 gain-of-
function have increased emodepside sensitivity in both EPG and locomotion assays. PLCβ 
egl-8 reduction-of-function mutants were found to have a decreased sensitivity to emodepside 
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in both EPG and locomotion assays. These mutants showed modest changes in sensitivity to 
emodepside. A similar decrease in sensitivity to emodepside’s effects on locomotion was 
observed in lat-2(ok301) VC158. After out-crossing, lat-2(ok301) XA3726 had an emodepside 
sensitivity similar to that of N2. This decreased emodepside sensitivity in lat-2(ok301) VC158
resulted from unidentified background mutation(s). The resistance conferred by these 
unidentified background mutation(s) indicates that mutants with reduced levels of emodepside 
sensitivity may be relatively easy to generate. Caution should therefore be taken when 
interpreting such results. Multiple reduction-of-function alleles were used to investigate the 
role of PLCβ egl-8 and Gαq egl-30, strengthening the evidence for an involvement of these 
genes in emodepside’s mode of action. However, rescue of the reduced sensitivity to 
emodepside in these strains would be useful to determine whether these genes have an 
important role in emodepside’s mode of action. Either way, it seems clear that this pathway 
plays a relatively minor role in emodepside’s mechanism of action, with regard to 
locomotion. The role of this pathway in emodepside’s effects on the pharynx, which was the 
focus of the paper by Willson et al (2004), may well be more prominent, although there is a 
clear involvement of SLO-1.
Whether or not emodepside acts directly on SLO-1 to open the channel remains to be 
answered. Unfortunately, attempts to address this by conducting patch clamp recordings from 
HEK293 cell expressing C. elegans slo-1 were unsuccessful. Based on the evidence presented 
in this thesis it would be predicted that emodepside would activate SLO-1, resulting in an 
opening of the channel and the flow of potassium ions. However, patch clamp recordings 
from the terminal bulb of slo-1(js379) expressing slo-1(+) in the pharyngeal muscle show that 
emodepside blocks SLO-1 (Bull 2007). The fact that BK currents are produced when slo-1 is 
expressed in the pharyngeal muscles but are blocked by emodepside rather than activated 
suggests that its mechanism may be altered in this system. This altered mechanism may result 
from post translational modification of SLO-1 specific to the pharyngeal muscle or the 
presence of a SLO-1 regulatory protein specific to the pharyngeal muscle. Xenopus oocytes 
have been successfully used to express C. elegans slo-1 (Wang et al 2001) and may provide a 
cleaner system to investigate the action of emodepside on SLO-1 currents.
The relevance of this mechanism in parasitic nematodes has recently been confirmed by using 
C. elegans as an exogenous expression system for parasitic nematode SLO-1 channels. The 
Ancylostoma caninum slo-1 and Coperia oncophora slo-1 were expressed in slo-1(js379) 
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using both snb-1 promoter and the native C. elegans slo-1 promoter (3.5 kb sequence 
upstream of the start codon). Expression of both slo-1 channels using the snb-1 promoter 
resulted in a partial rescue. Expression of both BK channels using the native C. elegans slo-1
promoter resulted in a complete rescue of emodepside sensitivity. These animals strongly 
resembled N2 animals on emodepside (Personal communication with Nina Krger). This 
process highlights the strength of using C. elegans as a model for parasitic nematodes. Similar 
techniques have recently been used to determine the mechanism of action of the novel amino-
acetonitrile class of anthelmintic compounds (Kaminsky et al 2008)
One concern about emodepside is the relative ease at which resistant C. elegans could be 
obtained. With many anthelmintics, screens for resistant C. elegans results in the generation 
of mutants with partial resistance. This is often due to the presence of multiple targets for 
anthelmintic compounds. For example, there are multiple nicotinic receptor subunits on which 
levamisole acts (Fleming et al 1997). Multiple mutations may therefore be required before 
resistance emerges. In comparison, there is only one SLO-1 subunit in C. elegans in which 
mutations are required to cause high level resistance. If the situation is the same in parasitic 
species then the potential for resistance to develop will be increased. Additionally, slo-1 loss-
of-function in C. elegans results in a relatively mild phenotype. If slo-1 loss-of-function in 
parasitic nematodes results in similarly mild phenotype, the potential for resistance to develop 
would increase. However, it should be remembered that the environment in which slo-1 loss-
of-function C. elegans are observed is highly controlled and seemingly mild phenotypes may 
be unsustainable in the wild. Parasitic nematodes may well be unable to maintain a slo-1 loss-
of-function.
Several key questions over emodepside’s mechanism remain to be answered. 1) Does 
emodepside increase the open probability of SLO-1 channels. 2) If emodepside functions in 
this way, does emodepside bind directly to SLO-1 in order to achieve this? The majority of 
the evidence indicates that this is the mechanism by which emodepside causes paralysis, 
however, this has not been shown directly. Investigating the effect of emodepside on C. 
elegans SLO-1 currents in Xenopus oocytes can hopefully be used to answer the question of 
whether or not emodepside increases the open probability of SLO-1. If it proves that 
emodepside can increase the open probability of SLO-1 in this system then it would also 
indicate that SLO-1 is the receptor for emodepside. Radio-labelled emodepside could be used 
in binding studies in order to determine if emodepside binds to SLO-1. If SLO-1 is found to 
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be the emodepside receptor it may be possible to characterize the binding site through the use 
of site-directed mutagenesis and analysis of SLO-1 currents in Xenopus oocytes. 
198
Appendix 1
Primers for detecting deletions in and sequencing latrophilin receptors
ok301 in left TGGAAAAATCGGAAAAATC
ok301 in right CCTCGCGTCTCACAATCAT
ok301 out left TTTTGTTATGGAACTCCGG
ok301 out right CTGGAAACTCGTCTCTTCC
ok301 in del left AACGACATCGCCGTGTTCGA
tm463 in left CGTAGGGCTTACCTTTTAGA
tm463 in right CGAGACGGACTAAGTATTAG
tm463 out left GGCAGACGTTTTTGTGACTA
tm463 out right AACGGAATGAATGCGCAACC
tm463 in del left TAACCTCACCTCCAGACGCA
tm463 seq CAGAAAGTTGATAACTTCCG
ok1465 out left CTTTTCTATCTTGCCGCCTG
ok1465 out right CTCCTAGCAAACTCGCCAAC
ok1465 in left GAAGTGGACATCTCGGGAAA
ok1465 in right AACATCGTGACGACATGGAA
ok1465 in del reverse GTGAAGTAGCACATTGAGTC
ok1465 seq ATTATGCAATAATTGCAAG
Primers for sequencing of slo-1 cDNA
slo-1 cDNA 0 ATGGGCGAGATTTACTCGCCT
slo-1 cDNA 1 GGACTGGGCTGGCGAGCTGAT
slo-1 cDNA 2 ACATTCTACAGTACCTCAACA
slo-1 cDNA 3 AAGCACATAGTGGTCTGTGGC
slo-1 cDNA 4 GGCCTACCTTCTAAATATCCC
slo-1 cDNA 5 TCATCCAGCCTCAAACTCAAG
slo-1 cDNA 6 AATTCGATGAGTATTCCGCCA
slo-1 cDNA 7 GCTATCTCGAGCAGATTTACG
slo-1 cDNA 8 TCGCCATTTCAGTGTTGGATT
slo-1 cDNA 9 AGGATTAAAAATACTGATTAC
Primers for confirmation of mutations in genomic DNA sequence
e66 confirm seq CCGCAAAGCGTCGTACAATAG
e66 confirm seq OF TCCAGGATTCCGTTTCCTCCG
e66 confirm seq IF CTACAGTACCTCAACATCCTG
e66 confirm seq OR CGCTAGGTTCCTAAAATCATG
e66 confirm seq IR GCCGTTTCCAGCCCGATTTCG
e42 confirm seq CGCATAACTCAGTCAGTTTTG
e42 confirm seq IF CATATCACCTACGATTCGGTG
e42 confirm seq IR TAATCTAGTGGCTATGGGTGG
e42 confirm seq OR TAATCTAGTGGCTATGGGTGG
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e76/13a confirm seq GTCCCATGATGTCCCATGTGC
e76/13a confirm seq OF TGCCTGGTCCTTGCCAACAAG
e76/13a confirm seq IF ACAAGTACAGTACCAATCCGG
e76/13a confirm seq OR GCCTGAAACGGCCTACTTTCG
e76/13a confirm seq IR TCACTAAGAAGAGCAAGTCCG
e13b confirm seq CACCAAGCTCCGTAATCATCG
e13b confirm seq OF GAACCAAGTTACAAGGATTTG
e13b confirm seq IF ACCCAAGGTTCCAAAATAGTG
e13b confirm seq OR ATGGCGAAGGCAGTTCCGCAG
e13b confirm seq IR GGTCGAGGAATTGCACATTTG
pd24 confirm seq (slo-1 gap 9 seq 3) GACAAGGTGAATCGAACAAG
pd24 confirm seq (slo-1 gap 9) IF TGTGGGCCGAAAATCTTTCC
pd24 confirm seq (slo-1 gap 9) OF ATTAGGCCGAAAGTAGGCCG
pd24 confirm seq (slo-1 gap 9) OR TCCTTCGGGCCTTTTTCAGC
pd24 confirm seq (slo-1 gap 9) IR CCAAAATCGGCCTGAAAACG
Primers for amplification and sequencing individual slo-1 exons 
slo-1 gap 1 OF GACAGATATGTCTAGGCACG
slo-1 gap 1 IF GCCTAACTGGTCCATTATG
slo-1 gap 1 OR TTCAACCGCGACGCGACCGC
slo-1 gap 1 IR GTCAATTGAAAGCTGGCAAC
slo-1 gap 1 seq TTCATTTATTCGTCGGGAGG
slo-1 gap 2 IF AGCCACAAACTCAAAGTATC
slo-1 gap 2 OF TTATTTTGAAGCTAGCGACG
slo-1 gap 2 IR AGCTGCATCGCTAGAGAATC
slo-1 gap 2 OR TGCGGTCCCGAATACTTCTG
slo-1 gap 2 seq AATTCCGACCGCGACGCGAC
slo-1 gap 3 OF TCAAATTGAAGCTGAAAACG
slo-1 gap 3 IF AGAACCGAGTGAGTTTGATG
slo-1 gap 3 IR CCAGGTCGATTTGTTGCGAG
slo-1 gap 3 OR TCGGACGCGGCGATGAACTG
slo-1 gap 3 seq TGTAGCCTACACCTGTTGAG
slo-1 gap 4 OF AATTGGTCTCAGAATGTCCC
slo-1 gap 4 IF TGTTCCCACAGTGTCGCCAG
slo-1 gap 4 seq ATGCCTGAATTTTGTGTCTG
slo-1 gap 5 OF CATATTGCCAATATGGACTG
slo-1 gap 5 IF CAAGTTTCGTCTATTCTACC
slo-1 gap 5 IR AAAGGCGTCTAAGGGTGTGG
slo-1 gap5 OR TTCTCTACCAAAACTACCAG
slo-1 gap 5 seq GGAAATTTGACGGAGAATCC
slo-1 gap 6 OF TCAAAACTCACATTTTCCCG
slo-1 gap 6 IF CCTCGTATCACTCGACACAC
slo-1 gap 6 IR CCAGTGGAACATTCCAGTAC
slo-1 gap 6 OR GTTGAGTACGGTCATAGCGG
slo-1 gap 6 seq CAGTCATCACCGCTTCCAGC
slo-1 gap 7 OF GCCACTTTCAAGCCCGAAGG
slo-1 gap 7 IF CCGTTTCGGGCCGTATTCAG
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slo-1 gap 7 seq ACCTAGCCAATATGAGTGTC
slo-1 gap 7 IR TATTGGTCCTTCGGAGTCGG
slo-1 gap 7 OR ATTCAGGTCCACACGATACC
slo-1 gap 8 IF CCCATATCGGCTATATTTGG
slo-1 gap 8 OF CGAACTCCTGATGTTTTAAG
slo-1 gap 8 seq 1 CTTAAAATCGCACGGATAAC
slo-1 gap 8 seq 2 GATGTACCCAAGTGTCCCCG
slo-1 gap 8 IR AAGTCGCATAACTCAGTCAG
slo-1 gap 8 OR TATGGGTGTCAAATTTACGG
slo-1 gap 9 IF TGTGGGCCGAAAATCTTTCC
slo-1 gap 9 OF ATTAGGCCGAAAGTAGGCCG
slo-1 gap 9 seq 1 GTGTTCGCATTGTCTATGTC
slo-1 gap 9 seq 2 AAATTGTCCGTTTCAGTCCG
slo-1 gap 9 seq 3 GACAAGGTGAATCGAACAAG
slo-1 gap 9 IR CCAAAATCGGCCTGAAAACG
slo-1 gap 9 OR TCCTTCGGGCCTTTTTCAGC
Primers for generation of slo-1 insert for insertion into pIRES2-EGFP
slo-1 cDNA 0 ATGGGCGAGATTTACTCGCCT
Kozak + part Nhe1 F AGCCACCATGGGCGAGATTTACTCG
Nhe1 + Kozak F CCGAGGCTAGCCACCATGGGCGAGAT
unc-54 R2 GTCAGAGGCACGGGCGCG
unc-54 R3 TACTCGTTAGTTAGTAGAACTC
unc-54 R4 AACTTACTCTGATGACAGCGGC
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Appendix 2
Genotype Allele Strain
Wild type N2
Wild type CB4856
lat-1 / mIn1 ok1465 VC965
lat-1 / lat-1 ok1465 XA3750 (selected from VC965)
lat-2 / lat-2 ok301 VC158
lat-2 / lat-2 ok301 XA3726 (VC158 out crossed 5X)
lat-2 / lat-2 tm463 TM463
lat-2 / lat-2 tm463 XA3727 (TM463 out crossed 5X)
lat-2 lat-1 / mIn1 tm463 ok1465 XA3744
lat-1 lat-2 / lat-1 lat-2 tm463 ok1465 XA3749 (selected from XA3744)
slo-1 js379 NM1968
slo-1 ky399 CX3940
slo-1 ky399 XA3751 (CX3940 out crossed 1X)
slo-1 ky389 CX3933
slo-1 pd17 XA3745
slo-1 pd19 XA3746
slo-1 pd21
slo-1 pd23 XA3747
slo-1 pd24 XA3748
slo-1 pd46
slo-1 pd47
dpy-20 e1282 CB1282
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Appendix 3
Construct name Description / Use
pPD118.33 Used as a transfection marker when generating transgenic 
C. elegans. Contains gfp driven by the myo-2 promoter.
pBK3.1 Used for expression of C. elegans slo-1(+) in neurons.
Contains C. elegans slo-1 cDNAa driven by the snb-1 
promoter.
pBK4.1 Used for expression of C. elegans slo-1(+) in body wall 
muscle. Contains C. elegans slo-1 cDNAa driven by the 
myo-3 promoter
pIRES2-EGFP Used for expressing C. elegans slo-1 in HEK293 cells. 
Expression in eukaryotic cells is driven using the CMV 
promoter. GFP and the insert (slo-1) are translated 
independently due to the presence of the internal ribosomal 
entry site (IRES).
pCMV4-XL6 Used for expressing kcnma1 in HEK293 cells. Expression 
in eukaryotic cells is driven using the CMV promoter. 
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Appendix 4
Variability in lat-2(tm463) XA3727 thrashing assays
1)
2)
3)
Figure A. lat-2(tm465) XA3727 thrashing assay. Effect of 10 M emodepside on N2 
(▲) and lat-2(tm463) (●) C. elegans thrashing behaviour over the course of 65 minutes. 
Graphs 1, 2 and 3 show data collected in three independent assays. Each point in an 
average of 10  the S. E. Mean. ** indicates P<0.01 and *** indicates P<0.001 compared
to WT.
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Effect of out crossing on lat-2(ok301) emodepside sensitivity in body bends assay
Figure B. lat-2(ok301) out crossing increases emodepside sensitivity. Dose response 
curve for emodepside on lat-2(ok301) XA3726 (), lat-2(ok301) VC158 (■) and WT (▲). 
Each point is the mean  S.E.Mean of 10 determinants. * indicates P<0.05 compared to 
WT.
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3159 bp
2076 bp
3159 bp
3159 bp
2076 bp
2076 bp
Example of tracking lat-2(ok301) deletion during out crossing using PCR.
1)
2)
3)
Figure C. Tracking lat-2(ok301) deletion during out crossing. Shows 1) the genotype 
of progeny from a WT hermaphrodite X ok301 homozygous male cross, 2) the genotype 
of progeny from a ok301 heterozygous hermaphrodite self cross, 3) the genotype of 
progeny from a ok301 homozygous hermaphrodite self cross.
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Identification of possible slo-1 splice variant
Amplification of slo-1 cDNA revealed the presence of a fragment of ~1600 bp (figure 
4.12). Sequencing of these cDNA was hindered by the presence of more than one  
sequence. Double sequence was present in a region not identified as encoding one of the 
three alternate splice variants, a, b and c (Wang et al 2001). By reading through the 
double sequence, a region between exons 2 and 3 (of the identified splice variants) was 
found to be encoded in the slo-1 cDNA of pd17, pd19, pd21, pd23 and pd24. The 
sequence of this region between exon 2 and 3 is shown in figure D. This sequence follows 
into exon 14, missing out exons 3 to 13. The sum of exons 1 and 2, the shown in figure D 
and exons 14 to 20 is 1630 bp. This corresponds to the size of the PCR fragments 
observed in figure 4.12. This may represent an alternate splice variant for slo-1.
gattctctagcgatgcagctttacagaagtattcgggaccgcagg
Figure D. Possible alternate slo-1 spice variant. The sequence between exon 2 and 3 in 
splice variant a is shown above in the gene model. 
However, the intron exon boundaries for this putative exon lack some of the conserved 
consensus sequence. The intron sequence at the 5’ end of the putative exon ends in AG, 
which is conserved. The intron sequence at the 3’ end of the putative exon begins in GC, 
whereas the conserved sequence is GT. Using a translate tool (www.expasy.ch) revealed 
that the proposed exons reads into exon 14 out of frame.
Exons 3 to 13
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